Pages where confidential treatment has been requested are stamped “Confidential
Treatment Requested and the Redacted Material has been separately filed with the
Commission,” and places where information has been redacted have been marked
with (***).

Exhibit 10.22I

 

NINTH AMENDMENT

TO THE

CSG MASTER SUBSCRIBER MANAGEMENT SYSTEM AGREEMENT

BETWEEN

CSG SYSTEMS, INC.

AND

COMCAST CABLE COMMUNICATIONS MANAGEMENT, LLC

 

 

 

 

This NINTH AMENDMENT (the “Amendment”) is made by and between CSG Systems, Inc.
(“CSG”) and Comcast Cable Communications Management, LLC (“Customer”). The
effective date of this Amendment is July 1, 2014 (“Amendment Effective
Date”).  CSG and Customer entered into a certain CSG Master Subscriber
Management System Agreement (CSG document #2501940) with an effective date of
March 1, 2013 (as amended modified or supplemented from time to time, the
“Agreement”) and now desire to amend the Agreement in accordance with the terms
and conditions set forth in this Amendment. To the extent any of the terms and
conditions in this Amendment conflict with the terms and conditions of the
Agreement, the terms and conditions of this Amendment shall control. Any
capitalized terms not defined in this Amendment shall have the meanings given to
such terms in the Agreement. Upon execution of this Amendment by the Parties,
any subsequent reference to the Agreement between the Parties shall mean the
Agreement as amended as and to the extent provided in this Amendment. Except as
amended by this Amendment, the terms and conditions set forth in the Agreement
shall continue in full force and effect according to their terms.

 

RECITALS

 

WHEREAS, Customer desires to migrate certain of its current subscribers who are
currently receiving billing and account services from another party to CSG’s ACP
billing platform; and

 

WHEREAS, Customer may in the future add additional subscribers by acquisition
and may desire to migrate such subscribers to Customer’s instance of CSG’s ACP
billing platform under the terms of this Amendment; and

 

WHEREAS, CSG desires to provide billing and account services to such Customer
subscribers; and

 

WHEREAS, the Parties desire to amend the Agreement to set forth, the terms on
which such migrations shall occur.

 

AGREEMENT

 

In consideration of the mutual covenants, terms and conditions, and intending to
be legally bound hereby, CSG and Customer agree that the Agreement is amended as
provided below.

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

1.

Amendment to Article 1 (Overview)

 

(a)

The Agreement is amended by deleting Section 1.2 in its entirety and replacing
it with the following:  

 

1.2 Term.  Unless earlier terminated pursuant to Section 6.1 or Section d.(v) of
Schedule L, this Agreement shall commence on the Effective Date and remain in
effect thereafter for an initial term expiring on June 30, 2019 (“Initial
Term”).  The term of any specific license for the Products and the term for any
specific Services to be provided shall be effective from the Effective Date or
the date set forth in the applicable amendment and shall terminate with this
Agreement, unless stated otherwise herein or as otherwise provided in the
applicable Schedule, Exhibit or amendment.  

 

(a)  First Extension Option.  CSG shall provide Customer with written notice no
later than nine (9) months prior to the expiration of the Initial Term that the
Initial Term is approaching its expiration.  Customer has the option in its sole
discretion to extend the Agreement for one additional year beyond the end of the
Initial Term upon written notice to CSG no later than six (6) months prior to
the end of the Initial Term (“First Extension Term”), subject to the fees set
forth in Schedule F.

 

(b)  Second Extension Option.  If Customer has exercised its option for the
First Extension Term, pursuant to the terms of Subsection 1.2 (a), CSG shall
provide Customer with written notice no later than nine (9) months prior to the
expiration of the First Extension Term that the First Extension Term is
approaching its expiration.  Customer has the option in its sole discretion to
extend the Term of the Agreement for one additional year beyond the end of the
First Extension Term, upon written notice to CSG no later than six (6) months
prior to the end of the First Extension Term (“Second Extension Term”), subject
to the fees set forth in Schedule F.

 

(c)  The Parties agree that the Initial Term or any duly exercised First
Extension Term or Second Extension Term shall be considered part of the “Term”
and/or “the term of this Agreement.”  

 

(d)  For the duration of the Term following the Amendment Effective Date, the
term “Contract Year” shall mean each twelve month period with the first Contract
Year commencing on the Amendment Effective Date and ending June 30, 2015.  Each
Contract Year thereafter, Contract Year shall mean each twelve month period
during the Term.

 

(e)  If Customer does not notify CSG of its intent to extend the Agreement in
accordance with subparagraphs (a) or (b) above, CSG shall not be required to
extend the Term, subject to the obligations set forth in Section 6.2
(De-Conversion Services).  

 

(b)

The Agreement is amended by adding the following at the end of Section 1.5
(Exclusive Rights):

 

In addition to CSG’s right to be the sole provider of Print and Mail services
for Connected Subscribers, Customer may have CSG provide Print and Mail services
to other Customer subscribers that are not on CSG’s ACP billing platform at the
same pricing as set forth in Schedule F (Fees) for such services.  In the event
Customer desires to utilize Print & Mail Services subsequent to the migration of
a subscriber onto CSG’s

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

billing platform, Customer shall be responsible for any related conversion fees
applicable to such later conversion to Print & Mail Services.  As clarification,
in the event Customer requests a converted subscriber to CSG’s billing platform
also simultaneously be converted to CSG’s Print and Mail Services, Customer
shall not be responsible for any Print & Mail conversion fees.  

 

At Customer’s written request, CSG agrees to meet with Customer within ***
************** (***) **** of the Amendment Effective Date, to discuss use of
********’* ********* ***** ****** for Print and Mail Services.  Nothing herein
shall be construed as a requirement for CSG to *** ********’* ********* *****
****** for Print and Mail Services.

 

2.

Amendment to Article 3 (Services)

 

The Agreement is amended by deleting Section 3.4 (Services Commitment) in its
entirety and replacing it with the following:

 

3.4  Services Commitment

 

(a)

Subject to Customer’s payment of Any Development Hours (defined in CSG document
#2504737), regardless of the effective date of CSG document #2504737, which are
provided prior to the Amendment Effective Date, Customer may elect to continue
to have CSG provide Any Development Hours under the existing Statement of Work
(identified in CSG document #2504737) after the Amendment Effective Date and
make payments as provided therein, or enter into a Change Order allocating the
Any Development Hours provided in the Statement of Work after the Amendment
Effective Date to the Annual Support Commitment (as defined below), which will
result in a reduction in the Annual Support Commitment accordingly.  

 

(b)

Customer shall be responsible for payment of the Customer Re-Investment through
February 28, 2014 and any Customer Re-Investment Hours which are unused through
February 28, 2014, shall be forfeited.  For clarification, Customer
Re-Investment as provided in this Section 3.4, shall have the definition
provided in Section 3.4 of the Agreement prior to Amendment by the 9th Amendment
entered into by the Parties.   

 

(c)

CSG shall continue to invoice and Customer agrees to pay the Customer
Re-Investment through June 30, 2014.  Any payment made by Customer for the
Customer Re-Investment which is invoiced by CSG for any month after February 28,
2014 for which there are unused Re-Investment Hours as of the Amendment
Effective Date, shall be applied at Customer’s request to fulfill Customer’s
obligations for the Service Commitment Fee. If as of the Amendment Effective
Date, Customer has utilized more Re-Investment Hours than what it has paid in
Customer Re-Investment, Customer and CSG shall proportionately decrement the
Annual Support Commitment.  

 

(d)

CSG shall provide ****** ***** of services per ********** ******** ****,
exclusive of Support and Maintenance and Migration services necessary to support
the Migration SOW, to support the research and development of (including
enhancements, updates and upgrades to) CSG’s ACP platform billing system unless
otherwise agreed by the Parties (“Annual Support Commitment”). After the *****
******** ****, Customer shall be entitled to use up to ****** ******* (***) of
its

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Annual Support Commitment for services for *** ******* ******* ** *** ***** **
******** *** *********** ** ***’* *** ******** ******* ****** but still related
to CSG’s ACP platform billing system, which excludes fees for software, hardware
or any third party fees, conditioned upon Customer providing CSG *** (*) ******
prior written notice of whether it intends to exercise this right in a
subsequent ******** ****.  Notwithstanding anything contained in the first
sentence of this subsection to the contrary, the Parties acknowledge and agree
that the Annual Support Commitment and the corresponding Service Commitment Fee
will be applied to work performed after the Amendment Effective Date under the
QA Refresh Solution SOW (document #2505232) (for recurring fees only) and under
the Dynamic Event Management and EST Couponing Solution SOW (document #2503499)
(for *** ******* ***** (***) *********** ***** (excluding any recurring fees)
only).  Further, any services hours which qualify under this Section 3.4 (a) and
are performed after the Amendment Effective Date under SOWs executed prior to
the Amendment Effective Date shall apply to the Annual Support Commitment and
the corresponding Service Commitment Fee. Customer agrees to pay the fees
provided in and pursuant to Schedule F (Fees) of the Agreement for the Annual
Support Commitment (“Service Commitment Fee”) for the first ***** ********
*****.  The Service Commitment Fees identified in Schedule F (Fees) of the
Agreement are non-refundable at the end of the applicable ******** ****, and are
a commitment by Customer for payment regardless of Customer’s use of the Annual
Support Commitment for any particular ******** ****.   Customer may carry over
up to ***** of the Annual Support Commitment hours into the **** ******** ****,
provided that any unused Annual Support Commitment hours at the end of a
******** **** ** ****** ** ***** shall be forfeited and shall not be carried
over to the **** ******** **** by Customer.

 

(e)

The Service Commitment Fee will be invoiced *******, based on ** ***** *******
********** of the applicable ****** fee.  Any service hours used by the Customer
in excess of the Annual Support Commitment shall be paid at the rate set forth
in Schedule F pursuant to a mutually agreed Statement of Work.

 

(f)

For any ******** **** after **** *** ****, Customer may, in its sole discretion,
purchase Annual Support Commitment services upon entering into a Statement of
Work for an Annual Service Commitment Fee as provided in Schedule F.  CSG shall
notify Customer on ******* ** **** and ******* * of each ******** ****
thereafter during the Term of Customer’s ability to purchase Annual Support
Commitment services each ******** ****.  Customer must notify CSG of its intent
to purchase the Support Commitment services no later than ******** ** of the
******** ******** **** and the Parties must execute the Statement of Work no
later than *** * of the ******** **** prior to its use of the Annual Support
Commitment.

 

3.

Amendment to Article 4 (Workforce Management)

 

The Agreement is amended by deleting Article 4 (Workforce Management) in its
entirety and replacing it with the following:

 

ARTICLE 4

MIGRATION

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

4.1

Customer shall identify Additional Subscribers for migration to CSG’s ACP
billing platform (the “Migration”) as part of a Statement of Work which will
identify Migration services and the responsibilities of the Parties (the
“Migration SOW”).  “Additional Subscribers” shall mean those subscribers of
Customer’s residential services who are receiving billing and account services
from any platform other than CSG’s ACP billing platform as of the date
immediately prior to the date of their migration to CSG’s ACP billing platform
pursuant to the Migration SOW (excluding any New Subscribers, hereinafter
defined).    

 

4.2

CSG shall perform Migration services and support for the Additional Subscribers
as set forth in the Migration SOW, including but not limited to those
development items identified in the Migration SOW as necessary to ensure that
CSG can support the Migration (“Development Items”), ** ** **** ** ********,
unless otherwise mutually agreed in writing or provided in the Migration
SOW.  Customer shall provide the resources as set forth in the Migration SOW to
perform its Migration obligations, including promptly providing the required
information, assistance and approvals, ** ** **** ** ***, unless otherwise
mutually agreed in writing.  

 

4.3

CSG shall migrate the Additional Subscribers in accordance with the Migration
SOW.  The Migration SOW shall include a schedule for the Migration (“Migration
Schedule”).  The Migration SOW shall include ******* ****** for which CSG shall
be accountable during Migration (“********* ****”) and a governance structure
which will identify necessary teams and level of participation by the Parties
(“Governance Structure”).  The Migration SOW may be updated or modified by
mutual written agreement of the Parties executed by the CIO of Customer and the
COO of CSG or each of their duly authorized designees.   The Parties will comply
with the Migration SOW, provided that it will be a working document and as such
may be updated from time to time as provided herein.  

 

4.4

If Customer or a party for which Customer is responsible or controls pursuant to
the Migration SOW causes a delay that materially and adversely impacts the
Migration Schedule (a “Customer Delay”) CSG shall be excused on a reasonable and
proportionate basis from its resulting inability to meet its Migration
obligations and the remaining milestones in the Migration SOW, including
adhering to the Migration Schedule.

  

4.5

The term “********* *****” means *** ***** ** *** ********* ****** ** *** ** ***
** ******** **** ***’* ******** ********* ************** ** **** ********
********* ******* ** ******* ******* ********* ********* **** *** **********
**** *** * ******** ******* ****** ** *** ********* ******** ** ********’*
******** **********.  Within *********** (**) ***** of Customer’s Executive
Director of Software Development and Engineering or someone of greater authority
in Customer’s organization, notifying CSG’s CIO and V.P. of the Strategic
Business Unit (e-mail shall be sufficient) that a ********* ***** has occurred
and been documented in *******’* ******** ****** ******** ******, the Parties
shall meet and confer in order to agree upon a ********** ******** *** *
********* ** ******* **** ********* *****.  If the Parties ****** ***** **** *
********** ******** ****** *********** (**) ***** of the foregoing notice, the
Parties shall ******** *** ***** ** *** ********** ********* (as defined in the
Migration SOW), which shall **** *********** (**) ***** from notice of the
******* ** ******* *** ******* *** ***** upon the ********** ******** ***
*********.  If the ********** ********* cannot ***** * **********, the Parties
shall further ******** *** ***** ** ***’* *** *** *** *** ********’* *****
******** *** *** *** (the “Executives”), who shall **** *** ******* *** *******
*** ***** **** *** ********** ******** *** ********* ****** *********** (**)
***** of ********** ** *** ****** ** provided herein.  Customer shall ****** ***
********* **

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

******* ******** **** *** ********** ** *** ********* *****.  In the event **
****** ********** ******** ** ******* * ********* ***** ** ************, the
Parties agree ** ***** *** ******* *** ********** ** * ********* ***** **** **
***** ** ******* *** ********* *****.  If the Executives ****** ***** **
********** ******** **** **** **** (*) ******** ****’ ******* ****** ** *** and
******* ******* *** ** *** **** *********** ******* ** ********* *** *********
*** *** ** * ****** *** ******* ********* ** ********** ***********.  Further,
if (i) the ********* ***** ******* ********** ** *** **********, (ii) ********
** ** ****** ******* ** *** **** **** **** ********* ********* ** *** **** **
**** ********* *****, and (iii) ******** ********** *** ********* **** **** ***
***** ******* ******** ********** ********* ************* ** ****** **********
***** ******** ** ******** ***** *** ********* ** ************ **********
******** ******** ** *** *** ***** ** * ****** ****** ** *** **********
********* ***** (the “********* ******”).  The Parties agree **** ** ** *****
***** *** ********* ****** ****** **** ******* ******* ($************).  ***
******* ** *** ********* ****** ***** ** **** ** ******* ****** ****** (**) ****
of the Parties’ agreement ** *** ****** ** *** ********** ********* ******.  In
the event *** **** *** ********* ****** ** ******** ** **** ******* **** ***
******** ******* ****** ** ******** ** ******** * (*)(*) (*) and (*) of the
******* ******** ******** ** ******** ******** ****** ****  ** ** ***’* *******
** ********’* ************ ** *********** ** *** ********* ***. Except for ***
******** ******** ** *** ******* ********, the *********** ** *** **** **** ****
********* ********* (if applicable), ** *** *********** ** *** ********* ******
(if applicable), *********** *** ** * ********* ***** ***** ** ********’* ****
*** ********* ****** *** ***’* ********* *****.  Customer agrees, in the event
** **** *** ******** *** ***** ** ********* ** ******** ** **** ******* *** ***
** ******* ********* *****, it shall ******* ***** *** ***** ** ********* ***
**** ********** ******* ********* *****.

 

4.6

Customer shall ** ******** ** ********* *** ********* **** ****** (**) ***’*
******* ****** ** *** ** *** **** ****** *** ***** ******* **** ** *** **** ****
**** ********* *********, if applicable.

 

4.7

If Customer desires to bring other subscribers (whether such subscribers were
previously on a CSG platform or a non-CSG platform and subsequently migrated to
a CSG platform) under this Agreement after the closing of a direct or indirect
acquisition (“Acquisition Closing Date”) of one or more entities occurring after
the Amendment Effective Date that are not currently included in the Migration
SOW (“New Subscribers”), the Parties will enter into the necessary amendment(s)
to this Agreement to migrate such subscribers, as applicable, and bring all such
desired subscribers under the terms of this Agreement as New Subscribers (the
“Migration and/or Integration Amendment(s)”). For the avoidance of doubt, the
******* *********** *** ***** **** **** *********** *** **** ********** ** * ***
******** *** ** ******* ***** **** ********* ******* ******** ****** ** *****
******* **** *********** ** ********’* ******** ** ***’* *** ******* ********.
For all purposes under this Agreement ****** *** *** ******* ** *********** ***
*** ** ******* ** ******** *, all New Subscribers who were (i) previously on a
non-CSG billing platform and are migrated onto Customer’s instance of CSG’s ACP
billing platform, or (ii) previously on a CSG platform and remain on a CSG
platform after the Acquisition Closing Date, but are no longer subject to an
agreement between CSG and the Acquired Entity (hereinafter defined) shall
thereafter become Connected Subscribers.  For the avoidance of doubt, fees for
New Subscribers shall be calculated using the *** ***** *** *** ***********
******** ** ******** *.

 

(a)  The Parties acknowledge it will be necessary to **** ** ******* *********
*** *********** ************** ** ******* *** ********* ********* ***/**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*********** ********** ** ******* *****, to bring New Subscribers under the
Agreement.  In the interim, if Customer acquires an entity (for purposes of this
subsection, an “Acquired Entity”) which is receiving CSG products and services
under another agreement, and Customer desires ** ******* **** *** *** **********
***** **** *********, but ******** ********* **** *** **** *** ***********
********** *** *********** ***** **** ********** *** *** *** ******** ******
**** ***** *** ******** ******’* ********* **** *** (“Acquired Entity’s
Agreement”) ** ******* ** ******** ****** ******* *** ****** (as defined below)
*** * ****** ** **** *** ** ****** *** (*) ****** (“Transition Period”) unless
otherwise extended by the mutual written agreement of the Parties (the “Acquired
Entity Agreement Amendment”).  The Parties shall work in good faith to negotiate
the Migration and/or Integration Amendment(s) during the Transition Period.

 

(b)  The Acquired Entity ******* *** ****** ***** **** *** ****** ******** **
*** ******** ******’* ******* ***** **** *** ********* *********** (“********
****** ******* *** ******”):

 

(i) CSG agrees to provide Customer with * ******** ********** ***********
********** ******** *** ******** ********* ** *** ******** ****** ***** ***
******** ****** ********* ***** *** **** ** * ******* ****** (“Acquired Entity
******* ***”) to Customer’s *** provided in Schedule F.  

 

(ii)  The Acquired Entity ******* *** ***** **** ** ******** ** ********* *****
(***** *** ** ****** ******** ** ******** *********** ********* **** ***
*************) ******** ** *** ******** ****** ******* *** **** **** ** **** **
**** **** **** ***** **** ** * ******* ***** (e.g., ****** ********* ** *******
******** *** ********* ****** ********* ******** ** ******* ********* ********)
in order to ******* ** ******** ************** ** *** ******** ******’*
********* ******* **** *** ********* **********, provided under the Acquired
Entity Agreement (“******** Acquired Entity ******* ***”).

 

(iii)  The ********** ******* *** ******** ******** ****** ******* *** *** ***
********** *** *** *** *********** (as shown in Schedule F, *** ***** *** ***
***********) shall be the ******* *** ****** (“******* *** ******”).    

 

(iv)  The Acquired Entity ******* *** ****** ***** ** *** ******* ** *** ******
** ********* *********** ** *** ******** ****** ********** ** *** ******* ***
******.

 

(c)  The Parties agree **** ********** ********* *** ** ******** ** *********
*** ******** ****** ******* *** (** *** ******* *** ******** ******** ** ****
*** *** ***** ******* ******* *** ******** *** *** ******** ******) *** ***
************* *********** ******** ** ********* *** ******** ******** ******
******* ***.  The Parties agree to work in good faith ** ********** *********
***** ***** ** *** ******** ****** ********* ********* *** ** ********* ******
*** ********* *** ****** *** ******* ***** ***** *** ** ******** ** * *****
***** **** ******** **** *** ******* ****** ** *** ******* ***** ** ******** ***
********** ******* *** *********:

 

(i)

******** ******** ****** ******* ***, and

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

(ii)

the *** **** ***** ** ********** ** *** ******** ******’* ********* ***********
**** ********** *** *********** ***** *** *********.

 

The ********* ** ********* *** ********* ***** **** **** ************* **** ****
******* ** ******** **** *** *********** ******* **** *** ***** ** *** *** **
*** ***** ** ***** *** ******** ****** ******* *** ****** *** ** ******
*********.

 

Example ** ******** ****** ******* *** ******

 

****** *** ******** ****** ******* *** ** $****, *** *** ******** *************
*********** *** ********** ** * ********* ** $****.  **** ****** *** **********
*** **** **** *** ********** *** ***** *** *** *********** ** $******, *** ***
****** ** ********* *********** ** *** ******** ****** ** ********* *** ***
******  *** ******** ******** ****** ******* *** ***** ** $**** (******** ******
******* *** ** $**** **** *** $**** ** ************* ***********).  *** ********
****** ******* *** ****** ***** ** $****** (******** ******** ****** ******* ***
** $**** **** $****** ********** *** ********** *** ****).  *** ******** ******
******* *** ****** ***** ** $******* (********* ******** ****** *********
*********** ********** ** *** ******** ****** ******* *** ****** ** $******).

 

(d) The Acquired Entity ******* *** ****** ***** **** ** ********* ***** ***
******** ****** ********* *********** ****** *** *********** *** *** ********
****** ********* ** *********** *** ****** ********* ****** ** *** ******** **
** ***** ***** *** ******** ****** ******* *** ****** ** ******** *** ******
**** *** ********** *******    **** *** ********* ** *** ******** ******
********* ********** *** ******** ****** ******* *** ****** **** ** ******** **
*** ***** **** ******** ***** ********** ** *** *********** ******* *****
******** **** ** *** ********* ** *** ******** ****** ********* ********* ******
***** *** ***** **** ******** ***** ********** ** *** *********** ******* *****
**** ****** **** ** ******* **************  ** ********** *** ************** **
*** ******** ****** ******* *** ****** ** *** ******** ****** ******** ***
******** ****** ******* *** ****** ********** *** *** ***** ***** **** **
******* ** *** ********* *****’* ******** ******’* ********  ** *** ***** ***
******** ****** ********* ** ********** *** ***** ** *** *********** ********
****** ******* *** ****** **** ** **** ** ********* ********* ** ** ********* **
*** ******** ****** *********.  

 

Example of ************* ** ******** ****** ******* *** ******

 

****** *** *********** ******* **** ** ******* *** *****  **** *** ********* **
*** ******** ****** ********* ********** *** ***** ***** *** ******** ******
******* *** ****** ***** ** ********* ***** ** *** *** ***** ** ********
*****  *** ******** ****** ******* *** ****** ********** *** ******** **** *****
**** ** ******* ** *** ***** **** ******** ****** ******* ********  *** ****
****** ***** ** ********* *** **** **** ***** ***** **** ** ******* ** ***
****** **** ******** ****** ******* ******* (**** *** (*) ****** ** *******
*******).

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

(e)  In negotiating the Acquired Entity Agreement Amendment, CSG and the
Acquired Entity shall consider the potential impact of the ***** ******* ****
********** *** as outlined in Schedule F, Section ******, and the *** *********
****** outlined in Section **** will also be considered, as these are an
integral part of the Customer’s ******* *** fee.

 

(f)  As a matter of clarification, ***** *** ******** ****** ********* **
*********** *** ******** ****** ***** ******** ** ** ******** *** *** ********
*** ******** ******** ***** *** ******** ****** ********** ******* ****
********* ** *** ******** ****** ********* ********** *** ******** ****** *****
** ******** **** ** ******** ****** ******* *** ****** ** ********* ******.

 

4.8

If Customer acquires subscribers from another entity without acquiring such
entity, the Parties shall ********* ** **** ***** ** ********* ** **** *********
** ***** **** ******** *********** ***** **** ********* ** *** ***********.  The
Parties acknowledge and agree **** **** ******** *********** ***** ***** **
******* **** *** *** ********** ***** **** ********* ** *** ***** **** ********
***** ********** ** *** ******* ** *** *********** ** **** ************ *******
** **** *********** ***** ******* ***** **** ********* ****** ****** (**) ******
(** **** ***** ****** ** **** ****** ** ** *** *******) ** *** ******* ** ***
*********** ** **** ************ ******** **** *** **** ******** ***********
********** ** * *** ********* *** ******* ***** *** *** ********** **
*********** ***** ************* ******* ** ***** ********* ** **** ******* *.

 

 

4.

Amendment to Article 5 (Payment Terms)

 

The Agreement is amended by deleting Section 5.4 (Adjustment to Fees) in its
entirety and replacing it with the following:

 

5.4Adjustment to Fees.  Effective January 1 of each year of the Term, fees
included in this Agreement shall be increased annually by an amount equal to the
****** **: (1) ***** ******* (**), or (2) the ******* ******* ** *** ********
****** ****** (******** ** *** ***** **** ** ******** ** *** **** ******* ****),
***** ** ***’* ******, of the ********* (“***”) ********* ***** ****** *****
********** *** ****** ******** ********** ********* ** *** **** ********** **
***** ** *** ********* ***** (“Annual Adjustment to Fees”).  The Annual
Adjustment to Fees shall be communicated to the Customer no later than December
1 of the preceding year, but in no event shall Customer be relieved of the
increase should CSG fail to provide timely notice described herein.  

 

The Annual Adjustment to Fees applies to the fees set forth in this Agreement,
with the following exceptions:

 

a)

The ******* ***, as set forth in Schedule F, Section *** entitled
“**********”.  The annual fee adjustments for these Services have already been
considered within the structure of the pricing tables, and thus, no Annual
Adjustment to Fees is applicable for these items.

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

b)

The ***** ******* *** *** ***, as set forth in Schedule F, Section *** entitled
“***** ******* *** *** *** ***********” until ******** *** ****.  Thereafter,
the ***** ******* *** *** fee shall be subject to a ***** ****** ********** **
**** ********* ******* ** ****, and for each applicable year thereafter.  There
is ** ****** ********** *** **** **** ***** ** ******* ** ****.

 

c)

The **** **** **** ********* *********, as set forth in Schedule F, Section ***
entitled “**** **** **** ********* *********”.  There is no Annual Adjustment to
Fees for this item during the Term of the Agreement.

 

d)

The ********* *********** ***, as set forth in Schedule F, Section ***. entitled
“****** ********* (***** *** ****)”, subsection ***. entitled “*********
*********** ***”.  There is no Annual Adjustment to Fees for this item during
the Term of the Agreement.

 

e)

The ***** *** *********, as set forth in Schedule F, Section ***. entitled
“****** ********* (***** *** ****)”, subsection ***. entitled “***** ***
*********”.  There is no Annual Adjustment to Fees for this item during the Term
of the Agreement.  CSG may increase the fees payable by Customer for ***** ***
********* (“*********”) at any time based upon the ****** ** a) **********
******* ** ********* ***** **** *** ** ****** ***** ** *** **** *** *********
******* or b) ****.  For the purpose of determining ********* fee increases,
“****” shall mean the ******** **** ******** ** * ******* ***** ******** *****
********* ** **** *** **** *** ***** *** ***** ******* ***** ******* ******
***** ******* *** *** ******* *** ******** ***** ***** * ******** *********
******** *** ******* ***** ****** *** **** ****** ************ (** ******* ***
***), *** *** **** **** ******** ** *** ********.  

 

In addition, the Parties agree that in the event CSG sells all or substantially
all of its stock or assets, or is under the control of an acquiring entity, any
increase in the fees for ********* ***** ** ***** **** *** ****** of a)
********** ******* ** ********* ***** **** *** ** ****** ***** ** *** **** ***
********* *******, or b) ****, or c) *** ******* (**).  In the event the **** is
replaced, the Parties will discuss in good faith a replacement measure.  

 

f)

The ******* ********** ***, as set forth in Schedule F, Section ***** entitled
“******* ********** ***” shall not be adjusted under this Section 5.4 until ****
*** ****.  Thereafter, the ******* ********** Fee shall be subject to Annual
Adjustment to Fees effective **** ** ****, and for each applicable Contract Year
thereafter through the Term of the Agreement, including any extensions
thereof.  

 

g)

The ******** ******* ****** **** *** *** *** ***** ********* *********** ***
*****, as set forth in Schedule F, Section *** entitled “******** ******* ******
**** *** *** *** ***** ********* *********** *** *****”. There is no Annual
Adjustment to Fees for this item during the Term of the Agreement.

 

 

5.

Amendment to Article 6 (Termination)

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

(a)

The Agreement is amended by deleting subsections 3 and 4 of Section 6.2 C. in
their entirety and replacing them with the following:

 

3.

*** ************** ** ********* *********** ******* ** ********* ***********
****** ***** *** ********* ** * ****** ** *** *********** ** ******** ***
******** ******** ******** **** **** ************** *** **** *********
********** ** ******** *** ****; ****

 

4.

*** ****** ** ********* *********** ***** ** *** ***** ** ******** *** **
********’* ******* ***********; ****

  

5.

*** ****** ** ********* *********** ***** ** *** ***** ** ******** *** ** ***
*********** ** *** *** ******** *******.

 

(b)

The Agreement is amended by deleting subsection 3 and 4 of Section 6.2 D. in
their entirety and replacing them with the following:

 

3.  *** *** ****** ********* ***** ** **** ** ******** *** ***** *** *****
************ ****** ***** ** ********* ** *** ******* (*********) *********
*********** *** * ********** ***** ** *** ******* **** ******* ********
(*********) ********* ***********.  

 

4.  *** *** ****** ********* ******* ** **** *** ****** **** *** **** *** *****
************ ****** ***** ** ** ****** ***** ** *** *** ***** ******* ****
******* ******** (*********) ********* *********** *** ***** **** *** ****
******* *** ********* ** *** ***** *** ***** ************ ****** ***** ** **
****** ***** ** *** ** *** ********* ********* ***********.

 

(c)

The Agreement is amended by deleting Monthly Subscriber Commitment Shortfalls
and its example under Section 6.2 D. in its entirety and replacing it with the
following:

 

******* ********** ********** ***********   ** *** ***** ** ***** *** ******
******* ********* *********** *** **** **** *** ******* ********** **********
(“******* ********** ********** *********”), ******** ****** ** *** ***
********** ******* **** ** *** ***** ** *** *********** *** ***** ******** **
******* **** (*) ** *** ********* ********** ** *** ******* **********
********** **********  ****** *** ****** ********* *********** ****** ***
******* ********** *********** ***** ***** *** ** * ******* **********
********** ********* *** **** ******  *** ************* ** *** ********** ***
**** *** ********** ****** ********* ** *** ***** ** ******** *** ******* ****
*** *** ********** ****** **** ** ***** **** *** ******* ** ********’* ******
********* *********** ** *** ******* ********** *********** ***** ******** ***
****** ** ************ ** **** ********** ********* *********** ** *** ***** **
*** **** ********* ** ********** ****** (********* ************ ******) ******
“**”.

 

** *** ** ******* ***** ** ** ***** ** ** *** **** *** ***** ****** ** ******
******* ********* *********** ** ********** *** *** ******* **********
********** ** *********** ***** ***** ** * ******* ********** **********
********* ** ********* ********* *********** *** **** ******  ** * ******* **
******** ** *** *** **** ******* ** ******** *** *** ********** ******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

********* *********** ***** *** ***** ** **** ********** ******** ***** **** **
*********** *** *** ******* ** *** ******* ********** ********** ********* **
********* ********* *********** ********** ** *** ********** ******* **** **
$****** (** ******** ** *** *********** *** ***** ** **** (*)), ** $**********
*** **** *****.  

 

6.

Amendment to Article 8

 

The Agreement is amended by deleting Section 8.1 in its entirety and replacing
it with the following:

 

8.1

Limited Warranty.  CSG warrants that the Products will (i) conform to CSG’s
published specifications in effect on the date of delivery, and (ii) perform in
a certified Designated Environment substantially as described in the
accompanying Documentation for a period of ****** (**) **** after the date of
delivery.  CSG warrants that, for a period of one year from the date the
applicable Technical Services are performed, such Technical Services were
performed in a professional and workmanlike manner.  CSG provides any Third
Party Software that is not Embedded Third Party Software AS IS.  Other than as
expressly set forth in this Section 8.1, Customer acknowledges that the Products
and any such Third Party Software may not satisfy all of Customer’s requirements
and the use of the Products and such Third Party Software may not be
uninterrupted or error-free.  CSG further warrants that it has not knowingly
inserted, or knowingly allowed to be inserted, and will use all commercially
reasonable efforts to prevent insertion, into the Products, Services or
Recurring Services, and the medium in which the Products, Services or Recurring
Services, and other materials are provided to Customer by CSG, any program,
information, code and commands, including viruses, bombs, worms, backdoors or
Trojan horses (i) that are designed to cause the Products, Services or Recurring
Services or any of Customer’s software or hardware systems to malfunction,
self-destruct or deny services, (ii) that are designed to cause damage to or
degrade performance of any computer, network, or any information, program or
data contained therein, or (iii) that are designed to enable or allow
unauthorized access to any of Customer’s software or hardware systems, or to any
Confidential Information (as defined below) of Customer  or Customer Data. With
respect to Customer’s access to Products, Services, or Recurring Services or to
any CSG hardware or software, Customer  warrants that it will use all
commercially reasonable efforts to prevent insertion of any program,
information, code and commands, including viruses, bombs, worms, backdoors or
Trojan horses (i) that are designed to cause the Products, Services or Recurring
Services or any of CSG’s software or hardware systems to malfunction,
self-destruct or deny services, (ii) that are designed to cause damage to or
degrade performance of any computer, network, or any information, program or
data contained therein, or (iii) that are designed to enable or allow
unauthorized access to any of CSG’s software or hardware systems or to any
Confidential Information (as defined below) or Customer Data.

 

7.

Amendment to Article 9 (Limitation of Remedies and Damages)

 

The Agreement is amended by deleting Sections 9.2 and 9.3. in their entirety and
replacing them with the following:

 

9.2 No Consequential Damages/Limitation of Liability.  

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

EXCEPT FOR *************** *********** *** ***** ** ******* * OR * ****** **
****** ***** ** ******* ** (***************), UNDER NO CIRCUMSTANCES WILL EITHER
PARTY OR THEIR RELATED PERSONS, LICENSORS OR VENDORS BE LIABLE TO THE OTHER FOR
ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE OR INCIDENTAL DAMAGES OR LOST
PROFITS, WHETHER FORESEEABLE OR UNFORESEEABLE.  

 

EXCEPT FOR **** ******* ** *** *** ****** ******* ** *********** ******* **
******** *** (*********** ********** *** ******** ****), *** ******* ***
(************ *********), ******* ** (***************) OR ****
(**************/********), IN NO EVENT WILL THE LIABILITY WHICH CSG, CUSTOMER,
THEIR LICENSORS OR THEIR VENDORS INCUR UNDER THIS AGREEMENT EXCEED ******
******* *** **/*** ******* ($*************) *** **** ******** **** (“DIRECT
DAMAGES CAP”).  ANY AND ALL CLAIMS (OR SERIES OF RELATED CLAIMS) ARISING DURING
A PARTICULAR CONTRACT YEAR OF THE TERM SHALL BE SUBJECT TO THE APPLICABLE
LIABILITY LIMITATION FOR SUCH CONTRACT YEAR AS DESCRIBED HEREIN.  THE PARTIES
AGREE THE DIRECT DAMAGES CAP SHALL BE ********* ** *********** ******* ***
**/*** ******* ($*************) UPON CSG PROCESSING ******** ******* *********
***********, THE DIRECT DAMAGES CAP SHALL BE ********* ** *********** *******
*** **/*** ******* ($*************) UPON CSG PROCESSING *********** *******
********* *********** AND THE DIRECT DAMAGES CAP SHALL BE ********* ** *****
******* *** **/*** ******* ($*************) UPON CSG PROCESSING ****** *******
** **** ********* ***********.  IN ADDITION, THE PARTIES AGREE THAT SHOULD
CUSTOMER DE-CONVERT CONNECTED SUBSCRIBERS THE DIRECT DAMAGES CAP SHALL BE
REDUCED TO THE SAME LEVELS PROVIDED IN THE PRECEDING SENTENCE, BUT IN NO EVENT
SHALL THE DIRECT DAMAGES CAP BE LESS THAN ****** ******* *** **/*** *******
($*************). THE APPLICABLE DIRECT DAMAGES CAP SHALL BE DETERMINED AS OF
THE DATE OF THE EVENT GIVING RISE TO THE CLAIM. IN THE EVENT THAT THERE ARE
MULTIPLE CLAIMS IN A CONTRACT YEAR, AND SUCH CLAIMS OCCUR UNDER DIFFERENT DIRECT
DAMAGES CAP AMOUNTS, IN NO EVENT SHALL THE DIRECT DAMAGES CAP ACROSS SUCH
MULTIPLE CLAIMS BE CUMULATIVE.

 

THE AFOREMENTIONED EXCLUSIONS AND LIMITATIONS OF DAMAGES SHALL BE INDEPENDENT
OF, AND SHALL SURVIVE, ANY FAILURE OF THE ESSENTIAL PURPOSE OF ANY WARRANTY OR
LIMITED REMEDY STATED HEREIN, AND SHALL APPLY EVEN IF THE LIABLE PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

9.3Pay-Per-View Liability.  

 

 

(a) Notwithstanding anything to the contrary herein, ***’* ***** ********* ****
******* ** **** ************ *********** *** *** *** *** ******* ******** ******
** ******** ******** ** ******** ******* ******** ** ********** *** ** ***’*
********** ** ************ *********** ** ********** **** ************
******  (“*** ******”) ***** ** ******* ** *** ****** ******* ******** ********
** ******** *** ****** ** ***’* ********** ** *** ******** ** ****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

************ ***** ********* ***** ** ******* ** *** *********** *** ***** **
******* *** *****.

 

(b)

Notwithstanding anything to the contrary herein, ***** *** ** ********** ***
******** **** ******* (*****) ** **** ************ ** ********** **** *
************ ***** ***** **** * *** ***** (“*** *****”), ***’* ***** *********
*** *** ******* ******** ****** ** ******** ******** ** ******** *******
******** ** ********** *** ** ***’* ********** ** ************ *********** *****
** ******* ** *** ****** ******* ******** ******** ** ******** *** ****** **
***’* ********** ** *** ******** ** **** ************ ***** ********* ***** **
** ***** ****** *** ******* ******** ******* ($**********) *** *** ***** (“***
***** ***”).  ******** ******* ****** **** ***’* ********* ** ********** ****
*** ********** ** *** *** **** *********** *** *** ****** ****** *** ********
**** ***** *** ****** **** ******* ******** ******* ($**********) (“********
**** *** ***”).  ** *** ***** *** ** ********** **** **** *** ******** ****
******* (*****) ************ ** ********** **** * *** ****** **** ***’*
********* ***** ** ******* ** *** *********** *** ***** ** ******* ***
******  *** ******** ** **** ******* **** “*** ******” ***** *** *******
*************** ******* *** ******* ***** *** *** ***** *** *** ******** ****
*** *** ***** ** ********* ************ ** *** ******* ***** ******** *******
($**********) *** *** ******* *********** ******** ******* ($**********) ****
*** ********** ******** ******* ********* ************ *** *** ***** *** ***
******** **** *** *** ***** ** ********* ************ ** ***** ******* *****
******** ******* ($**********) *** ***** ******* ************ ******** *******
($**********) **** *** ********** *********** ******* ********* *********** ***
*** *** ***** *** *** ******** **** *** *** ***** ** ********* ************ **
**** ******* ******** ******* ($**********) *** *** ******* *******
($************) **** *** ********** ****** ******* ********* ************  **
********* *** ******* ***** **** ****** ******** ********** *********
************ *** *** ***** *** *** ******** **** *** *** ***** ** ******* ** ***
**** ****** ******** ** *** ********* ********* *** ** ** ***** ***** *** ***
***** *** ** **** **** *** ******* ******** ******* ($**********) ** ***
******** **** *** *** ** **** **** **** ******* ******** *******
($**********).  *** **** ********** ** *** ***** ***** **** ***** **** *******
***(*) ***** ** ********** ** ** *** **** ** *** ***** ****** **** ** ***
******  ** *** ***** **** ***** *** ******** ****** ***** **** ******* ***(*) **
* ******** ***** *** **** ****** ***** ***** ********* ******** **** *** ***
******** ** ** ***** ***** *** ******** **** *** *** ****** **** ****** **
***********

 

(c)

CSG further agrees that, ** *** ****** ** ********* *********** **** *** ****
***** ***** ******* (*********) ****** *** ****** ****** ********* *** *****
****** **** ** * ***** ***** **** ******* **** ***’* ********* *****
************ ***(*) ***** ** *** ******* ***** ******** ******* ($**********)
*** *** ***** (“*** *** ***** ***”) *** ***’* ********* ********* ***** ** *****
******* ***** ******** ******* ($**********) *** *** ****** ****** *** ********
**** (“*** ******** **** *** ***”). *** ******* ***** *** *** *** ***** *** ***
*** ******** **** *** *** ***** ** ********* ************ ** ***** *******
****** ******** **** ******* ******* ($**********) *** **** ******* ************
******** **** ******* ******* ($**********) **** *** ********** ******** *******
********* ************ *** *** *** ***** *** ***

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*** ******** **** *** *** ***** ** ********* ************ ** **** *******
************ ******** **** ******* ******* ($**********) *** *** ******* *****
******* ****** ******** **** ******* ******* ($************) **** *** **********
*********** ******* ********* *********** *** *** *** *** ***** *** *** ***
******** **** *** *** ***** ** ********* ************ ** **** ******* ********
******* ($**********) *** *** ******* **** ******* ******** ($************) ****
*** ********** ****** ******* ********* ************  ** ********* *** *******
***** **** ****** ******** ********** ********* ************ *** *** *** *****
*** *** *** ******** **** *** *** ***** ** ******* ** *** **** ****** ********
** *** ********* ********* *** ** ** ***** ***** *** *** *** ***** *** ** ****
**** *** ******* ***** ******** ******* ($**********) ** *** *** ******** ****
*** *** ** **** **** ***** ******* ***** ******** ******* ($**********). ***
**** ********** ** *** ***** ***** **** ***** **** ******* ***(*) ***** **
********** ** ** *** **** ** *** ***** ****** **** ** *** ******  ** *** *****
**** ***** *** ******** ****** ***** **** ******* ***(*) ** * ******** ***** ***
**** ****** ***** ***** ********* *** ******** **** *** *** ******** ** ** *****
***** *** *** ******** **** *** *** ****** **** ****** ** **********.

 

(d)

*** ****** **** ** *** ** ******** ** ********** **** ***’* ********** **
************ *********** ** ********** **** **** ******* *** ***** ** ** ***
**** ** * ****** ******* ** *** ** ********’* ******* ******* ****
****  ******** **** ****** *** ** ******* ****** ***** (**) **** ** ***
********* ** *** *****(*) ****** **** ** * ***** ***** **** ******* ****  **
****** ****** ** *** ******** ** *** ****** **** ***** (**) *** ******* ****
******** ****** **** *** ***** **** ** ********* ********** *** ******* *******
**** ***’* **** ** ********* ********** **** ************ ********** ****** ***
****** ** ******** ** ******** ** ********* **** *****************  *** ******
***** ********* ** ******** ***** ******* *** ******* ********* *** *** ** *****
* ********* *****  **** ******* ***** ** *** ***** ************ ********** ****
******* ** ******* *** ******** ** ********* *********** ******* **** **
*********** ** ******** **** ***** **** **** ** *** *********
**********  ******** ************ **** *** ******* ******* ** ******** *****
**** ******* ***(*) *** ******* ** ***’* ***** ** ******* ** ******* ***.  

 

8.

Amendment to Article 10 (Confidential Information)

 

The Agreement is amended by deleting Article 10 in its entirety and replacing it
with the following:

 

ARTICLE 10

 

CONFIDENTIAL INFORMATION

 

10.1

No Disclosure.   Each Party agrees that during and after the term of this
Agreement, neither the receiving Party nor any person, firm, corporation or
other entity affiliated with, owned in whole or in part by, employed by or
otherwise connected with the receiving Party, shall directly or indirectly,
without the express written consent of the disclosing Party, divulge, use, sell,
exchange, furnish, give away, or transfer in any way any Confidential
Information (as hereinafter defined) of the disclosing Party, unless otherwise
expressly provided for in this Article 10.

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

10.2

Purpose of Access. Each Party acknowledges that any Confidential Information
that has been disclosed to it by the disclosing Party, or that the receiving
Party has come into possession of, has been disclosed solely for the purpose of
enabling the receiving Party to perform its obligations hereunder.  Each Party
agrees that all Confidential Information, whether provided by the disclosing
Party prior to or after the commencement date hereof or that the receiving Party
otherwise comes into possession of, is the exclusive property of the disclosing
Party and, in addition, CSG further agrees that all of Customer’s subscribers
are and shall remain customers of Customer, until or unless Customer de-converts
such subscribers to another provider for whom CSG provides billing services.

 

Customer shall indemnify, defend and hold harmless CSG, its Affiliates,
successors and assigns from any and all third-party claims, demands,
liabilities, costs or expenses, including reasonable attorneys’ fees, resulting
from Customer’s access to or use of Former Subscribers’ Customer Data retained
by CSG during the Customer-specified data retention period.  

 

10.3

Compelled Disclosure. If either Party is served with any form of process
purporting to require the disclosing Party to disclose any Confidential
Information to any third party, the receiving Party shall immediately notify the
disclosing Party who shall, in addition to the receiving Party’s similar
efforts, if any, have the right to seek to quash such process.  The receiving
Party shall cooperate with the disclosing party in a commercially reasonable
manner to quash such process or otherwise to limit the scope of any required
disclosure.  

 

10.4

Confidential Information Defined.  The term “Confidential Information” shall
include, without limitation, information provided to a receiving Party by a
disclosing Party that the disclosing Party designates as confidential;
information provided to CSG by Customer that Customer designates as
confidential; this Agreement (and all amendments thereto) and all of its terms
and conditions; all manuals and training materials provided to CSG by Customer
or provided to Customer by CSG; the names, addresses, e-mail addresses,
telephone numbers, government issued identifiers, and financial and payment and
related identifiers of all past, present, and subsequently acquired Connected
Subscribers to any product or service offered by or in conjunction with
Customer, as well as all other personally identifiable information relating to
such Connected Subscribers and Former Subscribers as further defined by
applicable local, state or federal regulations or law and applicable generally
accepted industry standards (collectively “PII”), subject to section 10.2 above
and section 10.5 below; any other information relating to any Connected
Subscribers, Former Subscribers, and Customer or CSG employees, including all
lists or other records containing any such information, even if such information
is aggregated; and all financial, technical, business, and credit information
relating to Customer, including without limitation, all market analyses and
market expansion plans, all revenue and profit analyses and projections and all
commission structures and statements; all technical information provided by
Customer, including, without limitation, all implemented or planned product and
service improvements or changes, and all information about Customer’s network
configuration, plant or any equipment attached thereto; and all other
information relating to the operations of Customer which was disclosed or
provided to CSG or became known to CSG through its relationship with Customer;
all other information not generally known to the public relating to Customer;
each Party’s trade secrets, know-how, design, inventions, plan or process;
information relating to its business operations, services, Products, research,
and development; each

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Party’s vendors’ or licensors’ information and products; and all other
information that the receiving Party should reasonably know from the markings or
the circumstances of disclosure to contain confidential information.  The
obligations of confidentiality and restriction on use in this Article 10 shall
not apply to any Confidential Information that:

 

(a)

was lawfully in the public domain prior to the date of this Agreement or
subsequently lawfully came into the public domain through no fault of the
receiving Party;

 

(b)

is rightfully obtained by the receiving Party from a third Party authorized to
make such disclosure without restriction or being in breach of any
confidentiality duty owed to the disclosing Party or an affiliate of the
disclosing Party;

 

(c)

is required to be disclosed in a judicial or administrative proceeding, but only
for purposes of such required disclosure, and only after all reasonable legal
remedies for maintaining such information in confidence have been exhausted
including, but not limited to, giving the disclosing Party as much advance
notice of the possibility of such disclosure as is practical so that the
disclosing Party may attempt to stop such disclosure or obtain a protective
order concerning such disclosure; or

(d)

is independently developed by or for the receiving Party without reference to,
access to, or use of the Confidential Information disclosed to it under this
Agreement.

 

10.5

Subscriber Information.  CSG hereby acknowledges that Customer has a
responsibility under the law to keep PII private and confidential.  CSG also
acknowledges that the PII to which it will have access pursuant to this
Agreement (if any) constitutes Customer Confidential Information and that CSG in
no way possesses or shall gain possession of any ownership or other proprietary
rights with respect to such PII.  CSG acknowledges and understands that PII is
subject to the subscriber privacy protections set forth in Section 631 of the
Cable Communications Policy Act of 1984, as amended (47 USC Sec. 551) (“Section
631”), as well as other applicable local, state and federal regulations and laws
and applicable information industry standards, provided however to the extent
that Customer informs CSG of a local law expanding the foregoing definition of
PII, CSG shall only be required to use commercially reasonable efforts to comply
with such expanded local requirements.  CSG agrees that it shall use all such
information in confidence, and in connection with its receipt and use of such
information, it shall perform its obligations under this Agreement in strict
compliance with applicable requirements of Section 631 (e.g., excluding (i)
requirements to provide a subscriber with access to his/her PII, (ii)
requirements to draft privacy notices to subscribers regarding the cable
operators collection, use and disclosure of subscriber PII, and (iii)
requirements that apply to actions or obligations that CSG does not undertake
under this Agreement) and all other applicable laws, rules and regulations
governing the use, collection, disclosure, storage and disposal of such
information.    CSG further agrees to restrict disclosure of such PII to those
currently existing CSG sub-contractors with a need to know and who are bound by
confidentiality restrictions that are materially similar to those herein and
shall not further disclose such information to any third Party except at the
direction of or with the prior written consent of Customer.  As of the Effective
Date, CSG shall cause all CSG employees and newly hired sub-contractors to be
bound by confidentiality provisions at least as restrictive in all material
respects as those contained

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

herein.  In addition, CSG shall cause all renewals of any agreements that CSG
has in place with its subcontractors to include confidentiality provisions at
least as restrictive in all material respects as those contained herein.   CSG
shall be liable for any breach by CSG of the confidentiality provisions
contained in this Article 10, regardless of whether such breach was caused by
CSG and its employees or any CSG vendor or subcontractor.  In addition, should a
security audit conducted by Customer pursuant to Schedule N reveal that any CSG
subcontractor is out of compliance with the confidentiality provisions contained
in this Article 10, then Customer shall have the right to cause CSG to cease
using such contractor on any matters in which such subcontractor may come into
contact with any PII.  Customer agrees that at all times during the term of this
Agreement, in connection with its performance under this Agreement, it will
comply with its obligations under all applicable privacy and other applicable
laws in relation to Subscriber Information, and where required by law, Customer
will either obtain the appropriate consents or provide the necessary
disclosures, as applicable, from its subscribers prior to such collection, use
and disclosure to CSG.

 

10.6

Usage and Employee Data.  Confidential Information shall include any and all
data relating to account activity and Subscriber usage of products and services
or other information collected from or about or otherwise regarding Connected
Subscribers (“Usage Data”) or a Party’s employees (“Employee Data”), in each
case whether in individual or aggregate form.  Such Employee Data or Usage Data
is and shall remain the property of the disclosing Party.  To the extent that  a
receiving Party has access to or collects such Usage Data or Employee Data, it
does so solely on behalf of  the disclosing Party  pursuant to the receiving
Party’s  obligations hereunder and shall maintain the confidentiality of such
data as required in this Article 10 and shall treat it in accordance with
applicable law.  A Party shall not use Usage Data or Employee Data for any
purpose other than to perform its obligations under this Agreement and shall not
disclose such data, whether in aggregate or individual form, to any third party.
A Party shall not collect or maintain such Usage Data or Employee Data except to
the extent necessary to perform its obligations under this Agreement.  

 

10.7

Security.  

(a)

CSG shall employ commercially reasonable controls for and shall limit access to,
and shall render unreadable prior to discarding, all records containing Customer
Data.  All Employee Data, PII and Usage Data that is collected, stored or
otherwise maintained by  a receiving Party  pursuant to this Agreement shall be
maintained in a secure environment that meets or exceeds prevailing industry
standards, taking into consideration the type of data and the services provided
hereunder, and that is subject to an information security program that contains
administrative, technical and physical safeguards reasonably designed to prevent
unauthorized access to and disclosure and use of Confidential Information and
Customer Data and reasonably designed to protect the security and
confidentiality of  Confidential Information.  Any PII, Employee Data or Usage
Data that is collected or obtained by a receiving Party must be stored and
transmitted in encrypted or otherwise secure form.  In the course of providing
services under this Agreement, CSG may obtain access to or otherwise store,
process or transmit payment card information of Connected Subscribers and Former
Subscribers.  In connection therewith, and in addition to its obligations under
subsections (a) and (b) hereof, CSG shall comply with PCI DSS rules and
standards applicable to a Level 1 Service Provider  in connection with CSG’s

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

networks, facilities, employees and operations.  CSG will provide to Customer,
as requested, evidence of its compliance as a Level 1 Service Provider with the
PCI DSS requirements and its registration as a Service Provider with the Card
Networks.    In addition to the foregoing, in connection with the performance of
its obligations, CSG shall comply with Schedule N and the Exhibits attached
thereto, to the extent applicable to CSG under the circumstances.

 

(b)

In the event of  an actual breach of security, or if a receiving Party suspects
based on reasonable evidence available to it that a breach of security of any
system, website, database, equipment or storage medium or facility in the
control of that party or its subcontractor or vendor may have occurred and has
resulted or may result in an unauthorized use, access, disclosure, acquisition
or loss of PII or Customer Data in the possession or control of CSG or its
vendor or subcontractor, (i) the Party with such knowledge shall notify the
other Party promptly after discovery or notification, in the most expedient way
possible and without unreasonable delay, consistent with applicable law
enforcement requirements or any measures necessary to determine the scope of the
breach and restore as soon as reasonably possible the integrity of the system,
(ii) CSG shall take all such action as may be required under law, by the Card
Networks or under rules applicable to CSG or as required under this Agreement,
and in any event shall use its best efforts to secure its system as soon as
reasonably possible; and (iii) CSG shall cooperate with Customer, the Card
Networks, and law enforcement authorities, as appropriate, and keep Customer
informed as to its investigation and remediation efforts.   In the event
Customer obtains any data of employees or other customers of CSG, Customer shall
be subject to the terms of this Section, as applicable, with regard thereto.  

 

(c)

In the event that there is a breach or reasonably suspected breach of security
as described in 10.7(b) of the Agreement, or Customer has a good faith belief
that CSG’s conduct in the performance of the Services may be in violation of
applicable law and could give rise to liability for Customer , Customer or its
designee will have the right, upon reasonable written notice and subject to
CSG’s reasonable security procedures and the confidentiality requirements of the
Agreement, to conduct a review of the books, records, operations and facilities
of CSG or its third party subcontractors or vendors to determine or verify CSG’S
compliance with its security and confidentiality obligations under this
Agreement and compliance with applicable law to the extent non-compliance could
give rise to liability for Customer.  Such audit shall include inspection of the
books and records and all other documents, materials and equipment and
facilities in the possession or control of CSG and its subcontractors and
vendors that relate directly to CSG’s compliance with the security and
confidentiality requirements herein and compliance with applicable law to the
extent non-compliance could give rise to liability for Customer, but shall not
include details of CSG’s security infrastructure except as may be required by a
card network, which will be provided to the card network as requested.  Customer
shall have free and full access thereto for such purposes that are within the
scope of the audit

 

 

(d)  

In the event of any breach as described in section 10.7(b), if Customer is
required by a Card Network or its card processor to have a third party forensics
expert conduct an examination of CSG’s security related to Card transactions,
upon

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

reasonable notice and subject to CSG’s reasonable security procedures, CSG shall
permit any person acceptable to that Card Network or card processor and CSG to
examine and audit the records, operations and systems directly relevant to such
inquiry.  The scope and standards of such examination will be determined by the
Card Network requesting it, and CSG agrees to cooperate with such Card Network
and forensic examiner.  After receiving the results of the examination, which
may include identified audit deficiencies, CSG further agrees to work with
Customer and the Card Networks in good faith to (i) promptly take such
corrective action to sufficiently remediate any  audit deficiency in order to be
in compliance with the PCI DSS standards, or (ii) to the extent permitted under
PCI DSS standards, employ sufficient compensating or mitigating controls to
remedy any identified breaches of the Agreement or deficiencies that could
reasonably be expected to lead to a breach of security of card data.  

 

(e)

CSG shall be responsible for all data security and compliance with law with
regard to that portion of the Kiosks within CSG’s Point of Demarcation (as
defined in Schedule L).

 

10.8

Remote Access.  To the extent that CSG is authorized by Customer to gain remote
access to Customer’s networks or equipment for purposes of performing its
obligations hereunder, CSG shall ensure that (a) such access is restricted to
authorized employees, subcontractors and vendors; (b) it provides Customer with
a list of all such authorized employees, subcontractors and vendors at
Customer’s request; (c) such remote access is used solely for purposes of
fulfilling CSG’s obligations under this Agreement; (d) such remote access is
obtained through a secure connection; (e) CSG uses such remote access capability
only to access equipment or software that is directly involved in CSG’s
performance of its obligations hereunder and does not access any other Customer
or third party systems, databases, equipment or software; and (f) CSG complies
with the provisions of Schedule N as applicable to this subsection.  Upon
Customer’s request, CSG will provide updates on the results of periodic security
audits of its access system and methods and will change authentication elements
periodically to maintain the integrity and security of CSG’s access as long as
such access and change does not cause a disruption to CSG’s business.

 

To the extent that Customer is authorized pursuant to this Agreement to gain
remote access to CSG’s networks, systems, facilities or equipment,  Customer
shall ensure that such access is restricted to authorized employees,
subcontractors and vendors whose access is required for purposes of this
Agreement.  Customer agrees further that any remote access to CSG networks,
systems, facilities or equipment will comply with CSG’s reasonable security
practices and controls that CSG will provide to Customer and as may be amended
by CSG from time to time, upon reasonable notice to Customer.  

 

10.9

Publicity. Except for disclosures required by law or outlined herein, each Party
will submit to the other all public disclosure(s), advertising and other
publicity matters relating to this Agreement in which the other Party’s name or
mark is mentioned or language from which the connection of said name or mark may
be inferred or implied, and will not publish or use such advertising or
publicity matters without the express prior written approval of the other Party,
said approval shall not be unreasonably withheld or delayed.  Regardless of
anything to the contrary herein, CSG may, without the prior written consent of
Customer, make reference to the existence of this Agreement and use Customer’s
name and mark on CSG’s customer reference lists, in CSG’s newsletters, in

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

CSG’s disclosure documents submitted to the SEC and posted on EDGAR, and on the
websites of CSG or its parent company.  The Parties agree that CSG shall provide
Customer the redacted version of this Agreement and related documents (which
shall not include letters seeking confidential request or a filing on form K or
a filing on form Q, as applicable) to be filed with the Securities Exchange
Commission and filed on EDGAR and allow Customer no less than *********** (**)
***** review prior to CSG’s filing.

 

10.10

Destruction/Return of Information. Upon the expiration or termination of this
Agreement and, except as permitted in Section 1.7, upon payment of Undisputed
Fees or charges, or during the Term of the Agreement, upon the disclosing
Party’s request, the receiving Party shall return all (or such portion of)
Confidential Information to the disclosing Party or at the disclosing Party’s
option, destroy or return all (or such portion of) Confidential Information upon
such timetable as may be mutually negotiated in good faith by the Parties, but
in any case no more than ****** (**) **** of the date of implementation of such
return or destruction activities.  Upon completion of such activities, the
receiving Party shall provide, a written certification signed by an officer of
the receiving Party, certifying that all Confidential Information in all
formats, including without limitation, paper, electronic and disk form, and all
backup copies thereof,  have been returned or destroyed, as the case may
be.  The requirements of this Section 10.10 shall not be applicable to the
extent necessary to be retained by a Party in the performance of its obligations
expressly provided for herein, provided, that such information shall be returned
or destroyed in compliance with this section upon completion of any such
additional performance.  

 

10.11  Indemnity Injunctive Relief.  Each Party will indemnify, defend and hold
harmless the other Party and its respective Affiliates, and respective
directors, officers, employees and representatives from and against all claims,
damages, losses , liabilities, costs, expenses and reasonable attorneys’ fees
arising out of such Party’s breach of any portion of this Section 10.  Each
Party understands and agrees that the other Party will suffer irreparable harm
in the event that the receiving Party of Confidential Information breaches any
of its obligations under this Section 10 and that monetary damages will be
inadequate to compensate the non-breaching Party.  In the event of a breach or
threatened breach of any of the provisions of this Section 10, the non-breaching
Party, in addition to and not in limitation of any other rights, remedies or
damages available to it at law or in equity, shall be entitled to seek a
temporary restraining order, preliminary injunction and/or permanent injunction
in order to prevent or to restrain any such breach by the other Party.

 

10.12  Compliance with Law.  In addition to any obligations of the parties in
Section 12.16 of the Agreement:  (i) CSG agrees that in connection with CSG’s
provision of the Products and Services and performance of its obligations under
this Agreement, it will not violate any applicable privacy, data security or
consumer protection laws and regulations; and (ii) Customer agrees that in
connection with Customer’s use of the Products and Services and performance of
its obligations under this Agreement, it will not violate any applicable
privacy, data security or consumer protection law and regulations.

 

 

9.

Amendment to Article 11 (Equitable Relief and Meetings)

 

The Agreement is amended by deleting subsection 11.1 “Governance and Steering
Committee” in its entirety and replacing it with the following:

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

11.1  Intentionally Left Blank.

 

 

10.

Amendment to Article 12 (General Terms and Conditions)

 

(a)

The Agreement is amended by deleting Section 12.3(b) in its entirety and
replacing it with the following:

 

(b)

*** ******** ** **** *********, (*) *** “************** ***” ***** ******* **
*** *** ** *** ********** ************** *** *** *** ***** *** ****
************** *** *** **** ******** **** ********* ** *** **** (** ******* ****
*******), ** **** **** ** ******* *****.

 

o

“********** ************** ***” ***** ** *** ******* ** *** **************
******* ********** ** *** *********** **** ********** ** *** ****** ** ******
********* ** *** ************ **** ** ** *** ********* **** ** ***********.

§

*** “************** ******” = ********** ***** ***** ************* (** *******
** ******* ***(*)) ***** *** *** ** *** *********:

·

*** ***** ****** ** ********* *********** ********* ****** *** ****** ***** **
*** ****** ** *********** *** ** ******* ********* (** ********** ** ******* ***
******* ********* ********** **********) ** ******** ***********; ****

·

*** ***** ****** ** ********* *********** ********* ****** *** ****** ***** **
*** ****** ** *********** *** ** ** *** ************* ******** **** **** ****
*** ************* ** *** ******* ** ********* *********** ****** ***** ***
********* ** * ****** ** *** *********** ** ******** *** *********.

§

*** “*********** ***” ***** ** *** ********** ******* **** ** ** *** **** **
****** ** *********** ** *** ***** ** *** ***** ***** ******** “*********** ***
*****”.

 

*********** *** *****:

*********** ** ****/**** ** *******

***** *** (*) ******* *****  ****** (**)

***** ******** (**) ******* ***** *********** (**)

***** *********** (**) ******* ***** ********** (**)

***** ************ (**) ******* ***** *********** (**)

***** ********** (**) ******* ***** ********* (**)

********** *** ***** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*********** ** ****/**** ** *******

***** *** (*) ******* *****  ****** (**)

***** ******** (**) ******* ***** *********** (**)

***** *********** (**) ******* ***** ********** (**)

***** ************ (**) ******* ***** *********** (**)

***** ********** (**) ******* ***** ********* (**)

********** ** ********** ********* *********** (***

********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ************ ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********** ** ********** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********* ** ********* ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********* ** ********* ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********* ** ********* ********* *********** (*** ********* *********r)

$******

$******

$******

$******

$******

********* ** ********* ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********* ** ********* ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

********* *** ***** ********* *********** (*** ********* **********)

$******

$******

$******

$******

$******

 

*** “***** *** **** ************** ***” ***** ** ********** ** (*) ***
************** ******* ********** ** ************ ******* (***), ********** **
$****** (***** ****** ***** ** ******* ** ******* **** ********** ** ****),

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*** **** ********** ** *** ****** ** ****** ********* ** *** ************ ****
** ** *** ********* **** ** ************ **** (**) *** **** ** ******** ******
********* (** ********’* ********* *** ****** ******** ****** ********* *** **
********* ** *** ** ******* ** ********* ******** ***** ******* ** ********).

 

(b)

The Agreement is amended by deleting the example contained in the second
paragraph of Section 12.3 (c) in its entirety and replacing it with the
following:

 

** *** ** ******* ***** ****** *** *********: (*) ******** *** **********
********* *********** ** *** **** ** ********’* *********** ************ ** ***
*** ******** ********** **** ********* ** ********** ** ********** (*) *****;
(**) *** ************** ****** ** ********** ** **** ********** *** *** *******
***** ** *** ***** ***** *** *********** *********** *** ********* ************;
*** (***) *** ********* **** ** *********** ** ** ** **** ***** ***
************** *** ****** ***** *** *********** *** ****** ** $***************
********** ** ******* (***** *** *** ** **** ******):

 

******

****** ** ****** ********* ** *** ******* ** *** **** ******* ** *** **********
************** ****

************** ******

*********** *** (*** *** *********** *** *****)

******* ** *** *******

**** **** ******* ******** ****

*

**********

$******

$*************

***** **** ******* ******** ****

**

**********

$******

$*************

******* **** ******* **** ****

*

*********

$******

$*************

********** ************** ***

 

 

 

$**************

 

* ***** **** *** ***** *** ********** ************** *** ***** ** ****** **
**********.

 

******

****** ** ****** ********* ** *** ******* ** *** **** ******* ** *** ***** ***
**** ************** ***

************** ****** ********** ** ***

***** *** **** *** *

********

**** **** ******* ******** ****

*

**********

$******

$************

***** **** ******* ******** ****

**

*********

$******

$************

******* **** ******* **** ****

*

*********

$******

$************

***** *** **** ************** ***

 

 

 

$***************

 

***** *** ************ ******** **** *** ** ***** **** *** **** ** *****
******** ***** ******* ***** ** **** *** *****  ****** **** **** ** ***** ** ***
************ **** ** ****** ** *** **** ** *** ***********.

 

 

***** ************** *** ***** **** *******:

 

·********** ************** ***$**************

·***** * **** ************** ***   $***************

***** ************** ***$**************

 

******:    *** ******* ***** **** ** *** ***** *** ** ****** ** ****** ********
****** ********** *** *** ******* *** ***** *** **** ******** ****** *********
** ******** ** *** ***** ************** ***.

 

(c)

The Agreement is amended by adding the following subsection (f) to Section 12.3
Discontinuance:

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

(f) The Parties acknowledge and agree that the **** **** **** *********
********* provided in Schedule F is a ******** ********* **** *** ***** ****
***** *** ******* **** ******* **** **** **********

 

(d)

The Agreement is amended by deleting Section 12.16 in its entirety and replacing
it with the following:

 

12.16

Compliance with Law; No Assumption of Obligations.  In connection with its
performance under this Agreement, each Party, and all of its Products, Services
and Deliverables, shall comply with, and each Party agrees that its performance
under all Schedules and Exhibits hereto is subject to, all applicable federal,
state, and local laws, rules and regulations, and all amendments thereto, now
enacted or hereafter promulgated in force during the term of this
Agreement.  Unless agreed otherwise in this Agreement or a Schedule, nothing in
this Agreement shall be construed as requiring a Party to assume any of the
other Party’s obligations, responsibilities or liabilities under applicable law,
regulations and rules, and neither Party shall be obligated to validate or
perform any investigation into the other Party’s compliance with laws.  Each
Party will indemnify, defend and hold harmless the other Party, its Affiliates,
successors and assigns from any and all third-party claims, demands,
liabilities, costs or expenses, including reasonable attorneys' fees
(“Liabilities”) resulting from a violation by the indemnifying Party of this
Section 12.16 of this Agreement.  The foregoing shall be subject to and limited
by the terms of Section 9.2 No Consequential Damages/Limitation of Liability.

 

 

11.

Amendment to Schedule A (Definitions)

 

(a)

The Agreement is amended by adding the following defined terms to Schedule A:

 

“Amendment Effective Date” shall mean July 1, 2014, which applies to the Ninth
Amendment entered into by the Parties under CSG document #2504963.

 

“Card Network” shall mean **** **** ***** ********** ************** ********
******* and ******** ****.

 

(b)

The Agreement is amended by deleting the definitions of “ACH Funds,” “Data,” and
“Unclaimed Funds.”

 

(c)

The Agreement is amended by deleting the definition of “Customer Data,” and
replacing it with the following:

 

“Customer Data” shall mean PII, as defined above, and any and all documents,
data, files or other information provided to CSG by Customer, its subscribers,
or to the extent that Customer Data is provided by other third parties on behalf
of Customer, or its subscribers, or is developed or obtained by CSG in its
performance under this Agreement and pertaining to subscribers, including and
not limited to compilations, summaries or the derivative information processed,
created or maintained by CSG relating thereto.  Without limiting the foregoing,
Customer Data shall include *** ********** ****** **** (********* **** *******
******** *** ******* ******), ***************** ******* (********** ********
****** *** ****** (**) **** *********** ***** ** *** ******** ** **** *******),
***** ****** ***** *** *** ***** ******* **** **

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

***** **** ** *** ** *** ******* or subcontractors on behalf of
Customer.  Customer Data shall at all times remain the sole and exclusive
property of Customer.  Customer Data shall include data maintained by CSG by
virtue of this Agreement on current Subscribers and Former Subscribers (for
periods when they were subscribers or customers).

 

(d)

The Agreement is amended by adding the definition of “Former Subscriber” as
follows:

 

“Former Subscriber” shall mean a customer or subscriber that is no longer an
active user of Customer’s services, whether or not the customer has been
de-converted to another entity.

 

12.

Amendment to Schedule C and associated Exhibits (Recurring Services)

 

(a)

The Agreement is amended by deleting Exhibit C-3(f) (Stored Payment Instruments)
in its entirety.

 

(b)

The Agreement is amended by deleting Section 5 (Non-Production ACP Services) of
Exhibit C-1 (Advanced Convergent Platform (ACP)) in its entirety and replacing
it with the following:

 

5.   Non-Production ACP Services.    All SysPrins will have data processing
functionality equivalent to those SysPrins used to provide the production ACP
Services described in section 1 of this Exhibit.  Each test SysPrin shall be
limited to a maximum of *** ******** (*****) ********** ******** before per
subscriber monthly service fees are assessed in accordance with Schedule F for
subscriber counts in excess of *** ******** (*****).  

 

(c)

The Agreement is amended by adding the following to Exhibit C-1:

 

No more than **** ** *** ****** ***** ******, Customer may request and CSG shall
provide Customer with access to *** ********** *** ******* ************* *****
******** ******** ** ***’* ******** ******** *********** ************* ***
************* ************.  As part of such a meeting, the Parties shall
discuss communications and notice procedures in the event of a disaster.

 

(d)

The Agreement is amended by adding the following new Section 5 to Exhibit C-4
(CSG Care Express Service Bureau):

 

5. Run Book.  CSG and Customer agree to ******* ****** *** ** ********* ******
** *********** *** **** (“*** ****”) which shall be mutually agreed upon by both
Parties for Care Express as it relates to CSG’s Kiosk Product only on a
********* *****.   The *** **** shall be approved by the Parties within *** (*)
****** of the Amendment Effective Date.  In the event the *** **** has not been
approved by the CIO of CSG and the CIO of Customer, the Parties shall escalate
the matter as provided in the Agreement or the Migration SOW to executive
management of the respective Parties for resolution.

 

(e)

The Agreement is amended by deleting Exhibit C-13 (Intelligent Business
Reporting) in its entirety and replacing it with the following:

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Exhibit C-13

 

InfoCast Files

 

InfoCast Files are scheduled applications that create data extracts which are
compressed, (if necessary) encrypted, and sent to an FTP directory maintained by
CSG on behalf of Customer (“InfoCast Pick Up Site”).  CSG authors the logic to
create the report files from Vantage data and enhances or modifies the logic in
the event the Vantage data objects change.  InfoCast Files applications can be
scheduled to run intraday, daily, weekly, monthly, or at specific
intervals.  Customer accesses the InfoCast Pick Up Site to retrieve the
extracted data.  CSG maintains the extracted data on the InfoCast Pick Up Site
until the earlier of pick up by Customer or *********** (**) *****.  CSG also
maintains a backup copy of each extracted dataset for *** ******* ****** (***)
*****.  At Customer’s request, CSG will restore a backup copy of an extracted
dataset to the InfoCast Pick Up Site.  See Schedule F in the Agreement for
applicable service fee per restoration.

 

 

13.

Amendment to Schedule F (Fees)

The Agreement is amended by deleting Schedule F in its entirety and replacing it
with the new Schedule F attached to this Amendment.  The fees provided in
Schedule F shall be effective on the Amendment Effective Date.

 

14.

Amendment to Schedule H (Support Services for the Products)

 

The Agreement is amended by inserting the following as an additional provision
at the end of Schedule H, Section I (Strategic Business Unit):

 

CSG and Customer agree to hold ******* ********* ****** ******** **** **********
** ***’* ***** ********* ******* *** ***** ********** ******* *** ********** **
****** ** ******** ** ********’* ***** ********* ******* ** ***** ***********
*******.  In addition, CSG and Customer agree to **** ** * ******** *******
***** **** *** *** ********’* ********** ***** ********* ******** **
**********.  The ******** may include, but not be limited to, such things as
******** ******* ** *** ********* **** ********* ****** *** *** *******
********* ***’* *********** ************ *** ***’* ******* **** *** *** *******
******** *********.

 

15.

Amendment to Schedule K (Guidelines for Passer and Transfer Program Requests)

 

The Agreement is amended by deleting the final paragraph of Schedule K in its
entirety and replacing it with the following:

 

During the Term, *** ***** ******* ******** * ***** ** ***** ****** *** ********
***** *** *** ** ****** *** ***** ******** ******* ******** ** ******** **
******** * (“** *****”).  Such Services shall be documented in a mutually
agreeable Statement of Work and will be provided to Customer ** ** **********
*******  ** *** ***** **** ******** **** *** ******* *** ***** ** ***** ** ***
******** ***** *** ********* ** ***** ***** ** **********  ** *** ***** ****
******** ******** **** **** ***** ***** ** *** ******** *****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

******** **** *** *** ***** *** ***** ** ******** * *** **** ******** ** ******
** *** ** *****.  CSG agrees ** ******** *** ****** ** ** ***** ** ***** *****
**** ******** ********* ********** ********* ************ ***** ** ***** ****
******** ********* ********** ********* *********** *** ***** ** ***** ****
******** ********* ********** ** **** ********* ************  *** ********** **
***** ***** ** ******** ******** ** *** ** ********** **** *** ***** ** ****
******** *.  Further the Parties agree that any necessary Passers or Agent
Transfers which are necessary to support the Migration SOW (********* ******* **
******* ** *********** *****), as determined by CSG, shall be ** ** **********
****** ** ******** *** ***** *** ********* ** ******** *** ** ****** ** ***
***** ** * ******* ******* *** ******* **** *** ********* ** ******* ** *****
********* ** ******* *** ********* **** *** ******* ***** ****** *** *******
********** ********** *** ***** ** *** ********* ****  *** ******** **
*********** *** ****** ** ** ***** ********** *** ***** *** *** ****** **
********* *********** ** *** ***** ***** ** **** ******** ******* ** *********
*** ****** ** ** ***** ********* ********** **** ******** ******* ** ****
******** **** ** * ******** *****.

 

16.

Amendment to Schedule L (Performance Standards and Remedies)

 

The Agreement is amended by deleting Schedule L in its entirety and replacing it
with the new Schedule L attached to this Amendment.  

 

 

17.

Amendment to Schedule N and associated Exhibits (Partner Connection
Requirements)

 

The Agreement is amended by deleting Schedule N, Section 1.2 in its entirety and
replacing it with the following:

 

1.2

Audit and Inspection of Records.  CSG will engage an independent external
auditor who is subject to CSG’s reasonable confidential and security procedures
to conduct an audit in accordance with SSAE16, in conjunction with the Services
provided to Customer under this Agreement.  On an ****** *****, CSG shall
provide Customer with a copy of CSG’s most recent SSAE16, but shall not be
required to include detail of CSG’s security infrastructure.  

 

Prior to *** ****** ***** *** ********** ******** ** ********, CSG and Customer
agree to utilize existing assessment reports and certifications (SSAE16 and PCI
Certification), to validate CSG’s compliance with confidentiality requirements
provided in Section 10 and security and privacy requirements set forth therein
and in Exhibit N-1.   In the event such reports and certifications are unable to
provide reasonable assurance of the security and privacy requirements, Customer
may ******* *** ****** ********** ** ********* CSG’s compliance with security
and privacy requirements set forth therein and in Exhibit N-1. ******** **** **
*********** *** *** ***** ********** **** *** *********** ** ******. CSG will
reasonably cooperate in all such audits or assessments.  Customer (or through a
third party designated by Customer) may ******* ******* *********** ** ***’*
********** ****** ****** ******** ****** **** *** (**) ******** ****’ ****** ***
******* ** ********** *************** *** ******** ************  **** ******
***** ** ********* ** * ******** ****** **** **** *** ***** ** ********* ******
* ************ ********** ****** ** ****.  If audit results find that CSG is not
in substantial compliance with security and

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

privacy requirements set forth therein and in Exhibit N-1, then ******** *****
** ******** ** ******* *** (*) ********** ***** ** **** **** ** ********** ****
*** ********* ********* ** **** ******** ******** **** ******* ** *** * **** **
**** ****** ******** ** ********** **** *** **** ***** ****** ***** (**) ****
*** ******* ******** ********* *** *********** ***** *** ************ **
********** *********  *** ****** ** (*) ******** **** ****** ** *** ******* **
******* ***** ******* ** ***** ********** ** *** **** ***** **** ******* ** ****
********* ********** **** *** ******** ********** ** *** ******** *** *******
************ *** ***** ******* *** ** ******* *** ** (**) ******** **********
************ ** ********** ********.

 

 

18.

Amendment to Schedule Q (Scenarios Illustrating Monthly Subscriber Commitments
and Related Items)

 

The Agreement is amended by deleting Schedule Q in its entirety and replacing it
with the new Schedule Q attached to this Amendment.

 

19.

Amendment to Schedule R (Governance and Steering Committee Members)

 

The Agreement is amended by deleting Schedule R in its entirety and replacing it
with the new Schedule R-1 (Common Stock Purchase Warrant) and R-2 (Registration
Rights Agreement) attached to this Amendment.

 

20.

Section II, Subsections 1 through 6, of the Second Amendment to the Agreement is
hereby deleted in its entirety and replaced with the following language and the
associated Fees shall be provided for in Schedule F:

 

(a)

Schedule C, Recurring Services, of the Agreement shall be amended to add the
following to the list of Recurring Services:

 

WFX Scheduling…………………………………………………….Exhibit C-30

WFX Resource Allocation Manager………………………………..Exhibit C-30

 

(b)

Additionally, Schedule C, Recurring Services, of the Agreement shall be further
amended by adding thereto the attached Exhibit C-30

 

(c)

CSG and Customer agree that CSG will provide ** ******* ************** ****
********'* ********** *********** *** ********'* *********** ******(*) ("**(*)")
(*** "******* **************") *** * ***** ****** (*** "***** ******") ** **
********* ** * ********* ** **** ** ** ******** ** *** *******.

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

21.

Additional Amendments

 

(a)

The Agreement is amended by deleting all references to the “Stored Payment
Instruments.”

 

(b)

The Agreement is amended by deleting all references to “Intelligent Business
Reporting” and replacing them with “InfoCast Files.”

 

(c)

The Agreement is amended by adding the following as a new Section f) Kiosk PCI
Responsibilities to Attachment A to Exhibit C-4 under Module E- Branded Payment
Kiosk:

 

f)  Kiosk PCI Responsibilities.  CSG and Customer agree the provision and use of
the Kiosk Product and its related Services shall be in accordance with each
Party’s respective responsibilities provided in the Kiosk PCI-Security document
which shall be binding on the Parties, subject to the terms of this Agreement
and may be updated from time to time by mutual agreement of the Parties.  The
Kiosk PCI-Security document (document #2507493) shall be updated periodically to
identify roles and responsibilities related to the Kiosk Product in a manner
consistent with then-current industry standards and PCI-DSS standards.  Any
modification or revision of the Kiosk PCI-Security document shall be approved by
the CIO of CSG and the General Counsel of Customer.  In the event the Parties
are unable to agree upon any modification or revision to the Kiosk PCI-Security,
the Parties shall escalate the matter as provided in the Agreement or the
Migration SOW to executive management of the respective Parties for
resolution.  CSG acknowledges and agrees that it is responsible for cardholder
data which it possesses or stores in relation to its Kiosk Product and related
Services.

 

 

IN WITNESS WHEREOF the Parties hereto have caused this Amendment to be executed
by their duly authorized representatives.

 

COMCAST CABLE COMMUNICATIONS MANAGEMENT, LLC (“CUSTOMER”)

 

CSG SYSTEMS, INC. (“CSG”)

 

By:  /s/ Peter Kiriacoulacos

 

By:  /s/ Randy Wiese

 

Name: Peter Kiriacoulacos

 

Name:  Randy Wiese

 

Title:  Executive Vice President & Chief Procurement Officer

 

Title:  CFO / EVP

 

Date:  July 22, 2014

 

Date:  July 25, 2014

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

List of documents attached to the 9th Amendment

 

 

Schedule FFees

 

Schedule LPerformance Standards and Remedies

 

Schedule QScenarios Illustrating Monthly Subscriber Commitments and Related
Items

 

Schedule R-1

Warrant Document entitled “Common Stock Purchase Warrant”

 

Schedule R-2Registration Rights Agreement

 

Exhibit C-30WFX Scheduling and WFX Resource Allocation Manager

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule F

FEES

 

INDEX

 

 

 

DEFINITIONS

 

I.

Processing

A.

Basic Services Charge (herein after referred to as “BSC”) for Non-Rated Video
and Non-Rated High-Speed Data and Residential Voice Services

B.

***** ******* *** *** *** ***********

C.

**** **** **** ********* *********

 

II.

Threshold Usage Items

A.

Data Processing, Smartlink BOS (“SLBOS”) and Event Notification Interface
(“ENI”)

1.

***** ******* **** ********** ***

2.

******* **** ********** *** *** *** ****** ***********

3.

******** ***** / *** ************ *** ****** (“***”) for New and Additional
Subscribers

4.

PVU Cost Management Committee

B.

BSC Threshold Level

 

III.

Direct Solutions (print and mail)

I.

AESP Statement processing

A.

Processing for AESP Statement Format

B.

Additional physical page

C.

Full Color Processing– Front and/or Back Side of Each Physical Page

D.

Additional logical page-ad/coupon

E.

Statement Composition Fee

II.

Customer letter processing

A.

Legacy customer letters

B.

Additional physical page for legacy customer letters

C.

Enhanced customer letters

D.

Additional physical page for enhanced customer letters

III.

Past due notice processing

A.

Legacy past due notices

B.

Enhanced past due notices

C.

Additional physical page

D.

Additional logical page-ad/coupon

E.

Modified generic/bilingual revision charge

IV.

Delinquency labels

A.

Spooled to site

B.

Printed 4-up labels

C.

Printed Cheshire labels

D.

Printed LAB labels

E.

Reports

V.

Inserts

A.

Printing services

B.

Processing

C.

Late insert notification

D.

Late arrival of Non-CSG printed inserts

E.

Holds or notification of insufficient inserts

F.

Returns to customer

G.

Destruction of inserts

H.

Affidavit

VI.

Other print and mail ancillary service fees

A.

Other print and mail ancillary service fees

B.

Support services

C.

Other services

D.

Mail Trace

E.

Braille/Large Print Statement Functionality

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

F.

Special Printer/Inserter Setup Fee

VII.

Paper and Envelopes

VIII.

Postage

A.

Statements

B.

Customer letters

C.

Past due notices and reminders

 

IV.

Ancillary Products and Services

A.

Ancillary services for Non-Rated Video and Non-Rated High-Speed Data and
Residential Voice Services

B.

CSG Care Express (Payment Kiosk) Module E

C.

Refund checks

D.

Check Verification

E.

Collections

F.

CSG’s Home Security Module (HSM)

G.

Configurable Lines of Business Functionality ("C-LOB Functionality")

H.

SLBOS / ENI Hardware / Data Processing - Software, Cost per PVU, and Data
Processing Fees

I.

Ancillary services for Workforce Management

J.

Third Party Software That May be Procured Through CSG

K.

Content Direct System and Services

 

V.

Technical Services/ Implementation Services/Training

A.

Technical Services/Professional Services

1.

Technical Services/Professional Services

2.

Services Commitment Fees

B.

Implementation and Startup Services

C.

Additional training and documentation

1.

User training at CSG facility

2.

Virtual classroom training

3.

On-site user training at Customer’s requested location

4.

Vantage training

5.

BCE Training Development-West Division

D.

Equipment Installation /Technical and Engineering Support Services

 

Schedule F-1: LISTING OF PRODUCTS AND SERVICES INCLUDED IN THE BSC

 

I.

Processing

II.

Interfaces

III.

Payment Procurement

IV.

Credit Management and Collections

V.

Manual and Programmatic Conversion Services

VI.

Additional training and documentation

VII.

Other Applications/Solutions

VIII.

CSG LICENSED PRODUCTS

IX.

MISCELLANEOUS

X.

DATA COMMUNICATIONS SERVICES

XI.

Network Services – timelines

 

Schedule F-2: PRICING FOR EXCESS BSC THRESHOLD LEVEL

 

A.

Precision eMail™

 

Schedule F-3: SUPPORTING EXAMPLES FOR SECTIONS I & II OF SCHEDULE F

 

 

 

 

 

 

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule F

FEES

 

DEFINITIONS

 

Definitions provided in this Schedule may be captured elsewhere in the Agreement
or in this Schedule, but in the event they are not defined in this Schedule,
they shall still have the meaning provided in the Agreement or Schedule F.

 

 

 

1.

Connected Subscribers – as previously defined in Schedule A, Definitions, means
an active subscriber as identified in the subscriber master file and ledger
activity report on the last processing day of a processing month.  ** * ***** **
************** ** *** ***** **** * ******** ** ********* **** **** *** *******
(**** ***** *** ***) ** * ****** ********** ******* ** *** **** ********** ***
** * ********** ****** **** ******** ***** ** ******* ** *** (*) *********
***********  ******** ** *** ***** **** * ******** ** ********* **** **** ***
******* (**** ***** *** ***) ** *** ******** ********** ******** ** *** ****
********** *** ** * ********** ****** **** ******** ***** ** ******* ** *** (*)
********* ************  ******** ************ **** ***** ***’* ********
********** ******** (“***”), ******** ********** ******** *** ******** ** ***
**** ** * ******** *** ******* ** **** ******** ********** ******** ** ********
** ******** ******** ***** ******** ** **** *********  ** ** ******** ** ***
***** **** * ******** ******* ** ******* **** **** *** ******* (**** ***** ***
***) *** **** ******* ** **** * ******** ********* (********** ** *****)
********* *** **** ******** **** ******** ***** ** ******** ***** *** ** ** ***
** ** *** ******** ********** ******** *** ********* ***** ** ******* ** *** (*)
********* ***********.  

 

2.

Additional Subscribers – as previously defined in the Article 4, Migration,
shall mean those subscribers of Customer’s residential services who are
receiving billing and account services from any platform other than CSG’s ACP
billing platform as of the date immediately prior to the date of their migration
to CSG’s ACP billing platform pursuant to the Migration SOW (excluding any New
Subscribers, hereinafter defined).    

 

3.

New Subscribers – as previously defined in Article 4, Migration, means other
subscribers brought (whether such subscribers were previously on a CSG platform
or a non-CSG platform and subsequently migrated to a CSG platform) under this
Agreement after the closing of a direct or indirect acquisition of (“Acquisition
Closing Date”) of one or more entities occurring after the Amendment Effective
Date, that are not currently included in the Migration SOW.  If Customer
acquires subscribers from another entity without acquiring such entity, the
Parties shall negotiate in good faith to bring such acquired subscribers under
this Agreement as provided by Section 4.8 of the Agreement as amended.

 

4.

Amendment Effective Date as previously defined in Schedule A (Definitions) shall
mean July 1, 2014, which is the effective date of the amendment entered into by
the Parties under CSG document #2504963.

 

5.

******* ******* *** *** ***** ***** $**********.

 

6.

***** ******* *** *** ***** ***** *** ******* ** *** ******* ******* *** ***
********** ** *** ******* *** *** ***** ** ********** **** **** ** ****.

 

7.

Connected Subscribers for Invoicing Purposes shall mean the ********** *******
1) ********* *********** ***** 2) ***** *** *********** ********.

 

8.

Planned Full Migration Subscribers Target ***** **** ********** *********
*********** *** ********* ********.

 

9.

New Subscribers Migrated During the Month shall mean those New Subscribers that
became a Connected Subscriber during the then current month.   *** *************
********* *** *** *********** ****** ** ******** ** *** ***** ** ***** *** ***
*********** *** ******* ***** **** *********; ** ********** ** ******* ***
(*********) ** *** ********** *** ** *** ******** ** * ********** ***** *** ***
******* ******* ******* ** ***** *** *********** **** *** ******  *** *******
******* ******* ** *** *********** **** *** ***** ***** *** ****** **** **** ***
******* ***** **** ********* *** ******** ** * ********* ********** ***** ****
*********; ** ********** ** ******* *** (*********) ** *** ********** *** ***
******** ** *** *** *********** *******.

 

10.

New Subscribers Migrated During Prior Periods shall mean the cumulative total of
New Subscribers that became a Connected Subscriber from the Amendment Effective
Date through the end of the prior month.

 

11.

Total New Subscribers Migrated shall mean the *** **: 1) *** ***********
******** ****** *** ***** *** 2) *** *********** ******** ****** ***** *******.

 

12.

Total Monthly Cap Subscribers shall mean the *** **: 1) ******* **** *********
*********** ****** and 2) ***** *** *********** ********.

 

13.

******* *** *** ***** ***** **** *** ******* **: 1) ***** ******* ***
*********** ******* ** ******* **** ********* *********** ******, or 2) ****.

 

14.

Transactions shall mean any transaction that processes through CSG’s billing
infrastructure regardless of originating source including a composite business
function (e.g., SLBOS call, ACSR function) and may be comprised of several
individual transactions.

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

15.

Items shall mean one or more service codes, including zero dollar tracking
codes, which Customer defines via CSG’s ACP back office and equates to one or
more products and services offered by Customer to its subscribers and are
related to each particular Connected Subscriber’s account.

16.

********* ************ *********** ****** ***** **** *** ********** ************
******** ** ** ****** **** ********* (***** *:** ** **:** *** **:** ** **:**)
****** *** ********* *****.

 

17.

********* **** ************ ***** **** *** ******** ****** ** ************
******** ****** *** ********* ************ *********** ******.

 

18.

Total Monthly Items shall mean the total number of Items at the end of each
respective invoicing month (i.e., the 21st of each calendar month) by summing
the total number of Items related to the number of Connected Subscribers for
each respective invoicing month.

 

19.

**** ********* *********** ***** ***** ********** ********* ***********.

 

20.

PVU shall mean processing value unit.

 

21.

******* **** *** *** ***** ********* *********** ***** ** *****.

 

22.

PVU Subscribers shall be the *** ** 1) ******* **** ********* *********** ******
*** 2) ***** *** *********** ********.

 

23.

******* ********* **** ************ ***** ** ***** ** *** ********* ****
************ ******* ** *** ****** ** 1) ********* *********** or 2) ***
***********.

 

24.

******* ******* ***** ***** ** ***** ** *** ***** ******* ***** ******* ** ***
****** of 1) ********* *********** or 2) *** ***********.

 

25.

******* ******* *** *** ***** ********* *********** ***** ** ***** ** *****
********** ** *** ******* of 1) ******* ********* **** ************ **********
** 2) ******* ******* *****.

 

26.

******* ****** *** *** ***** ********* *********** ***** ** *** ******* ** 1)
**** ** 2) ******* ******* *** *** ***** ********* *********** ***** *******
**** *** *** ***** ********* ***********.

 

27.

******** ********* *********** ***** ** *** *********** ***** ***** *** ** ****
**** ****, of 1) ********* *********** ***** 2) **** ********* ***********.

 

28.

******** ********** ****** ***** ********** ***** ** *** ******* of 1) **** **
2) **** **** *** ****** ** i) ******** ********* *********** ******* ** **) ****
********* ***********.

 

29.

******** ******* ****** *** *** ***** ********* *********** ***** ** *** *******
of 1) ******* ****** *** *** ***** ********* *********** ********** ** 2) ***
******** ********** ****** ***** **********.

 

30.

******* **** ********** *** ***** ** *** ******* of 1) ******** ******* ******
*** *** ***** ********* *********** ********** ** 2) ******** ******* ******
**** *** *** *** ***** (** ********** ** ******* ******).

 

31.

***** ******* **** ********** *** ***** ** *** ******* of 1) *** **** *******
***** ******* **** ********** *** ** 2) *** ******* ******* **** ********** ***
*** *** ***** ***** ** *** **** ******* ***** ********* **** *** ******* (**th)
***** ********* *** ********* ********* ****.

 

32.

*** ****** *********** ***** ** *** *********** ***** ***** *** ** **** ****
****, between 1) ********* *********** ***** 2) ***** ******* *** ***********.

 

33.

******* **** ********** *** *** *** ****** *********** ***** ** *** ******* of
1) *** ****** *********** ********** ** 2) **** ********** **** *** *** ******
********** (** ********** ** ******* ******).

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

I.

Processing

A.

Basic Services Charge (herein after referred to as “BSC”) for Non-Rated Video
and Non-Rated High-Speed Data and Residential Voice Services   

 

BSC Table for Connected Subscribers for Invoicing Purposes (as defined below)

 

*********** ** ****/**** ** *******

(*** ********* ********** *** ********* ********)

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

§** ** *********

$******

$******

$******

$******

$******

$******

$******

$******

§********* ** *********

$******

$******

$******

$******

$******

$******

$******

$******

§********* ** *********

$******

$******

$******

$******

$******

$******

$******

$******

§********* ** *********

$******

$******

$******

$******

$******

$******

$******

$******

§********* ** *********

$******

$******

$******

$******

$******

$******

$******

$******

§********* ** *********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** ** **********

$******

$******

$******

$******

$******

$******

$******

$******

§********** *** *******

$******

$******

$******

$******

$******

$******

$******

$******

 

*** ***** *** *** ***********

 

*********** ** ****/**** ** *******

(*** *** **********)

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

******* *** **** ******** ****

§***** *** ***********

$******

$******

$******

$******

$******

$******

$******

$******

 

*** ********* ****** ********* *** *** *** ********* ***** *** *********
********** **** *** *********** ***** ******** *** ******** *** ******** *****
**** *** ****** ** ********* *********** ***** ********* ** ****  ******* *** **
**** ******** * ******** * ******* ** ******** *** ******** ******** ** *** ****
** **** ** ********** ********** *** ******** ******** *** ******** ******** **
*** ****

 

1.

*** ******* *** *** ********* ***** *** ********* ********** **** ***
*********** ***** ******** *** ********* *********** ** *** *** ** *** ***
********* ************ ** *********** *(*) *** *(*) (******** ** ****** ***
“***** ******* ***”) ******* ** ********** ** ********** (*) ** **** *******:

 

a.

******** *** ****** ** ***** ******* ********* *********** ** * ***** ****** ***
******** **** **** ****** *** ***** *** *********** ******** **** *** **********
***** *** ********* *********** *** ********* ********* *** **** ******** ***
********* *********** *** ********* ******** ** *** ********** ******* *** ***
**** *********** ** *** ******* **** ** ***** ** *** *** ***** *** *********
*********** *** ********* ******** ***** *** *** ***** *****, ****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

b.

***** *** *********** ******** ********** ** *** ********** ******* *** *** ***
*** ********** **** ** ***** ** *** *** ***** *** *** *********** ***** *** ***
***** *****.

 

c.

** *** ********** ******* *** *** *** *** *** ***** *** ********* ***********
*** ********* ******** **** ** (*) ** **** **** ** ***** ** *** ********** ***
*** *** *** *** ***** *** *** *********** **** ** (*), **** *** ***** *******
*** ***** ** ********** ** ***** *** ********** ******* *** *** *** *** ***
***** *** ********* *********** *** ********* ******** **** ** (*) *** ********
**** ** *** ***** ******* ********* ***********.

 

******* * ** ***** ******* *** ***********

 

****** *** ****** ** ***** ********* *********** ** ******** **** ** ***********
*** *** ***** *** *********** ******** ** *****  *** ********* *********** ***
********* ******** ** ***********  *** ********** ******* *** *** ** ** **** **
*** *********** **** *** *** ***** *** ********* *********** *** *********
******** ***** ** ** *** ********** **** *** ***** ** $******.  *** ****** ***
*** *** ***** ** ******** **** ***** ********** *** ***** ***** ** $*********
(********** ********** ** $******).

 

*** ********** ******* *** *** *** *** *********** **** *** *** ***** *** ***
*********** ** $******.  ***** *** ****** ** ***** *** *********** ******** **
***** ***** ** ** ****** *** ***** ********** *(*) ***** *** *** ***** **
******** ****.

 

*** ***** ******* *** ** ********** ** **** ******* *** *** *** ***** **
******** **** ***** ** $*********.  

 

******* * ** ***** ******* *** ***********

 

****** *** ****** ** ***** ********* *********** ** ******* **** ** ***********
*** *** ***** *** *********** ******** ** **********  *** ********* ***********
*** ********* ******** ** ***********   *** ********** ******* *** *** ** **
**** ** *** *********** **** *** *** ***** *** ********* *********** ***
********* ******** ***** ** ** *** ********** **** *** ***** ** $******.  ***
****** *** *** *** ***** ** ******* **** ***** ********** **** ***** ***** **
$********* (********** ********** ** $******.).

 

*** ********** ******* *** *** *** *** *********** **** *** *** ***** *** ***
*********** ** $******.  *** ****** ** ***** *** *********** ******** **
**********  *** ****** *** ***** ********** **** ***** *** *** ***** ** *******
**** ** $********* (********* ********** ** $******).

 

*** ***** ******* *** ** ********** ** **** ******* *** *** *** ***** ** *******
***** ** $********** ($********* **** $*********).

 

******* * ** ***** ******* *** ***********

 

****** *** ****** ** ***** ********* *********** ** ******* **** ** ***********
*** *** ***** *** *********** ******** ** ***********  *** ********* ***********
*** ********* ******** ** ***********   *** ********** ******* *** *** ** **
**** ** *** *********** **** *** *** ***** *** ********* *********** ***
********* ******** ***** ** ** *** ********** **** *** ***** ** $******.  ***
****** *** *** *** ***** ** ******* **** ***** ********** **** ***** ***** **
$********** (********** ********** ** $******).

 

*** ********** ******* *** *** *** *** *********** **** *** *** ***** *** ***
*********** ** $******.  *** ****** ** ***** *** *********** ******** **
***********  *** ****** *** ***** ********** **** ***** *** *** ***** ** *******
** $********* (********** ********** ** $******).

 

***** *** ********** ******* *** *** **** *** *** ***** *** *********
*********** *** ********* ******** ($******) ** **** **** *** ********** *******
*** *** *** *** *********** **** *** *** ***** *** *** *********** ($******),
**** *** ***** ******* *** *** *** *** ***** ** ******* **** ********** *****
********** **** ***** ***** ** *** ******* ** *** ***** ********* *********** **
********** ********** ** *** ********** ******* *** *** **** *** *** ***** ***
********* *********** *** ********* ******** ** $****** ** $**********.

 

2.

*** ***** ******* *** *** ********** ** ******* * ***** ***** *** ****** ***
***** ******* *** ****  *** ***** ******* *** *** *** ** ******** ******** **
*** ***** ******** ** ******* **** ** **** ******** *.

 

******* ** *********** ** *** ***** ******* *** ***

 

****** *** ****** ** ***** ********* *********** ** *** **** ** *********** ***
*** ***** *** *********** ******** ** *****  *** ********* *********** ***
********* ******** ** ***********  *** ********** ******* *** *** ** ** **** **
*** *********** **** *** *** ***** *** ********* *********** *** *********
******** ***** ** ** *** ********** **** *** ***** ** $******.  

 

****** *** ***** ******* *** *** ** **** **** ** $********** ($********** *****
******* *** *** **** *** ****** ** ** ****** ********** ** ***** ***** ** *****
********* ******* ** ****).   *** ***** ******* *** *** ***** ** $*********** **
*** ***** ******* *** *** ********** ***** *** ****** ***** (***********
********** ** $****** ****** $**********) ***** ****** *** ***** ******* ***
***.

 

3.

*** ***** ******* *** *** ******** * ****** *** ********** **** *** *** *****
******* **** *** ********** ***** *** **** **** ******* *** ********** ****
******* ** *** **** **** **** ********* ********* (** ********** ** ******* ****
** ****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

******** *), *** ** ********* ***** ***** (** ********** ** ******* ** ** ****
******** *) ***** *** ********* *** **** ****** ****** ********* (** **********
** ******* **** ** **** ******** *), ********* ******** *** ******** (**
********** ** ******* *** ** **** ******** *), ********* ********/**************
********/******** (** ********** ** ******* ** ** **** ******** *), ** *** ***
******** ** ******** ****** ********* ****** ** *** ******* ** ******* *****
**** ****   *** **** ******* ** *** ********* ********** *** ******* *** *****
******* *** *** ************ *** **** ***** ** ** ******** ** *** ***** *******
*** ***.

 

B.

***** ******* *** *** *** ***********

 

1.

*** ***** ******* *** *** ***** ** ********** ** *** ***** ********* *** **** **
***** *** ********* *********** *** ********* ******** ** ********** ** *******
******* ***** ** ******* **** *** ******* **** ********* *********** ******.

 

** ** *** ********* ********* ***** *** ******* ******* *** *** ***** ***** ***
***** ******* *** ****  *********** *********** ** *** ***** ******* *** *** (**
***) ***** ** ********** ** *******:  ***** ******* *** *********** ******* **
******* **** *********** ****** ***** ***** *** ******* ** *** ******* *** ***
***** ** *****  *** ********* ******* *** *** ***** ** **** ********** ** ***
******* ******* *** **** ***** ***** ******* *** ***** ******* *** **** *****
***** *** ** **** **** *** ******* ******* *** ***.

 

2.

*** **** ******* ***** ******* *** *** ***** ** ******* ** ******** ******** **
******* **** ********** ** ***** ** *** ********* ********** ******* ** **** ***
**** ********** ******** **** ******* *** ********* **** ** *** **********
********* *** ********** ********  *** ****** ********** ** **** ** ***** **
**** ******** *** *** ***** ******* *** ***.

 

******* ** *********** ** ********** ** **** ******* *** ***** ******* *** ***

 

****** *** ********* ** ** *** **** ** ***********: *) ******* **** *********
*********** ****** ****** **********; *) ******* ******* *** *** ******
$**********; *) *** *********** ******** ****** *** ***** ****** *********; *)
*** *********** ******** ****** ***** ******* ****** ****; *** *) *** **********
*** ********* ******** ** ******* **** ********** ** ***** ** **** *** ***
******.

 

**** *: *** *********** ******** ****** *** ***** (*********) **** ***
*********** ******** ****** ***** ******* (****) ****** ***** *** ***********
******** ** *********.

 

**** *: ******* **** ********* *********** ****** (**********) **** ***** ***
*********** ******** (*********) ****** ***** ******* *** *********** **
**********.

 

**** *: ***** ******* *** *********** (**********) ******* ** ******* ****
********* *********** ****** (********** ****** ******* *** *** ***** (******)

 

**** *: ******* *** *** ***** (******) ********** ** ******* ******* *** ***
($**********) ****** ***** ******* *** *** ** $**********.

 

**** *: ******** *** ***** ******* *** *** ** *** ********** ******** ** *****
******** ** ******* **** ********** ** **** (********** **** *** *******
********* ***** ******* ** ****).  *** ******** ** ***** ******** ** *******
**** ********** ** ***** ** **** *** *** ******; ********** *** ***** *******
*** *** ** $**********.

 

C.

**** **** **** ********* *********

 

1.

*** **** **** **** ********* ********** ** ********* ****** ***** ** **********
**** ** *** ***** ******** ******** **** **** ********* ********** ************
***** ** *** ********** ** *** ******* **** ** *** **********  ** ******** ****
*** ******* ** ***** ********* ********** *********** ******* ** * *********
****** *** **** **** **** ********* ********* ***** *** ** ***********  **
*********** *** **** **** **** ********* ********* ***** ****** ********* ** ***
******** **** ** *** *********: (*) **** *** ******* ***** ** ******* **********
** ******** ** *** ********* *** **** *****; (**) *** ********** ** *** *******
****; ** (***) *** ********* ** ********** ** ******** ***** ** *** **********
** *** ******* **** *** *** ****** ***** **** ******** ** ******* ***(*),
******* ***(*), ******* *** (*), ** ******* **(*) ** ******** * *** ****
*********** ** ****** *********** ** ******** ** * ***** ******** ***** *****
******* *****  *** ******** ** *********** *** **** **** **** *********
********** *** ******** **** ********** ** *** ********* ******** ***** **
********** *** *********** **** (“*********** ****”).

 

2.

** ******** ***** ** ******* ** ***** ********* ********** *********** ** *****
** *** ********* *** ********** ** *** *th ********* ***** *** **********
******** ** *** ********* ******* * ** *** *********** ***** ******** ***** ***
* *** ***** **** *** ********* *********** (“**** **** **** *********
*********”):

 

a.

***** ****** ** ********** ******* ********* *********** **** *** *********
********* **** ******* *** *********** **** ********** ** $*** ****

 

b.

* ******* ****** ***** ** *** ***** ****** ** ********* *********** **********
** $**** ******* *** ********* **** ** **** *********.

 

3.

** ** **** ***** *** ********** ****** **** ** * **** **** **** *********
********* ****** $********** ******* *** **** ** **** ********** ******** ***
*** *********** **** ** ** *********** *** ********* ********* ** ********* ***
****** ******* ** **** ******** **** *** *********** ****** **** ********’*
******* ** ******* ********** *********** **

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

******** ** **** ********** ** (**** **** **** *********
*********).  ************ *** **** **** **** ********* ********* ** (*)
********** ******** *** *** * *******, (*) ********** *** *** ****************
** *** ******** ******* ** *** **** * ******* ** ******** ** ******* ** *****
********* ********** *********** ** ******** ** *** ********* **** *** (*) ***’*
**** *** ********* ****** *** ********’* ******* ** ******* ** ***** *********
********** *********** ** ******** ** *** ********* ***.

 

******* **** **** **** ********* *********:

 

****** *** ******** *** ******** ********* ********** *********** ** ***** **
*** ********* *** ** **** ***** *** **** ****** *** ** ******* *** ****
********** *********** ****** *** *****  *** ******** ** **** ******** **** ****
** *** *********** *****  ***** ****** *** ****** ** ********* *********** ***
****** **** ** ********** *** ***** ****** ** ********** ******* *********
*********** **** *** ********* **** ******* **** **** ** ************  *** ****
**** **** ********* ********* *** *** ****** **** *** ********* **** ** ***
*********** **** **** ** ** *******:

 

·

$********* (*********** ********** ******* ********* ********** ********** **
$***), ****

·

*** *** ***** ** ****** ***** *** *** *** ***** ****** **** **** *********
****** ****** *** ***** ***** ** $******* (********** ********* ***********
********** ** $****).

·

******** *** ***** ** *** ***** *** ************* ** ******* ** $********** ****
*** **** ** *** *********.

 

 

II.

Threshold Usage Items

A.

Data Processing, Smartlink BOS (“SLBOS”) and Event Notification Interface
(“ENI”)

 

1.

***** ******* **** ********** ***

 

*** ***** ******* **** ********** *** ***** ** ********** ** *** *********
****** *** *** **** ** **** ********* *** *** ******* ** *** ***** ******* ***
****  **** ********** ****** ***** *** ** ********** *** ******** ** ***********
*** ***** ******* **** ********** *** ***** ****** (**) ****** ********* ***
********* ********* **** (“***** ******* **** ********** *** ********* ****”) **
******* ** ******** ***** *** ***** ***** **** ********** *** ********* *****
*** *** ********* ** ****** *** ******* *********** *** ***** **** ****
*********** ***** *** ** ***** ** ********’* ***** **** *** ***** ***** ** ***
***** ******* **** ********** *** ********* ****.

 

**** *: ******* ****** ********* **** ************ *** ***** ******* ***** ***
*** ******* ******  *** ******* ***** ***** **** * ******* ********* ******
***** ******** ********** ******* ** ******* *** ************ ***** **** *******
***** **** ******* * ******** ********* ** *********** ***** **** ******** ***
********* **** *************  *** ***** ******* **** ****** ** ******** ** ***
*st ** **** *****.

 

**** *: ********* ******* ********* **** ************ *** ******* ******* *****

 

**** *: ********* ******* ****** ***’* *** ***** ********* ***********

 

**** *: ********* ******** ******* ****** *** *** ***** ********* ***********

 

**** *: ********* ******* **** ********** ***

 

**** *: ********* ***** ******* **** ********** ***

 

******* ** ***** ******* **** ********** ***

 

*** ******** *** *** ******* ******** ** *** ** ********* *** ***** ******* ****
********** ***

 

2.

******* **** ********** *** *** *** ****** ***********

 

*** ******* **** ********** *** *** *** ****** *********** ***** ** **********
** *** ***** ** ***** *** ***** ******* *** *** ******* *** ***** ******* ****
*** ********* ** ****** ** *** ***** ******* *** *** ** *** ********** ******
*** ********** ****** **** *** ***** ** **** ******* ***** *** ** ********** **
*** **** ************* *****.

 

******* ** ******* **** ********** *** *** *** ****** ***********

 

*** ******** *** *** ******* ******** ** *** ** ********* *** ******* ****
********** *** *** *** ****** ***********

 

3.

******** ***** / *** ************ *** ****** (“***”) *** *** *** **********
***********

 

*** ******** ** *********** *** ******** ***** / *** ******** ** ** ********* **
******** ***** *** ********* ********* ***** *** **** ***** / *** *** ** **
******** ** *** ***** ** *** *** ** ** *** ********* ********* **** (“****
***”).  *** ******* ******** ** ******** ***** ** ******** ********* ** *******
**** ******  *** **** *** ***** ** ******** ****** ** ****** *** **********
********** ** *** ********** ******** **** *** ****** ************ ** ***.

 

*** ******** ****** *) ********** *********** ****** ********** *) ***
*********** ****** ********* *** *) *** ****** *********** ****** ********** **
* ******* *** **** *** ***** ** ********* ** ********** (********* ****
********* ***** *********) ***** ** **** ** ********** ** ****** ** ***** **
******** ** *** **** *** ** *** *** ** * ******* **** *** ****** ** ***** (***
**** ***).

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

*** ********* ********* ** ******** ********* ********** *** ***** **** ********
*** ************ ******** ********** ** *** *********** **** **** *** ********
**** *** ** ******* **** *** ******* *** ******** ** ********* *** ***** ******
*** ******* *** *** ********** ***** / *** ***************** ***** ******* ****
***** ************ *** ***** *** ** ********* ** ****** ** ******** *** *******
*******.

 

*** ******** ****** **** ***** ** *** ********** ** *** ********** ** ***
************ ******** ********* ** ********** *** *** *** $***** *** **** **
******** ********’* *** ** *** (*** **** *** **** *** *********).  ***** (*)
****** ***** *** ******** ******** ******** ********* *** *** **********
*********** *** ******** ** ********** *** ** ******* *** ********
************  ** * ****** ** *** ********** ********’* **** *** ***** ********
*** *** (********* ********** ** ******) *** * ***** ** *** *** (*** **** ***
**** *** ******** **** ***).  ******** ** ***** ******* ******* *** ********* **
*** ********** *** ****** ******* ******* ******** **** **** ** ****** *** **
*** ** $***** *** ********* **** ****** **** *** ******** $******  ********
******** ***** *** ** ******** * ****** *** *** *** *** ********* ****.

 

4.

*** **** ********** *********

 

*** *** ******** ***** ** ********* * ********* ********* ** *** (**) ******
******* ** ** ***** ****** ** **** ** *** ******* (“*** **** **********
*********”).  *** ******* ********** ** *** *** **** ********** ********* *****
** ********** ** ***’* *** *** ***’* ************ *** ********’* *** ***
********’* ************ *** **** ******* **** ***’* *** *** ********’*
****  **** ********** *** ** ******* **** **** ** **** ** ******* **************
** *** *** **** ********** **********  *** ******* ******* ** *** *** ****
********** ********* ***** **** (“*** **** ********** ********* *******”) **
***** **** ****** *** **** *** ** * ******* ***** ********** ****** ***
********* ****** ** ****** *** ******* ********.  

 

*** ******* ***** **** *** *** **** ********** ********* ***** **** ** ****
***** ** ******** ************* ** ******* ******* *** ******** ********** **
***’* ******* *** ********’* ***** ** ***’* ******** *** ******** ** ***** ****
*****’* ***** ********** **** ****  *** ******* *********** **** **** ***** **
******* ** ******** ***** *** ******* ******* ** *** ***** **** ******* ******
********* ***** ****** *** **** ***** ** *********** ****** *** ****** ** *****
******** ***** *** ******* *** *** **** *** ***** **** *** ***** **** **** ***
***** *** ****** * ******** ******** ************ ** ******** ** *** ***** *****
**** ******** ** ******* ************  ** * ******* ** ** ***** * ***********
***** ****** *** **** ********** ********* ******** **** ***** ** ** ***** ****
** ***** *** ******* ***** ******** *** ******* *** ********* *********** ***
******* ** **** ***** ***** **** ******* ****** *** *** ******* ******* ***** **
**** ** **** ***** ** ******* * ********* ******** ** *** ***** ************
**** ** *** **** ********** ************ ************* ** ******** ** *** *****
*****.

 

B.

*** ********* *****

 

 

*** ******** *** ******** ******** ** *** *** *** ******** ** ******* ****
******  ******* ******** *** ******** ******** ** *** *** **** ******* *********
***** *********** (“*** ********* *****”), ***** *** **** ********** ** *******
**** ** *** ****** *** *** ********* ***** ** ******** ** *** ***** ***** *** *
********* ******* ** ******* **** ** ******** ** *** *** *** (“****** ***
********* *****”), ** ********** *** (“****** *** ********* ***”) ** *** *******
*** ***** ******* *** ****  *** ****** *** ********* *** ** ********** ***** ***
******* *** ****** *** ********* ***** (** ******** *** ********* ** *******
***).

 

 

III.

Direct Solutions (print and mail)

 

Description of Item/Unit of Measure

Frequency

Fee

I.AESP Statement processing (Refer to Section V.B entitled “Implementation and
Startup Services” for the fees associated with startup services, Section VII
below for the fees associated with custom paper and custom envelopes, and
Section VIII below for the fees associated with postage)

 

 

A.Processing for AESP Statement Format: First Physical Page (Duplex, Black Print
Only).  ******** ***** ******** **** ******** *** ********* ********* **
********* **** *** ********** ******** ** ****  ******** ********* *** ********
(*** ********** *** ****** *********)

 

 

§** ** ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** *** ******* ******* ******* **********

*******

$******

B.Additional physical page (Black Print Only) (*** ******** ***** *** ******
*********; **** *** ** ****** ***** **** ******* ******* ********* ******) (Note
1)

 

 

§** ** ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** *** ******* ******* ******* **********

*******

$******

C.Full Color Processing– Front and/or Back Side of Each Physical Page (Note 2)

******** ****

$******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Description of Item/Unit of Measure

Frequency

Fee

D.Additional logical page-ad/coupon (per logical page, per system principle)
(Note 3)

 

 

1.****** *** ********* ******** (*** ******* ***** *** ****** *********)

*******

$******

2.****** *** **** ***** ******** (** ********** **** *** ****** ****** *******
(***) (*** ******* ***** *** ****** *********)

*******

*/*

3.****** *** **** ***** ******** (** ********** ** ******* **** ****** (***
******* ***** *** ****** *********)

*******

*****

E.Statement Composition Fee (*** ********* ***** **********) (Note 4)

*******

$******

II.Customer letter processing (Refer to Section V.B entitled “Implementation and
Startup Services” for the fees associated with startup services, Section VII
below for the fees associated with custom paper and custom envelopes, and
Section VIII below for the fees associated with postage)

 

 

A.Legacy customer letters

 

 

First physical page (black print only; includes generic paper, generic carrier
envelope, generic remittance envelope, and the insertion of the letter and
remittance envelope) (*** ******* *** ****** *********)

*******

$******

B.Additional physical page for legacy customer letters (black print only;
includes generic paper) (*** ******** ***** *** ****** *********) (Note 1)

*******

$******

C.Enhanced customer letters (Note 5) (Note 6)

 

 

First physical page (black print only; includes the insertion of the letter and
remittance envelope, if any) (******** ***** *** ********) (*** ******* ***
****** *********)

*******

$******

D.Additional physical page for enhanced customer letters (black print only;
includes insertion of the letter) (******** *****) (*** ******** ***** ***
****** *********) (Note 1)

*******

$******

III.Past due notice processing (Refer to Section V.B entitled “Implementation
and Startup Services” for the fees associated with startup services, Section VII
below for the fees associated with custom paper and custom envelopes, and
Section VIII below for the fees associated with postage)

 

 

A.Legacy past due notices

 

 

First physical page (black print only; includes generic paper, generic carrier
envelope, generic remittance envelope, and the insertion of the notice and
remittance envelope) (*** ******* *** ****** *********)

*******

$******

B.Enhanced past due notices

 

 

First physical page (duplex, black print only; includes generic paper, generic
carrier envelope, generic remittance envelope, and the insertion of the notice
and remittance envelope) (*** ******* *** ****** *********)

*******

$******

C.Additional physical page (black print only; includes generic paper) (***
******** ***** *** ****** *********) (Note 1)

*******

$******

D.Additional logical page-ad/coupon (*** ******* ***** *** ****** *********)
(Note 3)

*******

$******

E.Modified generic/bilingual revision charge (Note 7)

*** **********

$******

IV.Delinquency labels

 

 

A.Spooled to site (*** ****** *** ****** *********)

*** *******

$******

B.Printed 4-up labels (*** ****** *** ****** *********)

*** *******

$******

C.Printed Cheshire labels (*** ****** *** ****** *********)

*** *******

$******

D.Printed LAB labels (*** ****** *** ****** *********)

*** *******

$******

E.Reports (*** ******* *** ****** *********) ($****** *******)

*** *******

$*****

V.Inserts

 

 

A.Printing services

 

 

1.Marketing inserts/envelopes

*** *******

*****

2.Other communication

*** *******

*****

B.Processing (******* ** * ******* *** *********)

 

 

1.Non-CSG printed inserts – machine insertion (*** ******* *** ****** *********;
**** *** ** ****** ***** **** ******* ******* ********* ******)

 

 

§** ** ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** *** ******* ******* ******* **********

*******

$******

2.CSG printed inserts - machine insertion (*** ******* *** ****** *********;
**** *** ** ****** ***** **** ******* ******* ********* ******)

 

 

§** ** ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** *** ******* ******* ******* **********

*******

$******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Description of Item/Unit of Measure

Frequency

Fee

3.Selectable business reply envelope credit (*** ********)

*** **********

*/*

C.Late insert notification (*** ******** *** ****** *********)

*** **********

$******

D.Late arrival of Non-CSG printed inserts (*** ******** *** ****** *********)

*** **********

$******

E.Holds or notification of insufficient inserts (*** ****** *********)

*** **********

$******

F.Returns to customer (handling fee, excluding shipping costs) (*** ******
*********)

*** **********

$*****

G.Destruction of inserts (*** ***** *******; ******* ** ***** *******; *******
******* ** **** ******* ********) (*** ****** *********)

*** *******

$*****

H.Affidavit (*** ******** *** ***** *** ****** *********) (Note 8)

*** *******

$*****

VI.Other print and mail ancillary service fees

 

 

A.Other print and mail ancillary service fees (Note 17)

 

 

1.File Transfer Set Up

********

******

2.Statement Image Archive File Transfer

*****

******** ** ***

B.Support services (Note 9)

 

 

1.Marketing/creative services support (*** ******* *** ****)

*** *******

$******

2.Advanced ESP support services (*** ******* *** ****)

*** *******

$******

3.Statement design consultation (*** ******* *** ****)

*** *******

$******

C.Other services

 

 

1.Flat file transfer for statement creation off-site (*** ********* *** ****
**********)

*** *******

*****

2.De-conversion fees

******* *** ** *** *********

D.Mail Trace

 

 

1.Mail Tracking, DirectNet View and Daily Scan File

 

 

a.Mail Trace Startup (Note 10)

*** *******

$********

b.Mail Trace Processing (per statement)

*******

$******

c.Mail Trace Scan Data View in ACSR B (Note 11)

*/*

*/*

d.Mail Trace – Data File Restoration (Note 12)

*** *******

$*****

e.Mail Trace Mailer Identification (MID) Fee (Note 13)

********

*****

f.Mail Trace Disk storage (*** ********) ($***** **** *** ********)

*******

$*****

2.Automatic Suspension of Delinquency Actions

 

 

a.Optional Mail Trace Automated Delinquency Delay Service (*** *********)  
(Note 14).  

*******

$******

E.Braille/Large Print Statement Functionality

 

 

1.Monthly Processing Fee (*** **** *****/*** ********** *** ******** **** ***
********** *** *******/***** ***** ********** (Note 15)   

*******

$******

2.Data File Restoration Fee (Note 16)      

*** *******

$*****

F.Special Printer/Inserter Setup Fee (*** ****** **** **** ***** *******
**********) (*** **** *** ****** *** ****** *********; **** *** ** ****** *****
**** ******* ******* ********* ******) (Note 18)

 

 

§** ** ********** ******* ******* **********

**********

$*****

§********** – ********** ******* ******* **********

**********

$*****

§********** – ********** ******* ******* **********

**********

$*****

§********** *** ******* ******* ******* **********

**********

******

VII.Paper and Envelopes:  (Statements, Customer Letters and Past Due Notices

 

 

1.Paper – 8-1/2 x 11, 24#, plain white with one perforation (used for SmartColor
Printing) (per page; this fee is tiered based upon monthly printed statement
volume))

 

 

§Up to 14,000,000 monthly printed statements

*******

$******

§14,000,001 – 16,000,000 monthly printed statements

*******

$******

§16,100,001 – 18,000,000 monthly printed statements

*******

$******

§18,000,001 and greater monthly printed statements

*******

$******

2.Carrier Envelope – CSG standard #10 envelope, 20# paper with one poly-covered
pistol window (*** ********; **** *** ** ****** ***** **** ******* *******
********* ******))

 

 

§** ** ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

§********** *** ******* ******* ******* **********

*******

$******

3.Remit Envelope – CSG standard #9 envelope, 20# paper with one open window (***
********; **** *** ** ****** ***** **** ******* ******* ********* ******))

 

 

§** ** ********** ******* ******* **********

*******

$******

§********** – ********** ******* ******* **********

*******

$******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Description of Item/Unit of Measure

Frequency

Fee

§********** – ********** ******* ******* **********

*******

$******

§********** *** ******* ******* ******* **********

*******

$******

4.Other Paper and Envelopes

*** *******

*****

5.Other Miscellaneous Shipping Materials (*** ***** *** ****** *********)

*** *******

*****

6.Custom Paper Set-up/Revision

*** *******

$******

VIII.Postage

 

 

A.Statements (*** ********* ******** *** ****** *********)

*******

****** *******

B.Customer letters (*** ****** ******** *** ****** *********)

*******

******** ************* ****

C.Past due notices and reminders (*** ****** ******** *** ****** *********)

*******

******** ************* ****

Note 1: ** ********** ******** **** ***** **** ****** **** ** ******* ******* **
**************** ********* ******** **** ******** **** ** ********** ********
**** **** ** **** ******** **** ***** ******** **** ** ******** *** ***
********* ******* ****** *** ** ********** *************  *** **** *** *******
****** ******* ************ **** *** ******** *** *********** ******* **********
********* ************ ****  ** ******** ** ***** **** ** ******** **** ***
******** **** ******** **** *** **** ******** ******* *** ** **** ** ***
********** ******** *****  ** ******** ** ***** **** ** ******** **** ***
******** *** ********** ******** **** *** ****** **********.

Note 2: Full Color is available on both sides of each physical statement
page.  *** *** ***** ** ******** ******* ********’* ***** ******** **** ***** **
* ******* ***** ********** ** *** ****** ****** ** ******** ***** **** ********
***** ********** (**** *** *** ** ******** ******* *** ******** **** ********
***** ** ***) “**** ***** ********** ***”.  

Note 3: Additional logical page - ** ****/****** ** **** ********* *** *********
***** **** ** ******** **** *** ********  ** ** ****/****** **** ***** ********
********* ******* ** ************** ***** ***** ******** *** ****** *******
********* ** ** ********** ******* *****  * ******* **** ** *** **** ** *
******** *****  ** ******** ** **** ****** *** ** ***** **** **** *****
*********  **** **** *** ** ********* *** **** **** *** ** ******* ** *** ****
****.

Note 4: The Statement Composition fee ** ******** *** ********** ********** ****
**** **** ******** ***** ******** ******** *** **** ***********  ****
*********** ** ** ****** ** *** ********** ***** ***** ******** *** ****** **
******** **** **** ******** ** *** **********  ******** *** **** **** ******
******** *** ********** ******** ***** ******** ** ********** *** ********’*
********* ************  *** ***** *** ****** **** **** *** ********** ********
***** ******** ** ********** *** *** ******** *********** **** *** *** *********
************  *** ******** *** ****** ****** ** ** ****** ******* **** ** ***
********** ******* ********’* ***** ********* *********** **** *** ***** ******
** ******* **********.

Note 5: *** ***** ******* ******* *********** ********* ***** ********* ***
******** ******** *******.

Note 6: ******** *** ***** ** *** ******** ******* ****** ******* *** ********
******** ******* ** ***** *** *** ******* ** ****** ****** ***** *********.

Note 7: ** *** ***** * ******** ***** ** ****** *** ****** ** ** ********
******** *******/********* ******* **** **** ** ******* *** ******* **** ** ****
*******  *** ******* ***** * ******* ** *** ****** **********.

Note 8: ** ********* ** ** ******** ********* **** *** ****** ******* ******
*********** ** *** ****** ** ********** ******** **** *** **********
*******  **** ********* ******** *** ***** ***** *** ***** *** ****** *** ***.

Note 9:  *** ******* ******** *** *** ********** **** ***** ** *** ***** ** *
******** ****** **** ********* ** **** ** ***.

Note 10: **** ***** ***** ******** *** ******* ** ***** **** ****** ******* ***
**** ** ****** ****** (****** ***** ******* ******** *********) ****** ** * ***
**** ** *** ********* ***/** ******  **** ******** ** ********* ** **** ********
*** ******** *****  **** ***** **** ******* ****** ** ********* ****** ***
****** ** **** **** ******* * ****** ** **********  *** ******* ****** ** *** *
****** ********* ****** *** *** ***/***** *** ******** ******** ** *********
******* ******* ** **** *********** *** ********** ** ***** **** **** *****.

Note 11: ****** ******** ** **** ** **** ** * ******** ********’* ******* ****
****.

Note 12: *** ******** ***** **** ***** * **** **** ********** *** ********’*
******** *********** (**) *****’ ***** ** **** **** *** **** ****** ** *** ****
****** ** ****** ** ********’* *** ******** **** *** ** ********* ** ********
*** ********* *** *********** (**) ******  *********** ***** *** ******** ***
****** (**) *****  ****** ******** ******* *** ** ******* ** ******** **** *****
******** ***** *** *** **** **** *********** ***.

Note 13: *** **** ***** *** *** ** * **** ************ *** *** *** *******
********  ******** *** **** **** **** *** **** ** ***** **** ******** ***** ***
*** ****** *** *** **** ***.

Note 14: ********** *** (***** ** ****) ****** ** ***® ***** ******** ** (*)
****** ***** *********** ******* ** ******** *** (**) ******** *** **** ******
*** ***********  ******** ******** **** ********** *** ****** ** ***_***** **
*** *******® **** ********** ** *** *** ****** *** *** ******* **** * *** ****
******* ******  ****** *******:

(a)

***_***_***:  ***** *** ****** ** ****** *** *** ******** *** *** *******.

(b)

***_****_***_***:  ***** *** **** ** *** **** ****** ***** **** *** ***
********.

(c)

***_****_***_***:  ********** *** **** ** *** ***** ***** **** *** ********.

Note 15:  * **** ***** ********** * ******* ********* **** ** ****** ****** ***
*** **********  *******: * ********** **** ********* ***** ***** * ****
*******  *** ******* **** ***** ****** ** ******** ******* *** ********* ****
***** ***** ********* **** ****** ****** **** ** ***** *** ***** *****.

Note 16: *** **** ***** *** ********* *** * ****** ** ***** (*) *****
*********** ***** *** *********  ** *** ***** *** ** ***** ** ******* **
******** **** ***** ******** ***** *** *** **** **** *********** ****  ***
*********** **** ***** ******* ** *** *** ********** ********* *** **** ******
**** **** ******** ** *** ********* ******* ***** **** *** ******* *** *****
******  *********** ***** **** ** **** ********* ** *** ******** **** *******
*** **** ** ****** **** *** ** *** *** ****** *** ********* ** *** ******.

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Note 17: **** ************** ** *** ********* ***** **** ******** ****
*********** ******** ** **** ******* ********* ** **** ** ** ******** ** ***
******* (*** ******** *** *******) ("*** ********* ***** **** ******** ***"),
*** ***** ******* *** ********* ***** **** ******** ** **** ** *********
******** ** ** ***/**** ** ** **** ******** ** *** ***.

Note 18:  *** ************* ********* ******* *******/******** ***** *** ******
**** **** ***** ******* ********** ** ******** ** *** *** *** ***********
********* ***********; *** ******* *******/******** ***** *** ********** *****
***** **** ** ******* *** ******* *******/******** ***** ** ******** **
********** ********.

 

 

IV.

Ancillary Products and Services

 

A.

Ancillary services for Non-Rated Video and Non-Rated High-Speed Data and
Residential Voice Services

 

Description of Item/Unit of Measure

Frequency

Fee

1.Database maintenance requests

 

 

a)Passers (variable lead time) (***  ******)

*** *******

******** *

b)Other mass adjustments (*** **** **********)

*** *******

******** *

2.De-conversion fees (Section 6.2 of the Agreement)

******* *** ** *** *********

 

B.

CSG Care Express (Payment Kiosk) Module E

 

1.

CSG Care Express (Payment Kiosk) Module E, Part 1 (Note 1)

 

Description of Item/Unit of Measure

Frequency

Fee

1.Payment Kiosk Unit (*** ****)

*** *******

    *****

2.Payment Kiosk Maintenance (*** ****) (Note 2)

********

   $********

3.Enterprise Care Express Kiosk Environment Configuration (*** *** ***
********)  (Note 3)

*** *******

$*********

4.Payment Kiosk Implementation and Set-up Fee (Note 4)

*** ******

$********

5.Payment Kiosk Extended Warranty (********* ******* ******** *** * ***** ****
**** ** ********) (Note 5)

*** *******

*****

6.Custom Design Services (Note 6)

*** *******

*****

7.Attract Loop (Note 6)

*** *******

*****

8.Kiosk Equipment Upgrades (specified when ordered) 

*** *******

*****

9.Kiosk Spare Parts Component Kit

*** *******

*****

10.Subscription Model Benefits Premium (*** ******** ***** ** ** *** ** *****
****) (*** ** ******** *** ******* ** * ******* ***** *** ** ******** ** **
****** ***** ***** **** *** ****** *** ******** *********** *** ******* *** ***
**** ****) (Note 7) (Note 8)

*******

$*****

Note 1: Fees subject to change ** * ******** ******* ***** ** ********** ****
***’* ***** ***** ****** ***********  ******* ******* ** *** ******** ********
***** ************* (********** **** *** ******* **********).  ******** *******
****** *** ***** ******** ************* *** ********* ** * “*** *****” ****** 
******** ******** ******** *** * ****** ** *** (*) **** ****** ******** ********
**** ** ********* ** ********.

Note 2: ******** ****** *********** *** ******* ** *** ******** *** ****** ***
******* ************ ******** ** ***’* ********.

Note 3: * ******** *** ********* *************** *************** *** *******
**** ********* ** * ********* ** **** *** ***’* ************* ** *** *** ****
******* *********** *** *** ***** *********  *** ************* ********* ***
**** “********” ****** ** *** ******* ************* *** ************* ** ***
******** *** ******** *** ********** ************* **** ******** *** *******
(**** ********* ************** ** ***** ******* ******* ************* ***
********* ** ***’* ******* ****).  ** **** ***** ********** ********
************* **** ** ****** ** ****** ******** *********** ******* * *********
** **** *** *** ******* ** ********** ******** ******.

Note 4: ********** ** *** ***** ********* ** **** ******** ****** * ********
******/******** (*** *** ******** ** *** **** ******* (******* *****) *
“******** ******”) ** * *** ******** ****** ***** *** **** ** ********’*
******** ******** (**) ******** ******** *** *** *** ********** ******** *******
***** ***** *** ********* ** *** ********* *** *** ************** ** *** *******
***** ********.

Note 5: ********** ******** ******** ******** **** **** ** ******** ** *** ****
** ******** *** ****** ** ********* ******* *** ** * ***** ****.

Note 6: *** ****** ****** **** **** ** ********* ******* * ******** ********* **
**** ******* ***** ***** ****** *** ****  *** **** ******* * ***** **** **
******** ***** ** ********’* ************ *** *** ***** ******** ** ***** *****
****** ******* *** ********* ** **** ********  ******** ***** *** *** *********
******** **** *** ***** *** *** ***** ********.

Note 7: ************ ***** ******** ******* *** *** ******** ***** ********:

·

********* ******* ******* *** ********** *** ********* ******** **** *******.

·

******* ***** ******* *** ******** **** ** *** ***** ** ********** * ** *******
* ** *** ******** ****** ******** *** ****** ** **** ******** ** ***** ** ***
****** ****** ***** *** ******* ******* ** ******** *** ***** **** **** **** **
******* ** *** ******** ******* *** ************ (**nd) ***** ** *** **** ****
******** **********.

·

********** ********** ******** ** *** ********* *** ** **** ************* ***
*********** **** ********* ********* *** ************.

·

****** *** ********** *** ******* ******** ** *** *** *** ********* (**) *****
**** **** ** **** **** ******** ** *** ************ ***** ******** *** **** ***
**** ******** ********* *** **** ****** *** ***** ***** **** ** ****** ***
********* ********** ***** ********* (**) ***** ***** **** ******* **** ****
***** ** ***** ********* ** ** ***** **** ** **** ***/** ***** **** ****
******** *** ***** *** ******** ******** ***** ******** ****** **** **** ****
*** *******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*** ***** *** ******** **** ** ******* ** *** ******** ******** *** **** *******
*** ** **** ********** *** ******** *** *** *** ********** ** *** ** ** ******
*** ********** ************* ***** **** **** * ********** **** ****** ****
******** *** ******* **** ******** *** **** ******** ****** **** ** ********
**** *** ******** *** ****** **********

·

* ***** **** **** *** ********** ***** *** ******** ****** ** ******* ***
******** ** *** ******* ***** ***** *** *** *** ******** ******* ** ****** ***
******** *** ******** **** **** ******* *** *** ****.

·

*** ************* ********* *** ************ ***** ******** ******* *** ***
******** ***** **** *** ******* ***’* ******* ***** ***********.

·

*** ******* *********** *** ***** ** ******** ****** ******** *** ************
(**nd) ***** ** ***** **** ***** *** ***** ** ****** ******* ******** *** ***
******* ***** *********** *** *** ***** *** ******** ** *** ***** ***** ***** **
********** **** ******* * ** *** ******** ****** *******.

Note 8: ******* ********* *** ***** **** ** ******** ******** ****:

** ********* **** ***** *** ***** **** ******* **** ********* **** **** **
********* *** ********* ***** ** *** ******** (********** ** *** ****** **** ***
*** ******** ******* ** *** **** ******* **** ** *** ******** ********** ** ***
********* ****** **** ** ********) **** ** ******** **** *** $**/***** ** *****
** ********** *** *** ***** ****** **** *** ******* ******** ****** ** ********
*** **** **** ****** ** *** ******** ******* ******* ********** *** *********
***** **** ************** ** *** ******** ******* *** **** ******* *** *********
** **** ** *** * ************ ********* ** *** **** ****.

 

2.

Precision eCare® (Payment Kiosk) Module E-Kiosk Subscription Program

 

Description of Item/Unit of Measure

Frequency

Fee

1.Kiosk Subscription Fee (*** ****) (Note 1) (Note 2)

********

$********

Note 1: ********* ****** ********* ***** *** ********* **** ** *** ********
****** ******** *** ***** ************ *** ***** ** ******** ******** *** *
****** ** ***** (*) ***** ****** *** **** ** **** *****  *** ***** ******* *****
** ******** **** ******** ** **** ***** ***** *** *** ********* *** (*) ********
**** ** ******** **** **** ** *** *********** ***** ** **** **** ***** **** ***
********* **********  *** ***** ************ *** ** ************* ***
*************** ******* ** *** ***** ** ******* * *** *** ********** *** **
******* ** *********** **** ** ******** ** **** ** ***’* ***** ***** *********
*** ** ******* ** ****** ********* ******** ** ******* **** ********** ** *****
** *** ********** ** *** ***** *** ***** ************ ** ********** *** ***
****** ***** **** ***** ** ********* ********** ****** **** *** ******* ********
**** ** ******** ** ********** **** *** ***** ** ******* ** ******* * ********
“Cancelation/Termination Policy”.

Note 2: ***** ************ *** ********:

·

***** **** *********

·

*********** *** ******** ** ****’* ********** ******* ********* *** ********
*******/*********  ***** ******** ********** ******* *** *** ******* ** ***
********** *** ***** ** ********** * ** ******* * ** *** ******** ******
*******.

·

*** ****** ****** ****** *** ****** **** ******** *** ******** *** *** ***** **
** *** ********* **** ** *** ******** ****** ******** ** ***** ***** ***
******** ** ******* ** *** ****** ** ********* *** ******** *** ***** **
******** *** ************ *****.

·

******* ***** *********** ***** ******** ****** *********** *** ******* ** ***
******** *** ****** *** ******* ************ ******** ** *** ********.

·

*** ******** ***** ***** ******** ******** ********* *** **’* ********* *******
*** *** ***** ***** *********** *** ****** ********.

·

*** ******* ********** / ************** ** *** ***** *** *********** *****.

·

********* ******* ******* *** ********** *** ********* ******** **** *******.

·

******** ********* (**) ***** ******* ***** ******* *** ******** **** ** ***
***** ** ********** * ** ******* * ** *** ******** ****** *******.

·

********** ********** ******** ** *** ********* *** ** **** ************* ***
*********** **** ********* ********* *** ************.

·

****** ********** *********** (*** ******** ** ***** ***** “****** ***”)
********** *** ******* ******** ** *** *** *** ********* (**) ***** **** **** **
**** **** ** ******** ** *** ************ ***** ******** *** **** *** ****
******** ********* *** **** ****** *** ***** ***** **** ** ****** *** *********
********** ***** ********* (**) ***** ****.

** *** ***** * ***** *** * ********* **** **** **** ********** ** *********** **
*** ********** *** ***** ** ******* ** ******* * ********
“***********/*********** ******”* ***** ****** ******* ** ****.

 

C.

Refund checks

 

******** ************ *** *** ** *** **** ***** ******* ********** *********
******** *** *****  ******** ********* **** *** ******* *** **** ***** ******
******* *** *** ******** ******* ******* ** ** **** ******  *** *********** ***
***** ** ******** ********** **** **** ********* ******* *** **** *** ***** **
********* ** **** #********  ** *** ***** **** ******** ******* ** *** ***’*
**** ***** ******* *********** *** ******** *** **** *** **** **** ** *** *****
** * ******** ****** **** ********* ** *** *********.

 

D.

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Check Verification

 

Description of Item/Unit of Measure

Frequency

Fee

1.Service Option 1 (*** ***********) (Note 1)

*******

$******

2.Service Option 2 (*** ***********) (Note 2)

*******

$******

3.Setup and Implementation (*** ******)

*** ****

$*********

Note 1:  ******* ****** * ******** ** **** ******** ******* ****** *** ********
******** ************.

Note 2:  ******* ****** * ******** ** ******* ****** * *** ******** ********
************.

 

E.

Collections - **** ******** ********* *********** **** ********** *******
*********  ******* *** *** ********** ******* ******** ********.

 

F.

CSG’s Home Security Module (HSM)

 

Description of Item/Unit of Measure

Frequency

Fee

1.Home Security Module

 

 

a)Access Fee

********

(Note 5)

b)Monthly HSM Subscribers (Note 1) (Note 4)

 

 

§** ** ********* (*** *** **********)

*******

$******

§********* ** ********* (*** *** **********)

*******

$******

§********* ** ********* (*** *** **********)

*******

$******

§********* *** ******* (*** *** **********)

*******

$******

2.Implementation Services (Note 2)

*** *******

*****

3.Additional Complex Composite Services for HSM (*** ******* *********
*******)   (Note 3-4)

*******

$******

Note 1: *** ******* *** ********** ****** ****** ** *** ***** ** ******* * **
*** ***** ****** *** ******** ** ** ********** *** *** ************  ***
******** ** ******** *** ********* *** *********** ** *** ******* ******* *****
*** ******** **** ***** *** ******* ****** ********** ****** ** *** *********
*** *********** ***** ** $****** *** *** ***********  *** *********** *** ***
****** ** *********** *** *** ******* *** ********** ****** ***** ** ***** ****
*** ****** ** ********* *********** **** *** ** *** **** ********** *** ** ***
********** ****** ***** ** ********* *** **st ** **** *****.  

Note 2: *** ******** ***** ** *** ************** ******** ***** ** *** ***** **
* ******** ********* ** ****.

Note 3: “******* ********* ********” ***** **** * ******* ******* **** ** ******
** ***’* ************ **** **** (***).  * ******* ******* ***** **** * ******
******* (**** *******) **** *** ** *** *** **** ******** ******** (**** ******
***).

Note 4: *** ************* ********* *** ******* *** ********** ******* ** ***
***** ** ******* * ** *** ***** ****** ***** ******* ********** *** ** ** ***
(*) ******* ********* ******* *** *********** *** ***** *** ** **********
*****  **** ********** ******* ********* ******* ***** ** ******* ** **********
$****** *** *********** *** *****.

Note 5: *** *** ******** *********** *** ***** **** *** *** ********
($********** ** *** ** **** *** $********** ** ******* ** ****), *** ********
*** ***** *** ******* ******** **** ******** ****** ****** ***.

 

G.

Configurable Lines of Business Functionality ("C-LOB Functionality")

 

Description of Item/Unit of Measure

Frequency

Fee

1.Implementation Services (Note 1)

*** *******

*****

2.Configurable Line of Business Functionality (C-LOB Functionality)

 

 

a)Monthly Subscription Fee (*** ********* ***** *************
**********)               (Note 2)(Note 3)

 

 

§** ** *******

*******

$***

§******* ** *********

*******

$***

§********* ** *********

*******

$***

§********* ** *********

*******

$***

§********* *** *******

*******

$***

3.Complex Composite Services (*** ******* ********* *******) (Note 4)(Note 5)

*******

$***

Note 1: The specific terms of the implementation services shall be set forth in
a mutually agreed upon Statement of Work.

Note 2: **** ****** ******* ******** *** ********** **** ********** **** ***
******** **** ** ******** **** ** ******* ******* *********** **** ******** ***
****** ***** ** *********** ***** *** ********** *********** *** ******
*********  *** **** ******* *** **** *** ************ **** ** ********* ** **
****** ** ********* ** ** ******* ********** ****** ** ***********  **** ****
********** **** ** **** ****** *** ***** ****** (**) ****** ***** *** *****
********** ** ********* ** *** *******  *** ********* **** ********** ***** ***
**** ***** ***** ****** (**) ** *********** **** *** ******** ***** **** **
********* *** *** **** ***** ******* *** *** ****** *** ******** ** ***** ****
**** *********** **** ** ******* ** ********* ************  ** ******** ** ***
**** ******** ****** *** ******** *** *** ********* ***** *** *********
********** **** *** *********** ***** ******** ****** ** ******* *** ** ********
* ** *** ********* **** ***** ** *** ******** ********** **** *** *****
************* *******.

Note 3: *** ************* ********* *** ******* ***** ************* ************
**** ** *** ***** ** ******* *** ****** ***** ******* ********** *** ** ** ***
(*) ******* ********* ******* *** ********* ***** ************* *********** ***
***** *** ** ********** ****.

Note 4: ******* ********* ******** ***** **** * ******* ******* **** ** ******
** ***’* ************ **** **** (***).  * ******* ******* ***** **** * ******
******* **** *** ** *** *** **** ******** ********.

Note 5: *** *** ****** ***** ***** ** ******* *** *** (*) ** **** *******
********* ******* *** ********* ***** ************* *********** *** *****.

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

Note: *** ***** *** ** ******** ** ******* ***** ************* *********** *****
*** ******** ********** **** ** ******** ** ******** ** *** *** ********** ***
*** ******* ***** **** * ******** ****** **** ********* ** **** ***
************** *** ******** ** *** ********** **** ** ********.

 

As a point of clarification, the C-LOB cannot be used for Video, High-Speed
Data, Residential Voice Services, ACP Commercial or ACP Wireless.

 

H.

SLBOS / ENI Hardware / Data Processing - Software, Cost per PVU, and Data
Processing Fees

 

Description of Item/Unit of Measure

Frequency

Fee

1.SLBOS / ENI Hardware - Software (Note 1)

 

 

a)Processing Level (********** ** ** *** ***) (Note 2)

*******

******** ** ***

b)Additional TPS (*** ********** ** ** ***)

******

$********  

2.Adjusted Average Excess Cost *** *** *** ***** ********* *********** ***
*****  (Note 3)

*******

$******

3.Data Processing Rate *** *** ****** ********** (*** *** ****** **********)

*******

$******

Note 1: SLBOS / ENI Hardware – Software:

•

******** **** ******* *** **** * ******* ************ ****** *** ******* *****
******** *** *** ******** ********** **** ******* ***** / *** ***** ** *** *****
*** ** **** ******** ******* ** ***** *** ** ******* *** ****** *********
*********** ** ** ***** ** *********** *** *** ******* ******** ** * ****** **
***** *** ********** **** ********’* ************* *** *** ******** *** ****
******* ***** ** ** ********* ******* *** ****** *** **** ******** ******** ****
*** ******** *** **** ******* ******* *** ******* *** ********** ****** *** ****
****** ******** ** *** ********** ** *** ********* ********* ******* ***
********* *** ********** *** ***/** ***** / *** ***************** ** ******** **
*** ***** ****** ** **** **** *** ********* *** **** ******* ******** **** *
****** ****** ******* **** ****** *** ***** ****** *** *** ******** **********.

•

****** *** **** *** ******** ** ********** ** ****** ** *** **** **** *** *****
****** ******** *** ******** ***** **** *********** (**) ***** **** ******* **
**** ****** ** ****** (** *** **** **********) *** ** ****** *** ** *** ********
******* (*) *** ***** ******* ***** ********** **** ** ********* ***** (*) ***
********’* ****** ***** ***** ** *** ****** ******** ** *** **** *** ** (*) ***
******** *** **** ***** ** *** *********** ****** *** ***** *** ******** ******
** *** *** ********** **** ******** ** *** ***** ****** ** (**) ******** ******
** ******** ********** *** *** ****** ** *** *** ********** **** ******** ** ***
***** ******  ** ******** ***** ** ****** *** ** *** ********* *** *****
************* **** ******** *** ********** **** ******** ** *** ***** ***** ***
*** ********** *** ******** ** ******* *** ****** ** *** **** ***.

•

******** **** ******* *** **** * **/* ********* *** ********** *** ********
********* ********* ** *** ***** *** ***** ********** ** ********** * **********
***** ********** **** *** ********’* *********** *** *** *** ** *** *********.

•

******** **** ****** **** ******** ** **** ** ******* ********* ***** ** ***
***** **** *** ********** ******* *** *** ********’* *********** ** ****** ***
**** *** ******** *** *** ******* ** ***** * ************ ****** ** ***********
** ****** *** **** *********** ********** *** **** ********* ** *******
********** *******.

•

******** *********** ******* ****** ** ******* ** **** (*) ****** *** ***** ****
(*) ****** ******** *** * ***********.

•

*** ******** ***** ************ **** *** *** ********** *** *** *** ********
**** ******** ***** **** *** **** ** *** *** *** ******** *** ***** ***** *****
************ **** ** *** ******* *** *** ******.

Note 2: ********** ***** (********** ** ** *** ***) ***** ** ******** ****** **
****** *** ********** ********** ** *** ********** ******** **** *** ******
************ ** ***.

Note 3:  **** *** ** *** ******* ** ******* **** ** *** ********* (********** **
****).

 

I.

Ancillary services for Workforce Management

 

Description of Item/Unit of Measure

Frequency

Fee

1.WFX Enterprise Interface

 

 

a)WFX Enterprise Interface Maintenance and Support Fee (Note 1)

 

 

§WFX Transaction Volume Tier (Note 2) (Note 3) (Note 4)

 

 

-* ** ********* (******* *** ************)

*******

$****

-********* ** ********* (******* *** ************)

*******

$********

-********* ** ********* (******* *** ************)

*******

$********

-******* **** ********* (******* *** ************) – *********** *** ****
********** ********* ******* *** *********** ******

*******

$********

2.WFX Scheduling and WFX Resource Allocation Manager

 

 

a)WFX Scheduling Implementation Fee for Trial and Initial Implementation  (*****
** **(*)) (Note 5)

********

$*********

b)WFX Resource Allocation Manager Implementation Fee for Trial and Initial
Implementation (***** ** **(*)) (Note 5) (Note 6)

*/*

******** **** *** Scheduling

c)WFX Scheduling Implementation Fee for Additional FC(s), (***** ** **(*))

********

$*********

d)WFX Resource Allocation Manager Implementation Fee for Additional FC(s) (*****
** **(*) (Note 6)

*/*

******** **** *** ******** ********** *******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

e)Monthly Service Fee For Xfinity Home National Dispatch Center (***** ***)
(Note 7) (Note 8) (Note 9)

*******

$********

Note 1: *** ************** ** *** *** ********** ********* ***** ** ******
******* *** ******* ********** **** *** ******** ***** * ******* *; ***********
** ******** **** *** ***** *** ******** *********** ******** ***** *** ***
**************** *** ***** *** ***** ** *** ************** ***** ** ******* **
******** ****** **** ********* ** ****.

Note 2: ***** ************ *** ************ ******** *** ***** ** ******* ***
******** ** ********** **** *** *** *********® / *** *********® *** ***********
*** ************ *** ****** (“***”) **** ** ******** ** ******** ** ******* **
(********* ***** *****), ********* **** (******** ***** / *** ************ ***
****** (“***”) *** *** *** ********** ***********).

Note 3: *** ******* *** *********** ****** ****(*), ** *** ***** ** ******* * **
*** ***** ****** *** ******** ** ** ********** *** *** ***********; **** ***
********* ** *** ******* **** ********* ***** ***** ** *********** ** ***
********* ** ********* *****  *** ******** ** ******** *** ********* ***
*********** ****** ** *** ******* ******* ****** *** ******* *** **********
********* *********** *** ******* *** ** *** ********* *** ******* ***
*********** ****** ***** ** $********.

Note 4: *** ******** ************ ******* *** *** ****** *** ** ******** ******
******* **** *** ***** ********* *** ******* ******** *** ********* **** ***
******** **** *** ********* ** ****** ******** ****** ************* ***** ***
******* ****** *** ******* *** ********** ********* *********** ****.

Note 5: *** ******* ************** ** *** ********** *** *** ******** **********
******* ***** ** *** ***** ** * ******** ****** **** ********* ** **** *** *****
******* *** **(*) ** *** ********* (*** "*********") ********* ** **** *********
** **** *** *** (*) ******** ******* ** ** ********* ****** *** ***** ****** **
*** ********* *********  *** ************** *** **** ** ******** ** *** ***** **
*** ***** ******* ***** ********* *** ********* **** ******.  

Note 6:  ** * ************ ** ******* *** *** ******** ********** *******
******** ********** ******** **** ** * ******* *** ********.

Note 7: *** ******* ******* *** ** * ***** *** **** ******** ***** ** *** ***
******* ******** *** *** *** *********** ** *** ********** ******** ** *** **
*** ******* **** ******** ******** ******.

Note 8: *** ***** ** *** ******* ******* *** *** ******* **** ******** ********
****** *** **** ********** ***** ** *** *********** **** *** ******** **** *****
**** ** ********* **** *** ** ****** *** ********** *** *** ******** **********
******* ****** *** ********* ***********  *** ******** *** ***** ** ******** ***
***** ** *** ******* ******* *** *** ******* **** ******** ******** ****** **
*** ******** *** *** **** ** ***** **** **** ** ********* ** ****** ***
********** *** *** ******** ********** ******* ****** *** ********* **********
****** ****** (**) **** **** *** **** ** ***** ****** **********.

Note 9: ****** ******** ***** ** ****** *** *** ** *** ********** *** ***
******** ********** ******* ****** *** ********* *********** *** ******* *****
**** *** ******* ******* *** *** *** ******* **** ******** ******** ****** *****
** ********** ** *** ******* *** ********** *** *** ******** ********** *******
********** **** ** ** *** ********* **** ** **** ********** *** ******* *****
**** ** **** ***** ** ****** *** *** ***** ************* ** *** ******* *******
*** *** *** ********** *** *** ******** ********** ******* ** *** ******* ****
******** ******** ****** ***** ** ******* ** * ******** ****** ** *** ****
*********** ** *** ******* *** ********** *** *** ******** ********** *******
********** ***.

 

J.

Third Party Software That May be Procured Through CSG

 

*** ***** ***** **** *** ******* ** ****** *** ***** ***** ****** ********** ***
**** ** ******** ** ******** ** ***’* **** ******* ******  ******** ** ******
*********** *** *** *** *** **** ********** **** ***** ***** ***** ******** ****
*** ** ******** ** *** ********** ***********.

 

K.

Content Direct System and Services

 

*** ***** *** ********** ** ********’* *** *** ***’* ********** *********
********** ***** ** ******* ****** ****** *** ******** ***** ** ******** ** ***
***** *** ********** ** *** ** ******** ******** ***** *** ******** #*******.

 

 

V.

Technical Services/ Implementation Services/Training

 

A.

Technical Services/Professional Services

 

1.

Technical Services/Professional Services (Note 1)

 

The hourly rates listed in the table below are for general guidance
only.  Actual fees may vary depending on the project requested by Customer via a
Service Request Form.  All projects and the associated fees shall be set forth
in a mutually agreed upon Statement of Work.

 

Description of Item/Unit of Measure

Frequency

Fee

1.Additional Annual Support Commitment Hours (Provided in addition to the
Services Commitment Hours) (*** ******* *** ****) ($******** **** *** ***)

*** *******

$******

2.Professional Services (*** ******* *** ****)

*** *******

$******

Note 1: *** ** ***’* ********** ********* *** ********* ******** ********* **
******** ******* *** *** ** ****** *********** ** ******** ********* **********
*** ******* ***** ** **** ***** ********* *** ***** *** **** ********* *********
*** **** *** **** ********* *** ** ****** * ******* ** $****** *** ****.

 

2.

Services Commitment Fees

 

Description of Item/Unit of Measure

Frequency

Fee

1.Contract Year through 6/30/2015

******

$************

2.Contract Year through 6/30/2016

******

$************

3.Contract Year through 6/30/2017

******

$************

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

4.Contract Year through 6/30/2018

******

$************

5.Contract Year through 6/30/2019 and beyond through the Term of the Agreement,
including any extension periods as described in Section 3.4, Services Commitment
of the Agreement (Note 4)

******

$************

Note 1: Beginning upon the Amendment Effective Date, *** ****** ** *******
************** (******) ***** ** ******** *** ********** ******** *****
********* ** ******* *** *********** *** ********* ******** ********* ** *******
*** ********* **** ** ******* *** ******** *** *********** ** ***’* *** ********
******* ******* ****** ********* ****** ** *** ******* (“****** *******
**********”).

Note 2: The Services Commitment Fee is an ****** **** ******** ** *****
*********** ******* ** * ******* ****** ** ********** **** *** **** *** ***** **
*** ***** ******  *** *** ******** **** ***** “******** **** ******* */**/****”*
******** *** ******** ************** (******) ***** ** ********* ** **********
**** *** ******** ********** **** *** ***** ** *** ***** ****** *** ***
********** ******** **** ******** ** * ******** ****** ********* ** *****  ***
****** ****** ******* ********** ***** ** *** *** ** * ******** **** ***** **
********* *** ***** *** ** ******* **** ** *** **** ******** ****.

Note 3: ** ********** ******** ********** **** ***** ****** ******* ***** ****
*** ********** *********** **** ** ** ********* ****** *** *** *******
*********** *** ***** *** *** ******** **** ********* *** ***** ******** ** *
********* ** **** ******** ** *** *********.

Note 4: *** ************* ********* ******* **** ********** ** ***** ** ***
********* ***** ***** ** *** **** *** ***** ** *** ***** ***** ********* ** ****
** **** *** **** ********** ******** **** ******* *** **** ** *** **********
********* *** ********** *******.

 

B.

Implementation and Startup Services

 

§

All implementation and startup services, provided by CSG and the associated fees
shall be set forth in a mutually agreed upon Statement of Work.

§

Interface startup service, certification and processing changes to existing
addressable controllers, provided by CSG and the associated fees shall be set
forth in a mutually agreed upon Statement of Work.

 

C.

Additional training and documentation

 

1.

User training at CSG facility

 

Description of Item/Unit of Measure

Frequency

Fee

1.Single seat (*** ***** *** *****)

*** *******

$******

§

Training materials will be provided by CSG.

§

Dates of specific class offering will be published by CSG.

§

****** ********* ******* *** ** ******** *** $*****.

§

******** **** ** ******* * *** ************ *** ** ***** ** ********* **
*********** ****** **** (*) ******** **** ** *** ***** *** ** *** *********
*****.

 

2.

Virtual classroom training

 

Description of Item/Unit of Measure

Frequency

Fee

1.Per instructor, per hour

*** *******

$******

2.Per port, per hour (******** *** ********* **** ******** ***** ****** *** ***
*****)

*** *******

$*****

3.Per port, per hour (******** ******** **** ******** ***** ****** *** ***
*****)

*** *******

$*****

§

One copy of class training materials will be provided by CSG for duplication by
the customer in a quantity necessary to distribute to all learners.

§

Classes offered are generic to the application.  Custom developed classes can be
arranged by a Quote.

§

******** **** ** ******* * *** ************ *** ** ***** ** ********* **
*********** ****** * ******** **** ** *** ***** *** ** *** ********* *****.

 

3.

On-site user training at Customer’s requested location

 

****** *** ******* ***$******** *******

§

*** **** ** ******** ********* **** ** ******** ** *** *** *********** **
******** *** *** ********.

§

* ******** *** ** ******* ** *** *** ******* ** ********’* ******** *** *****
***** (** * ******* *******) *** ***.

§

**** ******** ** *********** *** ********* * ******** **** **** * ******** ***
***** ******* *** ********** ****** ** *** **** ****** **** ******* **** *****
** ***** ** ********.

§

****** ********* ******* *** ** ******** *** $*****.

§

******** **** ** ******* * *** ************ *** ** ***** ** ********* **
*********** ****** ** ******** **** ** *** ***** *** ** *** ********* *****.

§

********* ***** **** ** ***** ** ****** ******** *** *****.

 

4.

Vantage training

 

 

Standard Class Size

Rate (On-site)

(Per trainer, per day)

Additional Students

(Per student, per day)

Rate (at CSG facility)

(*** ******** *** ***)

Basic

*

$********

$******

$******

Advanced

*

$********

$******

$******

Database literacy

**

$********

$******

$******

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Note: All classes include the relevant training materials and documentation.

 

5.

BCE Training Development-West Division

 

Description of Item/Unit of Measure

Frequency

Fee

1.  Training Module (*** ******) (Note 1)

******

$********

Note 1: **** ******** ****** ******** ** ** *** (**) ***** ** *********** ****
*** *****  ** **** ***** *** ******** *** * ******* ******** **** ** ****** **
*** *********** ****** **** *** **** **** ** ****** ** *** (**)
******  ********** ******** ******* ***** ** ********* ******** ** * *********
** **** ******** ** **** ********  ******** ***** ** ******** *** ****** *** ***
******** ****** ******* ******** ** * ********* ** ****.

 

D.

Equipment Installation /Technical and Engineering Support Services

 

1.

********* ************ ******* ** ****** **** *****

 

*********** *** ********* *** ************** ********* ************ ****** ***
***** ** *:** ** *** *:** ** *** ****** ******* ****** ** ** ********** ******
** *** ********* ** * ******** ******* ** **** * ****** ********* ******* ***
*********** **** ****** ** * ******** ** * ******** *** ******** **** ** ******
** * **** ** $****** *** **** (******* ** * ****) *** ********* **********.

 

2.

********* *** *********** ******* ********

 

*** ******* *** ********** ********* ************ ************ ******** ***
********* ********** ** ******** *****/****** ********* ** ******** *****/****
**** ********:

§

********* ****** ***** ** $****** *** **** (******* ** $******** *** ***)

§

********* ******* ******** *** ***** ** $****** *** **** (******* ** * ****)

§

*********** ****** ***** ** $****** *** **** (******* ** $******** *** ***)

§

*********** ******* ******** *** ***** ** $****** *** **** (******* ** * ****)

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule F.1

LISTING OF PRODUCTS AND SERVICES INCLUDED IN THE BSC

 

The below table provides the following information: (i) the Products and
Services included in the BSC for Non-Rated Video and Non-Rated High-Speed Data
and Residential Voice Services, (ii) the BSC Threshold Level (as defined in
Section II.B.1 above) for the Products and Services included in the BSC, and
(iii) the Pricing for Excess BSC Threshold Level for the Products and Services
included in the BSC.

 

*** ********

*** ********* ***** ******** ** ** *** *********

(***/**)

******* *** ****** *** ********* ***** (** **********)

I.**********

 

 

A.********* ******** *** ********* ***** *** ********* ********** **** ***
*********** ***** ********

 

 

1.******* ******* *** **** ****** ** ***** ********** ****** ******** *******
****** ******** **** ***** ****** ******** ******** *********** ** ***** ***
****** ** ****.

**

**

2.**** ********** ****** ****** ** *** ***** **** ** ** ***** *********
************  **** **** ****** ********** ******* *** *** *********** ***
******** ** ******** “***** **” ******** ******* ********* ********’* ******
*********  ******** **** ******** ** ******* *** *** ******* *** **** ****
****** *********.

***

*****

3.*** *** **** ************* ******** ******** ******* ******* *** ******* ***
***** ******** ********** *** ******* ******** ** *** ******** *********.

**

**

4.********* ********* ********** **** *********** ********** ***************
********** ********* ***** ******* *** **** *** ********* ******** *** ***
******** ** *** ********* ******.

**

**

5.****** ******* *** ****  *** ***** ******* ****** ******* ** ********’* ******
***** ***** ****** *** **** ******** ******** (“***”).  ** ********* ****
******** *** **** **** ****** ** **** **** *** (*) *** ** **** **** ***** (*)
****** ** ********** ****** **** ** ******* ********’* ******** *** ********
******** ********.

***

*****

6.******** *********** *** *********** ********:

 

 

a)******* ****** ****** ******: (*** ****** *********)

**

**

b)***** ** *** ******* *** *********/****** *** *** ******

**

**

c)**** ********* *** ********* *** ********** **** *** *** ***** **** *******
**** ******** ********** ****** ***** ***** ****** ***** ********* ****** *****
***** ***** ***** ******* ***** ******* **** ***** ******** ***** *********
***** ******** ********* ****** ***** *** **** ***** ****.

**

**

d)********* ****** (******** *** ************)

**

**

e)***** ******/*****

**

**

f)******* ****** ********:

 

 

§********* ******** *******; ********* ***** *******; ********* *****/***
*******; ********* ***/********* *******; ** ********* ***** ****** (*** ****
******* *** ****** *********)

**

**

§****** ******* ***** (********) (*** ******* *** ****** *********)

**

**

§******* ***** ****** ** **** ** ******* (*******) (*** ******* *** ******
*********)

**

**

§******* ******** ****** ** ******** (*** ****** *********)

**

**

g)**** ********:

 

 

§******* ****** ** ********* ******* (*** **** ***** *** ****** *********)

**

**

§******* ****** *** ********* ******* (*** ****** *********)

**

**

h)**** ****/****** **** ************* ******** ********:

 

 

§**** **** **** **** ***** (*** ****** *********)

**

**

§**** ******* **** **** ***** (*** ****** *********)

**

**

§**** ********* ******* **** (*** ****** *********)

**

**

§**** **** ***** (*** ****** *********)

**

**

§******* **** **** **** ***** (*** ****** *********)

**

**

§******* ******* **** **** ***** (*** ****** *********)

**

**

§**** ***** ******* (*** ****** *********)

**

**

§**** *** **** ***** **** ******* (*** ****** *********)

**

**

§**** *** **** ************ (*** ****** *********)

**

**

§************ ******* (*** ****** *********)

**

**

B.********* ******** ******** ** *********** ***** ********* **** **********
*****:

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*** ********

*** ********* ***** ******** ** ** *** *********

(***/**)

******* *** ****** *** ********* ***** (** **********)

****: ********* ******** ******** ** *** *** ******* ******** **********
*********** ******* ************ *** ******** *** ****** ***** **********
(****/****** *** **********).  ******** *** *** ************ ******** ***
********* ********* ********* ********* *** *** ******* *** ******* **********
***** *********** ****** *********** ***** ******** ***** *********** *****

********** ***** ***** ******** *** ********* **** ***** *** ****** ***
*********** *** ************** ** ********.

 

 

1.***** **** ** *** ******** *********** **** **** ** *** ** ** ******* ********
********* **** ******* ***.

***

*****

2.******* ********** ******* ********** **** *** ******** ** *** ******* *****
************ ********* **** **** ** ******** ** ******** ** ******* ***
************ ** ***** ****** ******* * ***** ***** ** ********’*.

***

*****

3.******* ********** ******* ********** **** *** ******** ** *** ***** *********
**** **** ** ******** ** ******* ******* ******* *********** **** ** ******** **
*** **** ** ******** *********** ** ********’*.

***

*****

4.***** ***** ********** ******** ********* ********** ** ***’* ******* **
******* ******* *********** **** ********’* ******** ************  ******** ****
******** **** *** ********** ********* ******* ********** *** ******** *******
********* *********.

**

**

5.******* ********** ******* ********** **** *** ******** ** *** ******** *****
***** ************ ********* *** *** ******** ** *** ******* ***** *****
************ ********* **** **** ** ******** ** ******** ** ******* *** *****
***** ************ ******* ******* * ***** ***** ** ********’*.

***

*****

6.******* ********** ******* ********** **** *** ******** ** *** ***** ****
********* ** * ***** ***** ** ********’* **** **** ** ******** ** ******** **
******* ********* ** ************ ***********.

***

*****

7.******* ********** ******* ********** **** *** ******** ** *** ***** *****
(******* *******) ********* **** **** ** ******** ** ******** ** ******* ***
**** ** ******** ******* *** ***** *********** **** *** ** ** ********
*********** ** ********’*.

***

*****

8.******** ********* – ******* *********** ***** ******* **********.

**

**

9.***** ******** ************  *** ********* *********** ***** *** ******* ** **
******** *** ********* ** ******** ** ***** ******* ***** ******** *** *** ***
**** ** ***’* ******* ******** ************** ** ***************  ******** *****
** *********** *** *** *** *** **** ********** **** ***** *****.

§******* *********

§****** **********

§************* ************

§************ ******** **********

§****** ******* *** **********

§****** *** ******** ** ***** *******

§***** ***** ************ ** ***** ******

§**** **********

§***** ***** ******** ******** ** *** **G

§******** *** ***** *********** ******** *** ********

**

**

C.**** ******* (*********) ************** **** (************ *************
***********) *** ********** **** ************

**

**

D.******* ********** *** ******** ******* ****** (***)

**

**

E.*** ***** ******* ***** **** (****) ********** ******* ***
************  ********** ******* ** ******* ** *** ******* ****** (***) *****
*** *****  ********** **** **** ** ******* *** ***** ********* **** ****** *****
*** **** ** *** ***** ** * ******** ********* ** **** ** ****** **
**************  *** ********** ******* *** *********** ****** **** **********
******** ********* ********* ********** ********* *** ********* ********
******** ********* *** ********* ******* *** ********* ******* ********
**********  **** ******** ******* **** ** ******** ** ****  ****** ***********
*** ******* ** *** ****** **** ******** **** ** *** ***** ** * ********
********* ********* ** *****  ****** ************ ******** *** *** *** *******
*** ******** *** ****** **** ******** ** ******* **** ******* ***** ****
****®*  ********** ******* *** *********** ** ******** ** ******* **********
****** **** *** **** *** ******* *********** ******** ** *** ******* ** ***
****** **** ******** ******** ** *** *** ** *** ********* ********** *********
** *********** ************* *******.

***

*****

F.******* *********** ********** *** **** ********  ***** ** ******* **** ******
********** ***** *********** *** ** ********* ** ********** ***** ***********
**** *** ***********  ***** ** ******* **** ****** ********** *** ***** ********
******** ********** **** ***** *** ****.

**

******* **** ****** *********

G.***** *********  ******** ***** ******** *** *******.

***

*****

H.*******

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*** ********

*** ********* ***** ******** ** ** *** *********

(***/**)

******* *** ****** *** ********* ***** (** **********)

a)*** ******* ***** *** ******** ************* *** ***** *********  *** *******
********* ******* *** ******** *********** ***** ******** ******* *** ******
******* ******* ******** *********** *** (*) *** ******* **** *** ******* ***
*********** *** ***** ***** ******** **** ******* ******* ********* ***********
(*****) (*** **** **/***

*******) (******** ******** ** ***** ***** ******** ******** ** ****** ***
******* *********  * ******* **** ** *** ******* *** (*) ** ********
*********  *** ******** * *** (**) ******* ******* **** ** *** ****** ** ** ***
(**) ******* ************** ***** * ****** ******* **** **.

 

******** ****** ** *** *******®* ******* ** *** ********* ******:

§****** ****** * ********* ****** ** ******** ****** **** *** *** ****
*******  ******** **** ****** ******** ** ** ******* ******  ********* ******
****** ****** ***** *** **** *********.

§******** *********** ****** ****** * ****** **** ***** ** ******** ***********
****** *********.  ******** *** ******** ************ ********* *** **********
******** ********* ***** *** *****  ******** *** ***** ** ** *** **** ** ****.

§********** ******** * **** ***** ********** ******** *********** **** ****
***** **********  ******** ********* *** ********* **** ***** ** ********** ****
*** ******** ****.

§*** ********* ********** *******

§******* ******

§***** ******** ******

§*********** ***** *******

§******* ********** ****** ****** *******

§******** ******** ******

§*** ***** ***** (******* **** ** ****** ** ** **** ********  ** ********
******** ********* ****** ** ***** *** ******* *** **** *****.)

§******* *** ***** *** *** ******* *******

§***

§******** *****

§******/******** ******* ** *** ********** ***** ******

§******* ***** ******* **** **********

§*** ********

§****** *** *** **** ******* * ************ **** ** ******** ** ******* ***
*********** (**) ****.

§********* ********** ** *** *******®

 

***

*****

b)******* ********* **** ******* ********* **** *****:

§*** *** ******** ******** ** * **** ********* *********.

§******** ***** **** ****** ** ***’* ******* ********* **** ********* *****  ***
********* **** ********* *********** **** ******* ******* **** *** ****** ****
***** ********** ********** ******** ******** ****** ********** *** **********
**** **** ****   *** **** **** **** ********* ** **** **** **** ******* ****
***** *** ***.

§******** ***** **** ****** ** ***’* **** ******* **** (“***”) ********* *****
***** ** * ********* ********* **** **** ****** *********** **** *** *** *******
********.

§******** ***** **** ****** ** ***’* ******** *********** ****** ******
********* ***** ***** ******* ***** *** ******* ** ***** *** *******
************ ********* ** *** ******* ****** ********** *** *** ******* **
******** ********* ************ **** ******** ****** *** ************ *** ***
***** ******** *********** ********* ** ***'* ******* *******  ********
*********** ****** ****** **** ** *** ** ****** *********; ********* **
********* **** ** *** ***** ** * ******** ********* ******** (****** *** **
***).

§******** ***** ** ******** ** ********* ****** ** ***’* ******* ********* ****
********* ****.

**

**

c)******** *****

§******** ***** *** ********* ************ **** ****** **** ******** ***** ***
*********** (** *********) ********** *** **** ** ** *** ********* ********** **
*** ** ****** ** ******** (“******** **** ** ****”).  *** ******* *** ***** **
****** *** ****** ***** **** ******* **** *** ******** ** ******** *** ***** **
*** ***** *** ******* **** ******* *******  ******** ***** ************ *** **
********* ** *** ********* ****** ******* ******** ** ** ********
**********  ******** ******** *** ******** **** ** **** ** ******** ***
********* *****  *** ********* *** ********* **** ** *** ******** **** ** ****
***** *** ******* ** **** ** ** ******** ** *********** (**) ******  *** ****
********* * ****** **** ** **** ********* ******* *** *** ******* ****** (***)
******  ** ********’* ******** *** **** ******* * ****** **** ** ** *********
******* ** *** ******** **** ** ****.

**

**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

I.******* ************ * ******* ************* ******* (***) *** *******
************ – ******** ***** ******* (***)

**

**

J.**** ****** ******** (***)

**

**

K.*** ********** ******* ******* *** ********’* ********** ********.

**

**

L.***’* *** ******** ******

**

**

M.****** *** (*** **** *****) *** ************ **** ** ******** *************
(***** *************)

**

**

N.***’* ***** ********** ******* *** ******* * *** *** ******** ******** ****
***** ******* *** *** ******* ** *** ******* *** ******** *** ******
**************  *** ******* *** ******* ** *** ******** *** ** ******* *** **
********* ******.

 

§************* ********** *********** – ***** * *** ********** *********** **
***** ***** ** **** *** (*) *********** ****** *** *** (*) ******** ****** ****
** ******** *************  **** *********** ******** ****** ******** ******* **
*** ***** ****** ***** *** *********** ****** ********** **** ***** *** *******
** ** ************  ***** ** ** ******** ******** ** *** ************ *********
*** ********* *** ******** ****** ******** *** *** ******** ** *** ********
******** ** *** ********* *** *** *********.

 

§** ** ********* ******* *************  *********** ****** ** ********** *****
**** *** ****** ** ******* ******** **** ***** ********** ********* ****
******** ** ********** ******** ********* ******** ** ************.

***

*****

O.*********** ******* *** *** **** (*** “****”) ****** **** *********** ** **
****** ** ** ***** *** ****.

**

**

II.**********

 

 

A.***** ******** ***** (***) *** ********* ****** ************** (***)

 

 

1.********* ******* ******** *** ********* ***** ***** *** *** *** ************.

**

**

2.*********** ******* ********** **** ********* ***** ***** *** *** ***
*************  ** *********** ****** ******* ** ******** ******** ** *** **
******** ** ********’* ****** **** ** ******** ***** ***** *** ** ***
*********** ********* ** **** ** ******* ***** ***** *** ** *** *********** ****
** **** ********* ** ***.

**

**

B.*****

 

 

1.***** ********* ******* ******** *** ********* ****** *********** **** *******
********** **** ** **** ******* ********** **** ******** ******* **********
***** ********* ******* *********** *** ******** ********* ***** ***** ***
************* *** ****** *** ****** (***** *** *** *** ***********).  ********
** *********** *** ***** ***** ****** ********* ** ******** ** ****** *** ******
(***** *** *** *** ***********) *** *** ********** ****.

**

**

2.******* ********* (****** ***********).  *** ** *** **** ********** **** ***
(*) ********* ************* **** *** ** *** ****** ******* *********
************  *** ********** ********* ************** ** ******* ** *** *******
********* ************* *** ** ********* ***** * **** ******** ********* ** ****
** ***’* **** ******* *****.

 

***

*****

C.********** ****

 

 

1.********* ******* ******** *** ********* ***** ***** ********** ****
************ ************.

**

**

2.**** ***** **** *** ***** ****** ********** (*** *********** ******)

**

**

D.*** *******

**

**

III.******* ***********

 

 

A.******** ******** ** ****** ********* (***** *** ****)

 

 

1.******* *******/******** ***** *** ********* ****** **** *** **** **** *****
******* *********** ******** ****** ****** **** *** **** **** *** *******
******** *** **** *** ****** ****** **** *** **** **** *** *******.

**

**

2.********* ***** ******* **** ******** *** **** **********.

**

**

3.****** *********** – ******* ****** *******.

**

**

4.********* ******* ********* ****** (**) ****** ** ******* ********* ********
*** ****** (*** ********* **********).

***

*****

B.**** ******* ******** (********** **** ***********) ********** ****
*********** *** ******* **** *******.

**

**

C.**** ******* )************ *******)

**

**

D.********* *****™* ***** ******* (**********) ********* ****** (**** **
***********) *** ******** ****.

***

*** ******** ***

E.******* ************ (************ *********** ******* ********* ***
**********/***** ******** ******* ***** ********* *** ** ** *** ******)

**

**

F.******** *** ********* ****** **** (******** ****** **** ********
************* *** ***********)

**

**

G.******* *******

**

**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

H.******** *** ********* ********** ******* (***) (******** *** ***** ***
********

************* ************ ***** ******* ************ ** ******* ********** ***
***********)

**

**

I.**** ******** ******** (******* *** **********).  **** ******** ********* **
*** ********** ** ***** ******* ******** *** ******* *** ********** ********
******** ********* ********* *** ******** **** ***** ** ******** ***********
******  ********** ******* *** ********* *** ***** ** ********* **** *******.

**

**

J.***** ******* ******* ********

**

**

IV.****** ********** *** ***********

 

 

A.**** ********** (******* *********)

**

**

V.****** *** ************ ********** ********

 

 

A.****** ********** *********  ******** ****** ******** ************ **** **
***** ***** *** ************ **** ** ********* **** *** ****** **********
******** ********** **** ***** *** ********** **** ************  ******** ***’*
******** ********** *********  ****** *********** *** *********** *** ***
******** ** ******* ******** ********* **** **** **** **** ****** ************  
*** ****** ********** ******** *** *** ********** **** ***** ** *** ***** ** *
******** ****** **** ********* ** ****.

**

**

B.************ ********** *********  ***** ********* *** ******* *********
************ ********** ******** ********** **** ***** *** ********** ****
************  ******** ***’* ******** ********** *********  *** ************
********** ******** *** *** ********** **** ***** ** *** ***** ** * ********
****** **** ********* ** ****.

**

**

VI.********** ******** *** *************

 

 

A.*********** ******* ************* *** ******** *** ******* ************* ***
***** (***’* ******** ******* ** *****://*****************).

**

**

VII.***** ************/*********

 

 

A.******** ********** ********** ****** *********** ******** **********
********** ****** *********** *** *** (*) ******* ****** *** *** (*) ********
*******  **** ****** ******** ** ******** ** ******* ***** **** *** **** *****
******** ****** **** *********** ** ********’* ************  ********** *******
** ******* ** ***** **** (**) ***** *** ******  ********** **** **** ** *******
*** ***** ********* **** ******* ***** *** **** ** *** ***** ** * ********
********* ** **** ** ****** ** *************.

***

*****

B.***** ******* ******* ******** ********** ******* *** ************  **********
******* **** ******** ***** *** ********** ** ***** ******* ******* ******** **
***********  ********** ******* ** ******* ** *** ******* ******* (***) *****
*** *****  ********** **** **** ** ******* *** ***** ********* **** ****** *****
*** **** ** *** ***** ** * ******** ********* ** **** ** ****** **
**************  *** ****** ********** ******* *** *********** *** ****** ****
********** ******** ********* ********* ********** ********* *** *********
******** ******** ********* *** ********* ******* *** ********* ******* ********
**********  *** **** ** *********** *** ********** ** ***** ******* *******
******** ********  ****** *********** *** ******* ** *** ******** **** ** ***
***** ** * ******** ********* ********* ** *****  ****** ************ ********
*** *** *** ******* *** ******** *** ******** ** ******* **** ******* ***** ****
******  ********** ******* *** *********** ** ******** ** ******* **********
****** **** *** **** *** ******* *********** ******** ** *** ******* ** ***
***** ******* ******* ******** ******** ** *** *** ** *** ********* **********
********* ** *********** ************* *******.

***

*****

C.****** ***** ******* *********  ********** ******* **** ******** ***** ***
********** ** ****** ***** ******* ********** ******** ** *********** 
********** ******* ** ******* ** ****** (**) ***** *** *****  *** ******
********** ******* *** *********** *** ****** **** ********** ******** *********
********* ********** ********* *** ********* ******** ******** ********* ***
********* ******* *** ********* ******* ******** **********  *** **** **
*********** *** ********** ** ****** ***** ******* ********** ********
********  ****** *********** *** ******* ** *** ******** **** ** *** ***** ** *
******** ********* ********* ** *****  ****** ************ ******** *** *** ***
******* *** ******** *** ******** ** ******* **** ******* ***** ****
****®*  ********** ******* *** *********** ** ******** ** ******* **********
****** **** *** **** *** ******* *********** ******** ** *** ******* ** ***
****** ***** ******* ********** ******** ******** ** *** *** ** *** *********
********** ********* ** *********** ************* *******.

***

*****

D.******* ******* ***** *********  ********** ******* **** ******** ***** ***
********** ** ******* ******* ***** ******** ** ***********  ********** *******
** ******* ** ****** *** (**) ***** *** *****  ********** **** **** ** *******
*** ***** ********* **** ****** ***** *** **** ** *** ***** ** * ********
********* ** **** ** ****** ** **************  *** ****** ********** ******* ***
*********** *** ****** **** ********** ******** ********* ********* **********
********* *** ********* ******** ******** ********* *** ********* ******* ***
********* ******* ******** **********  *** **** ** *********** *** ********** **
******* ******* ***** ******** ********  ****** *********** *** ******* ** ***
******** **** ** *** ***** ** * ******** ********* ********* ** *****  ******
************ *** ******** *** *** *** ******* *** ******** *** ******** **
******* **** ******* ***** **** ****®*  ********** ******* *** *********** **
******** ** ******* ********** ****** **** *** **** *** ******* ***********
******** ** *** ******* ** *** ******* ******* ***** ******** ******** ** ***
*** ** *** ********* ********** ********* ** *********** *************
********  *** **** **** *** ******* ******* ***** ******** ** *** ******* ***
******* *** (*) ******* ******** ** *** *** ********.

***

*****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

E.*** ** ******** *** ******* ********* ********** ******* **** ******** *****
*** ********** ** ** ******** *** ******* ******** ** ***********  **********
******* ** ******* ** *** ******* ******* (***) ***** *** *****  ********** ****
**** ** ******* *** ***** ********* **** ******

***** *** **** ** *** ***** ** * ******** ********* ** **** ** ****** **
**************  *** ****** ********** ******* *** *********** *** ****** ****
********** ******** ********* ********* ********** ********* *** *********
******** ******** ********* *** ********* ******* *** ********* ******* ********
**********  *** **** ** *********** *** ********** ** ** ******** *** *******
******** ********  ****** *********** *** ******* ** *** ******** **** ** ***
***** ** * ******** ********* ********* ** *****  ****** ************ ********
*** *** *** ******* *** ******** *** ******** ** ******* **** ******* ***** ****
****®*  ********** ******* *** *********** ** ******** ** ******* **********
****** **** *** **** *** ******* *********** ******** ** *** ******* ** *** **
******** *** ******* ******** ******** ** *** *** ** *** ********* **********
********* ** *********** ************* *******.

***

*****

VIII.*** ******** ********

 

 

A.******* ************ *** ***** ********** *****

 

 

1.********** ******* *** ***** **** (*** *******), **** ****** *** **** *****
***** ***** **** *** ****** *******/******* ******** *** ********* ******** ***
******** *** ********* *********** *** ********* ********** (******
***********), *** *** ******** ******** ** ***** *********** *** *********** ***
*** ******* ********* ************ ********** **** ***** ********* ********* ***
*** ******* *** ******** *** *********** ************ *** *********.

**

**

2.******* ******** *** ***** **** (***********), **** ****** *** **** *****
***** ***** **** *** ****** *******/******* ******** *** ********* ******** ***
*** *******.

**

**

3.*** ******** ******* ******** ********* ******* ******** ****** ********
****** ************ *** ******** ***********.

**

**

4.***** ***** ************* ******** *** *********** ***** ********.

**

**

5.*********** *********** **** (***)

**

**

6.*** ******* ********* ****** * ********** ******* *** *** ********’* ********
******** **** ***** ******** *** ** ********’* ************  *************** ***
***** ********** ** *** ********** **** ********** ******* ** ******* ** ***
********** ***** *** ********* *********** ********* ********* ** ***’* ***
********* ***** ***** ******* ******* ****** *** ******** ** *********
***********.

 

*** **** ******* *** ******** *** *********:

§*********** *** *********** ***:

§***** ******** (“***”)

§******** **** *******/******** *********

§******** ********* ************* ****

§***** ***** ************* ******** *** ****** *** ********

§************** ******** *** *** *********:

§***

§***

§******** **** *******/******** *********

§******** ********* ************* ****

§***** ********

§******** *** *** *********:

§***

§***

§*** ******* *** *** ******* ** ********

 

*** **** ******* *** **** *** ******* *** *********:

§******** *** *** *** ******

§************ ********

§****** ******* ***************

§***** ** ***** ************ ** *** *** ******

**

**

B.***** *** ******** ********

 

 

1.********* ********** ********** *** ***********; ********* ******* ******* ***
********* ******* (*** *** ** **** ****** *** *****), *** (******** *******),
*** ********* ******* ******* ******* *** ****** *** ******* (********
************** *** ****** ********* ** ******* ******* *** ***** ****
*********** ****** *** ** ********* ** ******* ***’* *** ****  *** ****** **
******* ***** ** ********** ** *** ***** ****** ** ****** ******* **** **** ****
******* ** *** *** *** *** ****** *** ******** *** **** **** **** ****** ******
*** ***** ****** ******** **** *** ***** *** ** *** ***** ***** ******* ***
***** *** ** *** ***** ***** (*** “*** ***** *****”)), *** ****** ******* ***
*** *******

**

**

2.****** ***** ******* – **** ******* ******* * *** ************* ******** **
“****** *** ****** ***** ****” ***** ** ******* ** **** ****** ****** *****
************** (***) **** ****** **** *** ****** *** ******* ******* **********
** *** ********* **** * *** **** *** *******’* ************** ***** ******* ****
** ********* *** **** *** **** ** *** ******* ***** ** *** **** ** *** *********
***** ** * *** ********* **************** ******* ******* ******* *** ****** ***
******* *** ********** ** *** ******** ****** *** *** ************** ****.

**

**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

IX.*************

 

 

A.******* ***/** ****** ********* **** ******** ** ** *** ** *** (**** **** ***
*** ************ ****** ** *** ***** ******* ** ******* ******* ** ******** *)

 

 

1.******* ******* *** ********’* ******* ******** ********** ******** (“***”)
***** **** *********** ******** ** ***’* **** ****** *** ***** ** *** **********
** ***** ******** *** ******** *** ****/*** *** *** ******* ** ***** **
********* ********* ** ****** ****** (********’* ***** *). (*** #********)

**

**

2.*** **** ****** * ****** ******** ** **** *** ****/**** *** **** **** **** **
********* ** *** *** *********** ** ******** *** ******** ********* ********
(**#* ******** #******** ** *** #********)

**

**

3.******* ******** ******* *** ********’* ********* ******/***** ***** ******
*** ****** *** *** ***** ******* ************ ***** *** ******* ********
********** ******** (“***”) ** ***’* **** *******  **** *** ** ******** ********
*** ********** *** ********* ******/***** ** ****** *** ********’* *******
************* (*** #********)

**

**

4.“*** ***** ****** *** **** *** ** ******* **:   *******:  ****/****/**** ****
***** **** *** ** *** *****”* (** #* ******** #******** ** *** #********)

**

**

5.******* ******** ******* *** ********’* ********* ******/***** ***** ******
*** ****** *** *** ***** ******* ************ ***** *** ******* ********
********** ******** (“***”) ** ***’* **** *******  **** *** ** ******** ********
*** ********** *** ********* ******/***** ** ****** *** ********’* *******
************* (*** #********)

**

**

6.******* ******** ******* *** ********’* ********* ******/***** ***** ******
*** ****** *** *** ***** ******* ************ ***** *** ******* ********
********** ******** (“***”) ** ***’* **** *******  **** *** ** ******** ********
*** ********** *** ********* ******/***** ** ****** *** ********’* *******
************* (*** #********)

No

No

7.“*** ***** ****** *** **** *** ** ******* **: *********:  ****/**** **** *****
**** *** ** *** *****” (** #* ******** #******** ** *** #********)

**

**

8.*** ** *** ********* **** ********* *** *** ******** **** **** ******/**** **
**** *********** ** ****** * ****** ********** ** ******** ************ **
*********** ****** *** ******* **** * ********** ******* ***********  ****
******* ******* ******* *** **** ************ (*** #********)

**

**

9.********* * ****** ******** ** ***’*® ********* *** **** ***’* **** ****
*********** *** ******* ********* *** *********** ********(*** #********)

**

**

10.************ ************** *** ************** ** *** *** *********® *******
********* ****** (“***”) ********** (“*** *********”) ** ******* ** ***
********’* ******* ********* ***** *********** **** * *** *************
*********** *** ******** ********** ************ (*** #********)

**

**

11.*** *********** ** ********’* *********** ************ (“**********”),
*********** *** ************* (“***”) *** *** ** *** ******* *** *** ***********
******** (********)

**

**

12.************ ************** *** ************** ** ***’* ***** ************
********* ** ******* ** *** ********’* ********** ******** *********** **** *
*** ***********/************* ************ *********** **** *********** (****),
********** **** *********** (****), *** ******** ********** ************ (***
#********)

**

**

13.*** **** *** ** *** ********* ******* ****** (****/****) ** **** *** ******
** ******* *** ******* **** ******* ******* ******* *** **** ************ (***
#********)

**

**

14.*** **** *** ** *** ********* ** ****** *** ********* *** (** ********) ***
****** ************* **** ******** **** ***** **** ** ** *********** ******* **
****** *** ***** **** *********** *** ******** ** ****/***** (*** #********)
(*** #********) (***********)

**

**

15.************** *** *********** ** ******* * ******** *********® ***
*********** **** ************ (*** #********)

**

**

16.*** ******* *** *** ****** ********** **** ******; ******* ***** **** ******
********; ********* ** ***** (*** #********)

**

**

17.****** ******* ******** **** ******* *************** (*** #********)

**

**

18.****** *************** *** ****** ******* **** *** *** *********** **********
(*** #********)(**** *)(**** *)(**** *)

**

**

19.**** ***** *********** ******** (“****”) **** ****** *** *** *** ***(***
#********)(*** #********)

**

**

20.*** ** *** ********* ** ******** ** * ******* ******* ******* ****** (“****”)
*********(*) *** *** ******** ****/**** ******/**** ** **** ************ ***
******** ** **** ********* **** ******* ****** ******* ** *** *** **** **** ***
**** ******* ******** ******* ********* ** **** *** *********** ************
**** **** ******* *** ***** ********** *** ***** ********** ** *** ********
****/**** ****** **** (*** #********)

**

**

21.*** *******®***** ******** **** ** ****** (*** #********)

**

**

22.******** ******** ********* **** *** ************ (*** #********)

**

**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

23.************* *** ****** ********** ********** ** *** ******** **** *** ****
(***

#********)

**

**

24.******** ****** *********** **** *** **** *******® ******** (*** #********)

**

**

25.********* ***** *** ** ******* * *** ******** **** ****** ********* ** ****
**** *********** (*** #********)

**

**

26.******* ********* ** ******* ********’* *********** ******* **** (***
#********)

**

**

27.*** *******® ************** (*** #********)

**

**

28.*** *******® ************** – **** (*** #********)

**

**

29.*** ** *** ********* * ******** ******** ********* (** ********) *** * ***
********** *** *** **** **** ** **** (*** #********)

**

**

30.***** *** ************* ** ****** *** ********* *** (*** #********)

**

**

31.****** *** ********* * ******** ********* ** **** *** **** **** *** **** ****
(*** #******** *** *** #********)

**

**

32.******** ******* **** **** (‘***’) ********** (*** #********)

**

**

33.********* ***** ************ ****** *** ******** ******* (*** #********)

**

**

34.*** **** ********* *** ******* *** ******* ****** *** *** **** *** ***
******** ********* ** **** *** ********** **** (****) *** **********
************ *** ******** (** #* ******** #******** ** *** #********)

**

**

35.****** *** ************** ** ***** ***** ******** ******* ** *******
********* ** **** ******* (*** #********)

**

**

36.*** ** *** ********* ** *** ********* *** **** ****** ***** **** **** ***
**** **** ** **** (*** #********)

**

**

37.********* ***** *** ** ******* ******** ****** ***** **** **** *** **** ****
** **** **** *********** (*** #********)

**

**

38.*** ** *** ********* *** ******** ********** *** ****** ***** ****/**** ***
****/**** ** **** (*** #********)

**

**

39.*** ** *** ********* ******** *** ********** *** ****** ***** ****/**** ***
****/**** ** **** (*** #********)

**

**

40.********* ***** *** ** ******* ******** ****** **** **** **** *** **** ****
** **** **** *********** (*** #********)

**

**

41.*** ** *** ********* *** ********* ****** (** ********) ********** *** ******
***** ****/**** *** ****/**** ** **** (*** #********)

**

**

42.********* *** ********* *******® *********** ******* ** **** (*** #********)

**

**

43.************** ** ******** *** *******® ******** *** ********’* **** ****
*********** (*** #********)

**

**

44.*** ** *** ********* ***** (*) ****** ***** *** *********** ********* ** ****
(*** #********)

**

**

45.********** ******* *** ********* *** *********â *** ********* ** ******* **
*** ********’* ********* ****** ********** ******** ** ***** ** ******* ***** **
****** ********** *** **** **** ****** * **** *********** ***** ******** ***’*
** *** **** ****** ** ******* ********’*  ********** ************ **********
(*** #********)

**

**

46.*** ** *** ********* *** (*) *** ****** ** ******* **** ********* ***
*********® *** ** ******* ** *** ********’* ********* ****** ********** ********
(****) ** ***** ** ******* ***** ** ****** ********* (*** #********)

**

**

47.*** ****** *******® ****** *** ******** ** **** ****** ** *** ********
******** (******** ******** ***** ******* *** ************ *******) (** #*
******** #******** ** *** ##********)

**

**

48.*** ** *** ********* *** (*) **** (** ********) ********* ****** *** ****
**** ** **** (*** #********)

**

No

49.********* ***** *** ** ******* ******** ****** **** **** **** ** **** ****
*********** (*** #********)

**

**

50.********* *** ******** ****** ** ***’* ****** *******®**** ******* (***
#********)

**

**

51.*** ********* *******® (***) ******* ** ******* ********************* *******
***** (*** #********)

**

**

52.********* ******** *** ********* *** ***** ************ ********* ** *******
** *** ********’* **** ******* *** *********** (*** #********)

**

No

53.********* *** ****** *******®**** ******* **** ***** ******* **************
******** (*** #********)

**

**

54.******* *** ********* ***** *** ** ******* ********’* ****** **** **** ****
** **** **** *********** (*** #********)

**

**

55.********* *** ****** *******®**** ******* **** ****** *******
***************** (*** #********)

**

**

56.*** *******®***** ******** **** ** ****** (*** #********)

**

**

57.*** ** *** ********* ****** ** ******* **** ****** *** **** *** **** *****
*** ******** ** **** ********* **** ******* ****** ******* ** *** ********’*
****** ******** *** **** ******* ******** ******* ********* ** **** ***
*********** ************ **** **** ******* *** ***** ********** *** *****
********** ** *** ******** ****/**** ****** **** (*** #********)

**

**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

X.**** ************** ********

 

 

A.****

**

**

B.** ******* ******** ** ******* *** **** *** ******* (********* *********)

**

**

C.****** ******* * *** *** ********* ** ***** ** ******* ******** **** ***** ***
********* *** ** ******* * ******** ** *** ********* ******** ***
*******  ******** ** *********** *** *** *** *******(*) **** *** ******** **
**** ** *** ********* ********** **** **** ******** ********* *** **** *******
***** *** ******(*).  *** **** ******* * "******" **** ***’* ***** ******
**********  ********* ******** *** ******** ******* ***’* ****** **********

 

*** ***** ***** ****** *********** **** ** ******** *** ******** ** * ***
********.

 

*** ****** ******* ******** *******:

1.***** **** *** ***** **** *******

§***'* ****** ** *** ********* ********

§********* ***** ********

§********** *** "*** *******" ** ******* ********** *** ***********

§******* ** ***** ** * */** *********** *********

§******** **** ****

§******** *** ***** ********* ** ****** *** ***** *** ***’* *********

2.******* ****

§********* ** ******* * "******" *** **** ******** ** * ******* *********
******* ** *** *******

3.********

§******* *** ********* **** ***** ** "*******" ***** *** *********

4.******** ***** *****

§* *********** *********** ***'* ******** *** *** ******** *********

5.********* *** **********

§*** **** * **** ********** **** *** ********** ** *** *********

6.****** **********

§***** ** ******* *** ***** ******** ***** **** ******** *** ******** *******

§***** ** **** ** ******* ******** **** * ********* *** **** ********

§***** ** ** ****** ***** ********

§***** ** ******* ***********/******** ********

7.******* ********

§** ******* ***'* ****** ******* *********

§**** *** ******* ******** *** *** ********'* *********

 

******** **** ***** ***** ********** *** ******* ******** *** *** ***** ********
**** **** *** **** ****** *** ********** ****.

**

**

XI.******* ******** * *********

 

 

 

**** ** *******

# ** **** ****

(****** ******* ******* ********* ********)

 

 

A.**** ******* *************

** **** **** **** ***** **** ***’* ***** ******* ****** ***** ****** ****** **
**** ******* ************** ***** *** **** * ** ** *****

**

**

B.********** ******* (****** ** *********)

** ******** ****

**

**

C.******* ****

** **** ****

**

**

D.******** ****

§**********

§************** (*** ***** **)

****: *** ***** ** = *** ******* *** ***** ** ******** ******** ********  ***
******** *********** ******* **** ****** ********.

 

 

****** ** **** ****; ******* ** ********* (****)

**

**

E.********

****** * **** ****; ******* * **** ****

**

**

F.****** ******* (****** ******* ***** ** ******* ******/********* ***/******)

****** * **** ****; ******* * **** ****

**

**

G.*********** ** ****** (*** ********)

****** * **** ****; ******* * **** ****

**

**

H.*********** (****) ******** **********/******** ********* (******* *****
*****/******* ******* * ************* **  *** **********/*********** ******)

****** * **** ****; ******* * **** ****

**

**

I.***/*********** ********* (****)

****** * **** ****; ******* * **** ****

**

**

J.*** *** *** ********* **’* *** ********** ********

****** * **** ****; ******* * **** ****

**

**

K.****** ***

****** * **** ****; ******* * **** ****

**

**

L.****** ***

*** **********

**

**

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

X.**** ************** ********

 

 

A.****

**

**

B.** ******* ******** ** ******* *** **** *** ******* (********* *********)

**

**

C.****** ******* * *** *** ********* ** ***** ** ******* ******** **** ***** ***
********* *** ** ******* * ******** ** *** ********* ******** ***
*******  ******** ** *********** *** *** *** *******(*) **** *** ******** **
**** ** *** ********* ********** **** **** ******** ********* *** **** *******
***** *** ******(*).  *** **** ******* * "******" **** ***’* ***** ******
**********  ********* ******** *** ******** ******* ***’* ****** **********

 

*** ***** ***** ****** *********** **** ** ******** *** ******** ** * ***
********.

 

*** ****** ******* ******** *******:

1.***** **** *** ***** **** *******

§***'* ****** ** *** ********* ********

§********* ***** ********

§********** *** "*** *******" ** ******* ********** *** ***********

§******* ** ***** ** * */** *********** *********

§******** **** ****

§******** *** ***** ********* ** ****** *** ***** *** ***’* *********

2.******* ****

§********* ** ******* * "******" *** **** ******** ** * ******* *********
******* ** *** *******

3.********

§******* *** ********* **** ***** ** "*******" ***** *** *********

4.******** ***** *****

§* *********** *********** ***'* ******** *** *** ******** *********

5.********* *** **********

§*** **** * **** ********** **** *** ********** ** *** *********

6.****** **********

§***** ** ******* *** ***** ******** ***** **** ******** *** ******** *******

§***** ** **** ** ******* ******** **** * ********* *** **** ********

§***** ** ** ****** ***** ********

§***** ** ******* ***********/******** ********

7.******* ********

§** ******* ***'* ****** ******* *********

§**** *** ******* ******** *** *** ********'* *********

 

******** **** ***** ***** ********** *** ******* ******** *** *** ***** ********
**** **** *** **** ****** *** ********** ****.

**

**

XI.******* ******** * *********

 

 

 

**** ** *******

# ** **** ****

(****** ******* ******* ********* ********)

 

 

M.*** ***** *** *********** ******* (*/* ****)

****** * **** ****; ******* * **** ****

**

**

N.****** ***** *** *********** ******* (*/* **** *** *******)

****** * **** ****; ******* * **** ****

**

**

O.*** ** *** *********** ******* (*/* ****)

(******* ***** **** ** ******** ** *:** ** *** *** ******** *******  ********
***** **** ** ******** ** *:** ** *** *** ******** *******.)

****** * **** ****; ******* * **** ****

**

**

P.*** ** ******* ****

******* ** * **** ****; **** ***** * ********

**

**

Q.*** **** *** ** ******* *************

****** * **** ****; ******* * **** ****

**

**

R.****** **** *** ** ******* *************

******* * **** ****

**

**

S.*** ****** ****

****** * **** ****; ******* * **** ****

**

**

T.*** *** *** ****** (******** *** ***********)

****** * **** ****; ******* * **** ****

**

**

U.****** *** *** ****** (******** *** ***********)

****** * **** ****; ******* * **** ****

**

**

V.*** *** *** ******** ****** ******* (******** **** *** *********** **********)

****** * **** ****; ******* ** **** ****

**

**

W.****** *** *** ******** ****** *******

****** * **** ****; ******* ** **** ****

**

**

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule F.2

PRICING FOR EXCESS BSC THRESHOLD LEVEL

 

 

A.

********* *****™

 

*********** ** ****/**** ** *******

*********

***

1.********* ****

 

 

a)****** **** ***** ** ****** ******* ******* ** *********** (**** ***)

 

 

§********** (******* *** $****** *** ********* *****™)

********

******** ** ***

§*********** ********** *** * ***** ** ********** (******* *** $****** ***
********* *****™)

********

   $*********

§*********** ********** *** * ***** ** ********** (******* *** $****** ***
********* *****™)

********

$*********

§*********** ******* *** * ***** ** *********** (******* *** $****** ***
********* *****™)

********

$**********

§*********** *********** *** * ***** ** *********** (******* *** $****** ***
********* *****™)

********

$**********

2.********* **********™

 

 

a)******** ** *******

*** ****

*****

Note 1: ********* *****™ ******* *** **** ** ****** ********  ******** ********
** ******* ****** ****** ******** ** *** ***; ** ******** ******* ** ********
*** ***** ****** **** *** ** ******* ****** ****** **** ** * ****** ***** ******
****** *** ****** ***** ******* *** **** ******* ******** *** *** ***********
***** ****** ** *** ******* *** ***** **** ** *** ******** ********* ******
****** *****  **** *** ********** ** *** ************ ******* *** **** *******
****** ** *** ************ **** *** *** *** ****** ****** ****** ****.

Note 2: ******* *** **** ** ******** ******* ** ******** *** **** ***** **
******** ******* *** ****** ****** ******* ********** * *** ******.

Note 3: ********* *****™ ****** ******* ****** **** ** **** ****** *** ******
(**) ***** ******.

 

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule F.3

Supporting Examples for Sections I & II of Schedule F

 

 

******** *

******** *

******** *

******** *

******** *

******** *

******* ******* * * ***********

 

 

 

 

 

 

**** ******* **** ** ***

             ******

               ******

             ******

               ******

               ******

               ******

********** ***********

                     *  

                 *****

               *****

                 *****

                 *****

                 *****

******* ******

                     *  

                       *  

               *****

                 *****

                 *****

                 *****

*********

           ******

               ******

             ******

               ******

               ******

               ******

 

 

 

 

 

 

 

*** *********** ******** ****** *** *****

                     *  

                       *  

                     *  

                 *****

                 *****

                       *  

*** *********** ******** ****** ***** *******

                     *  

                       *  

                     *  

                       *  

                 *****

                 *****

***** *** *********** ********

                     *  

                       *  

                     *  

                 *****

                 *****

                 *****

 

 

 

 

 

 

 

**** ****

                     *  

                       *  

                     *  

                       *  

                       *  

               (*****)

 

 

 

 

 

 

 

***** ********* ***********

             ******

               ******

             ******

               ******

               ******

               ******

**** ***** *** *********** ********

                     *  

                       *  

                       *  

                 *****

                 *****

                 *****

********* *********** *** ********* ********

             ******

               ******

             ******

               ******

               ******

               ******

 

 

 

 

 

 

 

********** ******* *** *** ********* **** (****)

$          ******

$           ******

$          ******

$           ******

$           ******

$           ******

********** ******* *** *** *** **** (****)

$          ******

$           ******

$          ******

$           ******

$           ******

$           ******

 

 

 

 

 

 

 

*** *** *** ********* ***********

$            *****

$           ******

$          ******

$           ******

$           ******

$           ******

*** *** *** ***** *** *********** ********

                     *  

                       *  

                     *  

                 *****

                 *****

***

                 *****

***** ******* ***

$             9,089

$           ******

$          ******

$           ******

$           ******

$           ******

 

 

 

 

 

 

 

******* ******* ***********

 

 

 

 

 

 

*) ********** ******* *** *** ********* **** (****)

$          ******

$           ******

$          ******

$           ******

$           ******

$           ******

*) ********** ******* *** *** *** **** (****)

$          ******

$           ******

$          ******

$           ******

$           ******

$           ******

 

 

 

 

 

 

 

** * **** **** *?

**

**

***

***

***

**

** *** **** *** ***** ******* *** ** ********** *****

 

 

 

 

 

 

 

 

 

 

 

 

 

** **** **** ***** ****** ****

**

**

$          ******

$           ******

$           ******

**

***** ******* *** ********** ***** ******* *******

$                  *  

$                    *  

$          ******

$           ******

$           ******

$                    *  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******* ***** *********** * *********** ** *** *** ***

 

 

 

 

 

 

 

 

 

 

 

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

** ********* *********** *** ********* ******** > ******?

**

**

***

***

***

**

** *** **** *** ***** ******* *** *** ** ****

 

 

 

 

 

 

** **** *** ***** ** ******* ***** *****

$                  *  

$                    *  

$          ******

$           ******

$           ******

$                    *  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

***** ******* *** **** *****

$            *****

$           ******

$          ******

$           ******

$           ******

$           ******

***** ******* *** *** **** *****

$                  *  

$                    *  

$          ******

$           ******

$           ******

$                    *  

 

 

 

 

 

 

 

***** ******* ***

$            *****

$           ******

$          ******

$           ******

$           ******

$           ******

 

 

 

 

 

 

 

******* ***** * *** ***********

 

 

 

 

 

 

 

 

 

 

 

 

 

******* **** ********* *********** ******

             ******

               ******

             ******

               ******

               ******

               ******

***** *** *********** ********

                     *  

                       *  

                     *  

                 *****

                 *****

                 *****

 

 

 

 

 

 

 

***** ******* *** ***********

             ******

               ******

             ******

               ******

               ******

               ******

******* **** *********** ******

             ******

               ******

             ******

               ******

               ******

               ******

 

 

 

 

 

 

 

******* **: ******* *** *** ***** ** ****

****

****

****

****

****

****

******* ******* ***

$          ******

$           ******

$          ******

$            ******

$           ******

$            ******

***** ******* *** ***

$          ******

$           ******

$          ******

$           ******

$           ******

$           ******

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

 

Supporting Examples for Sections I & II of Schedule F

 

 

 

 

******** *

******** *

******** *

******** *

 

******** *

******** *

 

******** *

******** *

******** ********

(****** ********** ********* ****** **** ****** ******* **** ******* ********)

**** ****

******** ** ************ ***** *** *********** (** ****** ** ***** *** ***)

**** ******** ** ************ / ** ****** ** ***** ** ***********

*** ******** ** ***** / ** ****** ** ************ ** ***********

******** * **** *** ******** ** *********** (******* ** ****** ** *** *****
***************)

 

*** ********* ***** ** *** ***** ** ****** ** ***** *****

*** ********* ***** ** *** ***** *** ****** ** ************

 

*** ********* ***** *** *** ***** ** ****** ** ***** *****)

*** ********* ***** ****** ***** *** ****** ** ************

**** *: ******* ****** ********* **** ************ *** ***** ******* ***** ***
*** ******* *****

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

********* **** ************

            *********

            *********

            *********

            *********

            *********

 

            *********

            *********

 

            *********

            *********

 

***** ******* *****

       ***********

       ***********

       ***********

       ***********

       ***********

 

       ***********

       ***********

 

    *************

    *************

 

 

 

 

 

 

 

 

 

 

 

 

 

**** *: ********* ******* ********* **** ************ *** ******* ******* *****

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

********* ***********

          **********

          **********

          **********

          **********

          **********

 

          **********

          **********

 

          **********

          **********

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******* ********* **** ************

                 ******

                 ******

                 ******

                 ******

                 ******

 

                 ******

                 ******

 

                 ******

                 ******

 

******* ******* *****

               *******

               *******

               *******

               *******

               *******

 

               *******

               *******

 

               *******

               *******

 

******* ******* *** *** ***** ********* ***********

                   *****

                    *****

                   *****

                    *****

                   *****

 

                    *****

                    *****

 

                    *****

                    *****

 

 

 

 

 

 

 

 

 

 

 

 

 

Step 3: Determine Excess PVU’s per 1,000 Connected Subscribers

 

 

 

 

 

 

 

 

 

 

 

 

******* ******* *** *** ***** ********* ***********

                    *****

                    *****

                    *****

                    *****

                    *****

 

                    *****

                    *****

 

                    *****

                    *****

 

******* **** *** *** ***** ********* ***********

                    *****

                    *****

                    *****

                    *****

                    *****

 

                    *****

                    *****

 

                    *****

                    *****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

 

******* ****** *** *** ***** ********* ***********

                          *  

                          *  

                       ***

                         **

                         **

 

                          *  

                       ***

 

                          *  

                       ***

 

 

 

 

 

 

 

 

 

 

 

 

 

**** *: ********* ******** ****** *** *** ***** ********* ***********

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

********* ***********

          **********

          **********

          **********

          **********

          **********

 

          **********

          **********

 

          **********

          **********

 

****: **** ********* ***********

          **********

          **********

          **********

          **********

          **********

 

          **********

          **********

 

          **********

          **********

 

******** ********* ***********

                          *  

          **********

                          *  

                          *  

            *********

 

          **********

          **********

 

          **********

          **********

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******** ********** ****** ***** **********

******

******

******

******

******

 

******

******

 

******

******

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******** ******* ****** *** *** ***** ********* ***********

                          *  

                          *  

                       ***

                         **

                         **

 

                          *  

                       ***

 

                          *  

                    *****

 

 

 

 

 

 

 

 

 

 

 

 

 

**** *: ********* ******* **** ********** ***

 

 

 

 

 

 

 

 

 

 

 

 

******** ******* ****** *** *** ***** ********* ***********

                          *  

                          *  

                       ***

                         **

                         **

 

                          *  

                       ***

 

                          *  

                    *****

 

******** ******* ****** **** *** *** *** ***** ********* *********** *** *****

$                    ***

$                    ***

$                    ***

$                    ***

$                    ***

 

$                    ***

$                    ***

 

$                    ***

$                    367

 

******* **** ********** ***

$                       -  

$                       *  

$              ******

$                *****

$                *****

 

$                       *  

$            *******

 

$                       *  

$            *******

 

  ***** ** ** **** **** ****

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

**** *: ********* ***** ******* **** ********** ***

 

 

 

 

 

 

 

 

 

 

 

 

a) ******* ***** ***** ******* **** ********** *** (******* ****)

$                       *  

$                *****

$              ******

$                *****

$                       *  

 

$                       *  

$            *******

 

$                       *  

$            *******

 

b) ******* ***** ******* **** ********** ***

$                       *  

$                       *  

$              ******

$                *****

$                *****

 

$                       -  

$            *******

 

$                       -  

$            *******

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******* ** *) ** *) ***** ****** ***** ******* **** ********** ***

$                       -  

$                *****

$              ******

$                *****

$                *****

 

$                       -  

$            *******

 

$                       -  

$            *******

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

******* *** ******* **** ********** *** *** *** ****** ***********

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

********* ***********

          **********

          **********

          **********

          **********

          **********

 

          **********

          **********

 

          **********

          **********

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******* **** ********* *********** ******

          **********

          **********

          **********

          **********

          **********

 

          **********

          **********

 

          **********

          **********

 

*** *********** ********

                          -  

                          -  

                          -  

                          -  

                          -  

 

                          -  

                          -  

 

          10,000,000

          10,000,000

 

*** ***********

          **********

          **********

          **********

          **********

          **********

 

          **********

          **********

 

          **********

          **********

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*** ****** ***********

                          -  

                          -  

                          -  

                          -  

                          -  

 

            *********

            *********

 

            *********

            *********

 

********** ****** ****

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

**** ********** **** *** *** ****** **********

$              ******

$              ******

$              ******

$              ******

$              ******

 

$              ******

$              ******

 

$              ******

$              ******

 

 

 

 

 

 

 

 

 

 

 

 

 

 

******* **** ********** *** *** *** ****** ***********

*                       *  

*                       *  

*                       *  

*                       *  

*                       *  

 

$            *******

$            *******

 

$            *******

$            *******

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule L

 

Performance Standards and Remedies

 

While this Agreement is in effect, CSG shall provide the Products and Services
to Customer in accordance with the following performance standards:

 

a.*********** ********* (*) ******* (****)

 

(i)****** *************   ***’* ******* ******* ** ******** ** ***’* *** ****
********* ***** ** ********* *** ******** *** ** *** ****** ***** ** ******* **
*********** (**) ***** *** **** ***** **** *** ***** *********** *** * ****
******* (*****) ** *** ***** ******** ** * ***** ****** ********* ********
******* ******* *** ********* ********* *********   ** ********* ***’* *******
******* ** ******** ** ***’* *** **** ******** ***** *** ** ************ ***
**** **** ***** ******* (***) ********** ******* ** * ******** ****** *********
******** ******* ******* *** ********* ********* *********  *** **** **** **
************** *** *** ******** ******* ****** ** *** ************* ** *******
******** ******** ** ******** ** *** ******** ****** ** ******** ** ********
***** ** ****** ******** ** ******** ******* ** ******** *********  ********
************ **** *** ****** ** *** *********** ******** ***** **** ************
(*)(*) ***** *** ********** * ****** ** *** *********** ********* *** ***** **
************* (*)(**) – (*)(***) ******  *** ************* ********* ** ***’*
*** **** ******** ** *** ********** *** **** *** ** ******* ** *** ********* ***
******* ** **** *** ** *** *********** ********* *** ***** ** *************
(*)(**) – (*)(***) **** ***** ***** ***’* *** **** ** ***********.

 

(ii)******** *********** *** ***** ** *:** **** (***) ** *:** ***. (***), *****
(*) **** * ***** ******** **** *** **** ******* *********** ***** ** **********
** *** (*) ******* ** ***** ************ (***) ******* ** *** ***** ******** **
* ***** ***** ********* ******** ******* ******* *** ********* *********
*********  *** ******** ** **** ********** (*)(**), ******** **** *** ****
******* *********** ** ******** **** *** ***** **** ***’* *** **** *** **** ****
***’* *** **** *** **** *** ******* *** **** ********* **** ******* ** *** ***
*****  **** ********’* ********** ******** *** **** ******* ******** **** *
***** ****** ** ***** **** *:** ** (***) ** ****** ******* ****** (*********
********) ** *** ******** ******** ***’* ******** *****  ******* ********* ***
****** ******** ***** ***** ** ******** ** *** ****** ********* ** ******** **
*******  *************** *** ********** *** **** ** ******* ** ***** **** ***
**** ** ********’* ******* ** ******* *** ******* *** ***** ******** ****
*******  ******** ****** *** ***** ****** (**) **** **** *** ********* *****
***’* ******* ** ******* * ****** ** ********** **** *** ********** *** *****
***** **** *** ******* *** ** *** ******* *** ***** ** ************ (*)(**)
****** ******* *** ***** *** ************ ********** ******* ** ******* * ******
** **** **** ****** ** **** ** *********  *** ***** ****** (**) **** **** ***
********* ***** *** ******** *** ********** ** ******* * ****** ** **********
**** *** ********** *** ***** ***** *** *** *** ***** **** ****** ****** ****
(*) ******** ***** **** ****** ***** ******* *** ** *** ******* *** ***** **
************ (*)(**) ******  ******** ** ** ***** ***** *** ** ******* ** ***
********* ******* *** ******** ******** ****** * *********** ****** ***** ******
*** ***** ** ************ (*)(**) ***** *** ** * ******* ** ******* * *****
****** ** ********** **** **** ************ (*)(**).    

 

******** ******* ****** **** ** ***** ***** *** ****** ** ************ **** *
****** ******** ******** ******* **** ******* (***) ****** * ******* (**) ******
****** *** ** ********’* *** ** ****** ******** ***/** ******* *** *** ******
*** ****** ** ************ ** **** ******* (***) ** **** ************ ****** *
******* (**) ****** *******  **** ********’* ******** *** ***** *******
********** ********** **** ******* *** ****** ** ************ *** ** ******
******** ***/** ****** ****** *** *********** ** *** ******** **** ****** ****
******* (**) ****** *******

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

(iii)*** ****** ****** ********  *** *** ******* ****** **** ** ******* **
*:****(***) ** *** **** ******** *** ** ***** ************ ******* (***) ** ***
***** ******** ** * ******* ****** *** *** *** ******* ****** ***** *** ** ****
*** **** **** ****** (**) ******* ** ********** **** *** **** ***** ******
******** ** * ******* ******* ******  ** ********* ** ** ***** ***** *** ***
****** ****** ** **** *** **** **** ***** (**) ******* ****** *** ****** ****
(**) **** ****** *** ** ******* ********** **** *** ****** ******
********    *** ********* ******** ***** *** ***** ** **** ** ***** *** ********
*** ******* ******** ** *** ** *** ********* ** *** **** *** ****** **
*********  

 

 

(iv) *** ***** ********* ***** ** ***** *********** *** ********* *** ********
*** ** *** ****** ***** ** **** **** *********** *** ***** ******** *******
(******) ** *** ***** ******** ** * ******* ****** ********* ******** ***
*********** *** ** ** **** (*) ***** *** **** ** ***** ****** ***’* *********
******** ** ************ ** ******** ** ***** ***** (**) **** ** ********  **
*** ***** ******** ******** ** *********** ********* ********* *** **** ***
************ ********** ******* ** *********** ********’* ********  ********
****** ******** ****** ** ** **** ******** ** ** ***** ***** ***** *** *******
******* ** ******** ****** **** (*) ***** *** *****    *** ******** ** ****
********** (*) (**), ***** *********** **** **** **** *** ****** **** ****** ***
************ ******* *** ** *** ********** ********** ** *** ************* ***
******  *** ***** ********* *********** ******** *** ***** ** **** ************
(**) ***** *** ***** ****** ******* ** ***** ******** ** ********** ** ****** **
*** *** **** ********** ***** *** ***** ******** ** **** ****** ***** ** *******
********* ** ******** ** “*****” ******* ******** “*** ******** *********”
******* *** “*** *********/********* *** ************ *** ***** **********
*****” (*** “************ ****”).  **** *** *********** ** ******** **
********** ** ** ***** *** ************ ***** *** *********** ******** ****
*******  ** ******** **** *** ******** **** ** ********* ** ******** * **
******* ******** ** *** **** ********* *** **** ********** ****** **** *** ****
********** ***** ***** ****** *** “************ ****” *********.  

  

*** *** ******** ******** ***** ** ******* ****** ****** (**) **** ** **********
*************** *** ***’* ********* *** ****** ******* ******** **** ** *****
*** *** *** ** ************ ******** **** ***** (**) ****** ********* *** ***
*** *** ***** ************  *** *** ******* ***** ** ******** ********* ***
***** **** *** *** (**) **** *********** ************ ** ******* *** **** ******
*** **** ** *** **********  ****** **** ****** (**) *** ********** *** *** ***
***** *********** **** ******* ******** ***** *** *** *** ** ************ ****
*** ****** **** *** ******* ***** ************  *** ******** ****** **** ***’*
***** ** ******** *** ** ********* ******** ** **** ********

 

(v)******* ********** ********   ******* ******** ******** ** *** ** ***** ****
*:** ** (**) **** ** ********* ** **** *****'* ***** *** ****** ** ****
**********'* ******* ** ** ****** *** ********* **** ** ***** *********** ***
***** ******** ******* (******) ** *** ***** ******** ** * ******* ******  *****
******** ***** *:** ** (**) **** ** ********* ** *** **** *****'* ***** *****
*** ****** ** **** **********'* ******* ** ** ****** *** ********* **** ***
******* ******* (****) ** *** *****  *** ***** *** ** ****** *** *** ******* **
**** *** *********** ******** *** ***** ** **** ******* *** ** *** ******* **
*** ********'* ****** ** **** *** *** ******** *** **** *************

 

(vi)

*** ***** ********* **** ***** ************   *** ***** ********* **** ******
**** ** ********* *** ***** ** *:**** *** ** ****** ******* ******** *** *:**
*** ** ******.  

 

 

(vii) **** *******  

1)

*** **** ******* ******* ***** ** ***** *********** *** ********* *** ********
*** ** *** ****** ***** ****** **** *** *** ******* ******* (******) ** ***
***** ** * ******* ****** ********* ******** *** *********** ********* ********
*** *********** *** ** ** **** (*) ***** *** **** ** ***** ****** ***’*
********* ******** *** **** ******* ***** ***** ** ********* ** **** **** ******
(**) **** ** ********  ** *** ***** ***’* ********* ******** *** *********** **
******** ** ****** **** (*) ***** ** * ********** ***** *** ***** *******
******** **** ******** (**) **** ***** *******  ******** ****** ******** ******
** ** ****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

******** ** ** ***** ***** ***** *** ******* ******* ** ******** ****** **** (*)
***** *** *****    *** ******** ** **** ************ (*)(***), ******** **** ***
******* ******* ************ ****** *** *** ***** ** ************  *** *** *****
** *********** ** ******* ** *** **** ******* *********** ******* ***
************* ********* *** *** ***** ********* ********* *** **** ******* ***
*** ******** ******* ** ***’* ********; ********* ******** **** ** ***** ***
******* *** ** *** ********* ********* *** *** ******* ** ***’* *********  

 

2)

**** **********’* **** ***** ** ******** *** *** **** ******* ****** ******
***** (*) ******** **** ********* *** *** ** *** ********* ********* ***** ***
********** ****** ******** ******** *** ** * **** ** ***** *** ********

 

 

(viii)

********* ***********  ********* ********** **** ** ********* *** ******** **
*** ****** ***** *********** *** ***** ******** ******* (******) ** *** *****
******** ** * ******* ****** ********* ******** *** *********** *********
******** *** *********** *** ** ** **** (*) ***** *** **** ** ***** ****** ***’*
********* ******** *** ********* ********** ***** ***** ** ********* ** ****
**** ****** (**) **** ** ********   *** **** **** ** ************** *** ***
******* ** **** *** *********** ******** *** ***** ** **** ********* (****)
****** ** *** ************* ** ******* ******** ******** ** ******** ** ***
***** ***** ******** *** ***** ** ******** ** ***.

 

(ix)

********  ******* **** ** ********* *** ******** ** *** ****** ***** ***********
*** ***** ******** ******* (******) ** *** ***** ******** ** * ******* ******
********* ******** *** *********** *** ** ** **** (*) ***** *** **** ** *****
****** ***’* ********* ******** *** ******* ***** ***** ** ********* ** ****
**** ****** (**) **** ** ********   *** **** **** ** ************** *** ***
******* ** **** *** *********** ******** *** ***** ** **** ********* (**) ******
** *** ************* ** ******* ******** ******** ** ******** ** *** ***** *****
******** *** ***** ** ******** ** ***.

 

(x)

*********** ***** *********  *********** ***** ******** **** ** ********* ***
******** ** *** ****** ***** *********** *** ***** ******** ******* (******) **
*** ***** ******** ** * ******* ****** ********* ******** *** *********** *** **
** **** (*) ***** *** **** ** ***** ****** ***’* ********* ******** ***
*********** ***** ******** ***** ***** ** ********* ** **** **** ****** (**)
**** ** ********   *** **** **** ** ************** *** *** ******* ** **** ***
*********** ******** *** ***** ** **** ********* (*) ****** ** *** *************
** ******* ******** ******** ** ******** ** *** ***** ***** ******** *** *****
** ******** ** ****    

 

(xi)

(a) ********  ******* **** ** ********* *** ******** ** *** ****** *****
*********** *** * ******* ******* (******) ** *** ***** ******** ** * *******
****** ********* ******* ******* *** ********* ********* *********   **
********* *********** ******* (***) ** ***** ******* **** ** ********* ** *:**
***. (***) ******** ** * ******* ****** ********* ******** *** *********** ** **
**** (*) ***** *** **** *** ** ** ***** (*) ***** **** *** ******** ******** **
***** ****** ***’* ********* ******** *** ******* ***** ***** ** ********* **
**** **** ****** (**) **** ** ********  *** **** **** ** ************** *** ***
******* ** **** *** *********** ******** *** ***** ** **** ********* (**) ******
** *** ************* ** ******* ******** ******** ** ******** ** *** ***** *****
******** *** ***** ** ******** ** ****  *** *** ******** ***** **** *** ********
***** ******** ***** ** ******* ** *** **** ********* *** ******** ** ******* **
*** ***** ** *** **********  ******** ******** *** *** ***** **** ******** *****
**** ** ******** *** ****** ** *** ***** **** ** *********** ******** ** ******
** **** ******** ** * ****** ** *** **** ******** ********** ** *** ****** **
***** ******* ******** ** *************

 

(b)  ******* ********* **** (****)*  **** **** ** ********* *** *********
*********** *** * ******* ******* (******) ** *** ***** ******** ** * *******
****** **** ******* (**) *********** **** ******* ******** ********** *** ****
********* ******* ******* ***

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

********* ********* ******** ****  ******** ***** ******* ********** **** *****
********* ******** ******* *** ********** *** **** **** ** ************** ***
*** ******* ** **** *** *********** ******** *** ***** ** **** ********* (**)
(*) ****** ** *** ************* ** ******* ******** ******** ** ******** ** ***
***** ***** ******** *** ***** ** ******** ** ****

 

(xii) ********* *******  

(1)

********** ********* ******** (** ******* ** ******* ***), ***** ** *********
*** ****** *** ******* ******* ** *** **** ****** ***** (*) ******** ****
********* ***** *********** ******** ** * ******* ******  *** *** ******** **
**** ******** * ******** *** ** ****** ******* ******** ********* ********
*********  *** ******** ** **** *********** *** **** “******** ********” *****
*******: *** ****’** ******** **** ************ **** ***** **** ************
(******** *** ******), *** **********  ** *** ***** * ******* ***** ** *
********* **** ******* ** ********** ** *** ***** ****** *** ** * ******* *****
** * ******* ** ** ********** ** *** ********* ******.  

(2)

*** ***** ******* ** ********** ********* ********* *** *** *** ****** *********
********* ** ********* ******** **** ********* *** ******** ** ***’* *********
********** ****** **** (*) ******** **** ****** *** ***** ***** ******** ** ***
**** ******* *** *** ******** ** ****** ********* ** *** ** *** *********
**********

(3)

*** ********* **** ** ********* **** *** **** ******** ** *** **** (******
****** ****** *******) ********* ******** **** ******* **** *** *********
******* **** *** ****** *** ********* **** *** ********* ** **** *******
*************

 

(xiii)  ******* ********* **** *** ******* ********* ********** *** ******** **
**** ******** * ***** **** *** ********** *** *** ********* ***** *** *******
****** ******* *** ************* *** *** ***** *** ******** ******* ******* ***
**************    *** ******* ********* ********** ***** ** ***** ***********
*** ********* *** ******** *** ** *** ****** ***** ** **** **** *********** ***
*** ******* ******* (******) ** *** ***** ******** ** * ******* ****** *********
******** *** *********** *** ** ** **** (*) ***** *** **** ** ***** ****** ***’*
********* ******** ** ************ ** ******** ** ***** ***** (**) **** **
********  ** *** ***** ******** ******** ** *********** ********* ********* ***
**** *** ************ ********** ******* ** *********** ********’*
********  ******** ****** ******** ****** ** ** **** ******** ** ** ***** *****
***** *** ******* ******* ** ******** ****** **** (*) ***** *** *****    ***
******** ** **** ********** (*) (****), ***** *********** **** **** **** ***
****** **** ****** *** ************ ******* *** ** *** ********** ********** **
*** ************* *** *** *** (********* *****).  

 

 

b.Monthly Report  

****** *** (**) ******** **** ** **** ******** ***** *** (“****** ****”), ***
***** ******* ******** **** * ******* ****** ******* ***** **** ** ***
*********** ********* ********* ** **** ******** * *** *** *********** ******
*** **** ********* ******** ***** ******** ** **** *********** *********  ***
********** ** ******** **** ** **** *** *** **** ******** ********* *** ********
*********** ********* ** *** **** *** ****** ** *********  **** ******* ****
**** ******* *** ****** *** ** ******* ***** ** ******** *** ****** ********
********** ** *** ******** ******* *******  *** ******** ** **** ******** ** *
******* ** **** * *********** ******** ***** ** ********** * “******
********”*  *** ***** ****** *** *********** ********* *** ***** ** ****
******** **** ******** ** * ******* ****** ** **** ********** ** ********* **
*********  ***’* ******* ** ******* *** ******* ****** ** ********** **** ***
********** *** ***** ***** **** ****** ** * ****** ******** **** ******* ** ***
** *** *********** ********* ** ************* (*)(*) ******* (*)(***) ******
******  ***** *** ******** * ****** *** **** *** ****** ** *** *** ***********
********** **** ******* **** ****** ** * ****** ******** **** ******* **

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

*** ******* *********** ********(*).  *** ********** ** * ******* ****** ****
********* ** ************ *********** **** ****** ** * ****** ******** ****
****** ** *** ********(*) ********** *** ********** ** ************
************  ******** ** ****** ******** ***** ***** ** *** ******** *** ******
** ***** *** ********* ****** ****** **** (*) ******** **** ** *** ******
*****  *** ***** ** ******** ** **** **** (*) *** **** ****** *** ***** ** ***
********* ******** ** **** **** *** **** ****** *** ******** ********  ** ***
***** ** ******* * ****** ** ******** * ********* ****** ****** *** ***** ******
(**) **** ** *** ********* ***** *** ***** *** ************ ********** *******
** ******* * ****** ** **** **** ****** ** **** ** ********* *** **** ******
**** *** ****** ** * ****** *********

.

 

c.***** ***** ********** ** ************

 

** *** ***** **** ******** **** *** ***** **** *** *********** ** ********* **
*** ** *** *********** ********* *** ******** ** *** ******* ******* *** ******
** ******* ******** **** *** **** ** **** *** ************ **** ** ***
*********** ** *** *******  ******** ***** *** ************ ********** *******
** ******* **** **** ** **** ** ******** ***** *** ******** ** ********* *** **
****** **** ****** (**) **** ***** *** ******* ** *** ****** ******** ** ***
*********  ** *** ***** ******** ******** **** ***** *** ***** ** ********* **
****** *** ******** **** *** ****** (**) **** **** **** ****** *******
********  *** ****** *** (**) ******** **** ** *** ******* ******** ********
******** *** ** ******* **** ** ******** *** ***** *** ***** ****** *** **** ***
* ***** ** ***** **** (**) **** **** *** **** ****** ******* ********  **
******** ***** **** **** **** ** ********** *** *********** ** *** ***********
********* ** **** *** ***** **** *** ************** ** *********** ** ***
************* **** ******** **** ******* * ****** ****** ** *** ********** ***
********** ** ***** ************* ** ************  **** ******* ** *** *******
*** ***** ******** ******** * ******* **** ******** ** ****** *** ******* ***
*******  *** ****** ****** (**) **** ** **** ******* ******** *** ******* ****
*** ******** *** ******* *** ******* ***** ***** **** * ********* ***********
***** ***** **:

 

(a) ********* ** *** *********** **** ** ***** ********* ********* *** *********
** ********** **** ******** ******** ******** ********* *** ** * ****** **** **
**** *** ********* ** **** *** *** ********; ***

(b) ** ********** ****** ***’* *********** ***/** ********* ***********.  

 

*** **** *** *** *********** ***** ***** ****** **** ** ********’* ****
************** ****** *** ***** ***** ****** ********** **** ***** *** *
******** ********* ********** **** ***** **** ******** ** * ****** ******** **
********** ** ***** **** *** **** ** *********** *** *** ***** ********** ****
*** ***** ***** *******

 

d.Remedy for Failed Standards  

 

(i) ****** *************  ** ****** *** **** ** **** ********** ***’* ******
************ **** *** **** *** ******** *** ***** ** ************ (*)(*), ****
*** ***** ** ******* *** ******* ** $***** ********** ** *** ****** **
********’* ********* *********** ******** ** *** ****** ******** *** **********
** *** *** ****** ** *** ***** ** ***** *** ****** ******** *********  ** ***
***** * ****** ******** ***** **** ************ (*) ********* ****** ***
*********** ****** ***** ******* *** ****** ******* ** *** **** ******* ** ***
***** ** **** ************ ***** ** ********** ** *** ****** ** ***** *** ******
******** *** *********** ****** *** *********** ****** ***** *******  ***
******** ** *** ****** ******** ** **** ************ (*) ****** *** * ***** ****
** *** *********** ****** ***** ******  *** ***** ** ******* *** ******* **
$****** ********** ** *** ****** ** ********’* ********* *********** ******** **
*** ****** ******** *** ********** ** *** *** ******* ********** ** ***** (*).
*** ****** *** ***** ** *** ********* ******** ***** ** ******** ** * ****** **
********’* **** ******* ********  ** ******** ** *** ********** ** ***’* *******
******* **** *** **** *** ******** ** ***** ********* *** **** **** *****
******* (***) ********** ******* ** * ******** ****** ********* ******** *******
******* *** ********* ********* ******** ** ******** ** ************ (*)(*),
**** *** **** ****** ** ****** ** ***** ******* (***) ******* ****** *** *****
**: *) *:** **** (*** / ***) ** *:** **** (*** / ***) (“*********”), *** *****
** ******* $***** ********** ** *** ****** ** ******* ********** ** *** ******
** ******** *********

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

***********; ** *) ******* *** ***** **  **:** **** (*** / ***) ** *:** ****
(*** / ***) (“*************”), *** ***** ** ******* $****** ********** ** ***
****** ** ******* ********** ** *** ****** ** ******** *********
************  *** ******* ** ****** ** ***** ******* ******* ***** **
*********** ******* ********* *** ************** ** *********** *** *********
****** ***** ** ******* ** *** ****** ** **** ******* ******* (*************)
*** **** ** **** ******* (**) ** ***** ****** ****** *** **** *** *********
******** **** ********* **** ******* ******* (***** *******).  

 

 

(ii) ******** *** *********** ********* ** (*)(**) ******* (*)(*), (*)(***)
******* (*)(*) *** (*) (***).  ** ****** *** **** ** **** ********** *** ****
*** **** *** ** **** ** *** **** (*) *********** ********* *** ***** **
************* (*)(**) ******* (*)(*), (*)(***) ******* (*)(*) *** (*)(***), ****
*** **** ****** ********* *** ***** ** ******* $***** (****** *** ******
******** (*) (**) ***** ***** ** ******* $*****) ********** ** *** ****** **
********’* ********* *********** ******** ** *** ****** ******** *** **********
** *** *** ****** ** *** ***** ** ***** *** ****** ******** *********  ** ***
***** * ****** ******** ***** *************  (*)(**) ******* (*)(*), (*)(***)
******* (*)(*) *** (***) ********* ****** *** *********** ****** ***** *******
*** ****** ******* ** *** **** ******* ** *** ***** ** **** ************ *****
** ********** ** *** ****** ** ***** *** ****** ********  *** *********** ** ***
*********** ****** ***** *******  *** ******** ** *** ****** ******** ****** ***
* ***** **** ** *** *********** ****** ***** ******* *** ***** ** ******* ***
******* ** $****** (****** *** ****** ******** (*) (**) ***** ***** ** *******
$*****) ********** ** *** ****** ** ********’* ********* *********** ******** **
*** ****** ******** *** ********** ** *** *** ****** ** *** ***** ** ***** ***
****** ******** ********* ********** ** ***** (*).  *** ****** *** ***** ** ***
********* ******** ***** ** ******** ** * ****** ** ********’* **** *******
********

 

(iii) ****** *** *********** ******** ** (*)(**).  ** ****** *** **** ** ****
********** *** **** *** **** *** *********** ******** *** ***** ** ************
(*)(**), **** *** **** ****** ********* *** ***** ********** **** (** *******
*******) *** ********* ** **** *** *********** ********* *** ***** ******* *
****** ** ***** ******** ******* (*********) ** ********’* **** *******
********  *** ******** ** * ***** ********* **** ***** ** *** **** ********* **
******** *** ***** ** *:**** *** *** **** ***** ********* **** ***** *******
*********** ***** *:** ** **** *** ***** ******* * ****** ** *** ****** **
****** ******** ******* (**********).

 

 

(iv)

****** *** *********** ******** ** (*)(**) *** (*)(****).  ** ****** *** **** **
**** ********** *** **** *** **** *** *********** ******** *** ***** **
************ (*)(**) ** (*) (****), **** *** **** ****** ********* *** *****
******* * ****** ** **** ******** ******* (*********) ** ********’* **** *******
********

 

(v)

**** **** ****** ** *** *** (*) *********** ********* *** ***** ** *************
(*)(*) – (*)(**), ** *** ***** ** **** *** **** ******** **** (*) ***** ******
*** *********** ****** ***** ******* **** ******** ** *** ********* ****
********** * ******** ****** ** *** ********* ** ****  **** ********’* *********
** *** ****** ****** ** ****** *********** ******** *** ***** ****** *********
** *** ********* *** ****** ****** (**) **** ** ******* ** **** **********
********* **** ********* ** ********** ******* ****** ** *** ** ***** ***** (**)
**** ***** ** *** ********* **** ** **** ************  *** ************ ***
****** **** **** ******* ** ****** ** **** ******** ******* *** ***** **** **
***** ** **** ******** ** ******** ***(*) ** *****

 

(i)

*** ******* ***** **** ** *** ***** *** ***** *** ** ************* *** ** ***
***** ** ******* ** ** ***** *** ******* ** ** ********* ****** *** ***** ***
***** ** *** *********** **** ****** ** *** *********** ******** (***), ** ***
***** ** **** *** **** *********** ******** ** (***) *** (*) ****** ****** ***
*********** ****** ***** ******* **** ****** (**) **** ***** ******* *******
******** *** ********* *** *********** ***** ******* *** ******** “*********
******” *** ***** ** ****** ** ******** ** **** *** ***** *** **** ***********
************ ******** ** ******* ****  *** ****** (**)

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

**** ***** ******* ****** **** ** ******** ** *** ****** ***** (**) **** ****
**** *** ******** *** ****** ******** ** ******* **(**) ***** *** ** *******
****** ** *** ****** ****** ** ******** *** *** ***** (***) ********** **
********’* ****** ****** ***** ** *******  *** ******** ** **** ******* (**), *
“*****” ***** **** * ****** ********* ***** ** * ****** ***** **** ******* ****
**** *** *********** ********* ******

 

(ii)

***** ***** *** **** ***********.  

 

(a)

*** ***** ** *********** *** *) ************ ** ****** ******* *** ******** ****
*** ******** ******** **** ********’* ******* **********; **) ************ ****
********* “** *****” *** ******** ******* *** ******** **** *** ********’*
******* **********; *** ***) ********* ********** *** ******** *******
*********** *** ********* *********** (*), **) *** ***) ** **** **********
(****), ************* “******* **********”); ********* ***** *** ***** *** **
*********** *** ********** ** ********* *********** ******** ** ******** ***
********* **** ******* ***********   ** *** ******** *** *********** ****
******* ** *** *********** ** ******* ********** (*** ******** ** ****
********** * “******* *********”), **** *** ****** ** (*) ******** *** *******
*** ********* ********** ********* ********** ******* ********** ** **
********** **** ** ******** *** (*) ********* ******** *** *** ********** *** **
****** ******** ******** ** ****** **** ******* ********* (* “******* *********
*************”). ***’* ******* ********* *************  ***** **** **********
(*) ***** ** ******* ** * ****** ** ******** *** ********** *** *********
******** ***** ***** *** ****** $**** ********** ** *** ****** ** ********
******* ********** ** *** ***** ** ***** *** ******* ********* ******** (***
********* ****** ** **** ************** *** ** ****** *********** ********
******* (*******) *** ******* *********).  *** ****** *** ***** ** ****
********** ***** ** ******** ** * ****** ** ********’* **** ******* ******** ***
************* ********* *** ******* ********* ******* **** * ****** ***** *****
**** ** ******* **** *** ******** ** *********** *** ****** ** *********** ***
******** ** *** ************ ** ********** (*) *** (*) ******* *** ******** **
**** ******* * “****** *****” ***** **** *** ***** ******* **** *** **** ****
***** **** ********* *** ** *** *** *** **** ***** ***** (*) **** ** ***** *
******* ***** ******* *************** *** ********** ******** ************ ***
****** **** ** **** ** *********** *** *** ************** *** *********** **
******* ************ ********** *********** ******* ********* ********* ********
** ***** ** ******** *** ******** ** ********** ********* ********** ***** ***
**** *** ******* ** *** **** ** ******** ******* **** ********** *** ** *
************ ****** ** ***** ** *** ******* ********** ************ ** ****
****** *** ******* ***** ***** ** **** ***** * ************ ********* (**
**********) ** *** ************* ********* *** **** *** ******** ** ****
********

 

(b)

** *** ***** ** *** ********** ** ****** (**) ** **** ******* ********** ******
*** *********** ****** (**) ***** ****** *** **** ******* ********** ****** **
***** *** ******* (*********) ********* *********** ** *** ********** **** ****
****** (**) **** ***** ******* ******* ******** *** ********* *** ***********
***** ******* *** ******** “********* ******” *** ***** ** ****** ** ******** **
**** *** ***** *** **** *********** ************ ******** ** ******* ****  ***
****** (**) **** ***** ******* ****** **** ** ******** ** *** ****** ***** (**)
**** **** ****

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

**** ***** ******** ******* ***** ** *** ******* ********** *** ***** ** ****
********** (*).  

 

 

e.********* ***** **********.

(i)

***’* *********** *************  ********’* ******** ********* ******** ******
***** ******* *** ******* ******* ********* ** *** ************ ** *** ***
************ *** ******** *** ** *** ****** ****** ******* ***** ******* **
******* ****** ************ ******** ** *********** *** ********** **********
******* (******), ********* ********* ******** *** ******** *** *********** ***
***** ** ******** ****** *** ************* *********  ************ ***** **
******** **** ********* ** ********’* ********* ****** *** ******** *
(********), * (****) *** * (******) ********* ** ********* ** *** ***** ***
“************* ******* **** ******** ******” ***** (************ “**********
*********”) ***** ******** *** ********** *** *** *** ******** (*)  *** ***
*********** ** ********* (**) *** *** *********** ** *** ********* ***
********’* *** ** (***)  ************ ** **** ******* *** *** ***********
********* ** ******** *** ** ***’* *******

(ii)

**** **** ** ****** (“****”).  ***’* **** ***** *** ****** ***** (**) *******
*** ********** ********* ******** *** ******* *** ******** ** * ******* *****
*  ***** ** ********** ** *** **** “**** ** *****” *** *** ********** ******(*)
*** *********** ********* ********* ****** *** *********** ******* ***** “****
** *****” ***** ** ******** ** *** ********** ******* *** ****  * ****** **
****** *** *** **** *** ******* *** **** ******  *** ********* ****** ********
******** ********* **** * ******* ***** ******* ******** **** ******** ******
*** *** *** **** ******* *** ******** ****** *** *** ********** **** ** *** ***
******* **** ** ******** ** *** **** ************ **** ***** ** ******** *****
********’* ******** ********* ******** *******  

(iii)  ****** ********* *********** ********** ********** ** ******* ***** *****
** **** **** ***** *** ***** ******** ** * ****** ******  **** ***** ** ********
***** ********’* ******** ********* ******** ******.

(iv)

**** **** ******* ********* (“****”).  ***’* **** ***** *** ** **** **** ***
***** ******** ** * ****** ****** *** ********** ***** * ******* ****** ****
******* **** ** ********** ** *** ****** ** ***** ** ****** ***** (*****),
******* ** *** ****** ** *********** ********* (********** ** ******) ****
******** ****** **** **** *******     **** ***** ** ******** ***** ********’*
******** ********* ******** *******  *** ******** ** ***** *** * **********
********* ** *** ********* ** ***** ** * ******* ****** *** **** *** *** **** **
*** ******

(v)

  ** *** ***** **** *** ***** ** *** **** *** *********** ********* ********* **
************* (*) ******* (**) ** **** ********* [(*)] ** **** ****** ****** ***
*********** ****** ***** ******* ***’* *** *** ********’* *** ** **********
********* ****** ****** *** ******** **** ** ***’* ******* ** * ******* *******
**** ********* **** ** ******* *** ***** *** *** **** *****(*).   *** *****
******* * ********** ******** *** ************ ********** ******** ******** **
** ********** ** *** ** ******* *** ****** ********** ******** ***** **** ****
*** ******** **** ** ****** (*) ****** ***'* ******** ** (*) ******* *** ***
********* ********* *** ******* ***** *** ************ ********** ******* **
***** **** * ******** ****** *****   *** ***** ********* **** ******** ********
****** ****** **** ********* ********* ****** ********* ** **** **** (** ****
****** ****** ** *** ** ****** ** ******** ** *******). *** *********** ** ***
***** **** ********* (*) ***** ** ** ******** *** *** *** ** **** *** *** *****
*********** ** *** *** ***** ** **** ********** ******* *** **** ******* ** ***
** **** *** *********** ********* *** ***** ** ********** (*) ******* (**) *****
*** **** **** ** *** ******** ******** ** *** **********

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

***** ** ** ************* ******* **** ******** ******* *** ******** **
********* ********* ***** ********** ** ********** ** ****.

************* ******* **** ******** ******

 

*********/**********

* ******** ******* ** * ***** ********** ****** ***** ******* * ******** ******
** ******* ******** ******** **********

****** *********** *********** ** * **** ********** ****** **** ********** ***
********* ******* * ********'* ******** *** ***********

***********/*****

******* **** ** ******** ****** **************  *** ********’* ****** *** **
********* *** *** ********** ** ********

********/*******

******* **** ** ************ ****** **************

 

********’* ********** ******** ********** *** *** ************* *********

*****/*********

* ******  ***** **** ** ***** ** ******** ** ****** ********* ** *****
*************  ** ********’* ********** ********  **********

********

*** ***** ** ********* *** ***** ** ******* ******** **** ** *********

******** (**)

******** ************* **** *************

**** ************** **** ******* ******

**** (**)

******** ************* **** ******** *****

**** ******** ****** ***** ********* *****

****** (**)

******** ******* ***** * ***** ************

**** ******** ****** ******************

*** (**)

******** ******* ***** * ***** *************

**** ******** ****** ******************

****

*** ***** ** ********* * ***** ********** ** **** ***** ** ******* ******** ****
** *********

**** (**)

******** ************* **** ******** *****

**** ******** ****** ***** ********* *****

**** (**)

******** ************* **** ******** *****

**** ******** ****** ***** ********* *****

****** (**)

******** ******* ***** * ***** ************

**** ******** ****** ******************

*** (**)

******** ******* ***** * ***** *************

**** ******** ****** ******************

******

*** ***** ** ********* * ******* ****** ** ***** ** ******* ******** **** **
********** **********

****** (**)

******** ******* ***** * ***** ************

**** ******** ****** ******************

****** (**)

******** ******* ***** * ***** ************

**** ******** ****** ******************

****** (**)

******** ******* ***** * ***** ************

**** ******** ****** ******************

*** (**)

******** ******* ***** * ***** *************

**** ******** ****** ******************

***

*** ***** ** ********* * ****** **** ** ******* ******** **** ** ****

****** (**)

******** ******* ***** * ***** ************

**** ******** ****** ******************

*** (**)

******** ******* ***** * ***** *************

**** ******** ****** ******************

*** (**)

******** ******* ***** * ***** *************

**** ******** ****** ******************

*** (**)

******** ******* ***** * ***** *************

**** ******** ****** ******************

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

f.*************

 

(i)*** *********** *** ****** **** *** *********** ********* (*) ******* (****)
********** ** ********* ** **** ** ******** *********** ** **** ***** *** *****
****** *** ********* ********** *** ****** ********* ********* **** ***’*
******* ****** *************** ** ** ******** ** **** ******** ****** *********
****** *** ****** ********** ** ******* **** ****** ********* ****** **** *
****** *********** ********** ** ******** *************  *** ******* ****** ****
*** ********* ******** ******** ****** *** ****** ********* *** ** ** **********
**** ******** ****** ********* ***** ** *** ***** *** **** *** ******** *** ****
***** *** *********** ** *** ******** *** ****** ********* ********* ** *
******** *******  

 

(ii)******** *** *** *********** **** ** ** *********** *** ********* *********
** ********* *** ****** ******* ** **** ******** **** *** *********** ******
**** ***’* ******* ** ******* ******* *********** ***** ****
**********  ************ *** *** ******* ******** *** ***** **** ******** * **
******* ** ***’* ****** ** *** *********** ********* ********* *** (*)
********** ******** *** *** * ******** (*) ********** *** *** ****************
** *** ******** ******* ** ******** **** * ******* ** *** ** ****** **** ***
********** *********** ********* *** ***** ** **** ******** ** *** (*)
********’* **** *** ********* ****** ***** **** ******** *; *********
*************** *** ********** (*) ** ******** ** ********’* ***** ** *********
***** ********** (*)(*) ****** ******** **** ******** ** ******* ***(*), ******
** ******* ****** ** *** ***** ******** **** ** ********* ***** *** *********
(****** *** ***** ************ *** ***** ** **** ******** *), *** (**) *******
********* ** **** ********** ***** ***** *** ** ********’* ****** ** ******** **
*** ****** **** ***’* ******* ** ******* *** *********** ******* ** * ***** **
********* ******* ** * ******* ** ****** **** **** **** ** ********** **********
** ***’* *********** ***** **** **********  

 

--------------------------------------------------------------------------------

***

Confidential Treatment Requested and the Redacted Material has been separately
filed with the Commission.

 

Schedule R-1

 

Common Stock Purchase Warrant

 

(See Attached)

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

THE SECURITIES EVIDENCED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND MAY
NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OFFERED FOR SALE, OR OTHERWISE
DISPOSED OF EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
SUCH ACT AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS OR (B) IN A
TRANSACTION THAT QUALIFIES AS AN EXEMPT TRANSACTION UNDER SUCH ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.

Issue Date: July 24, 2014 (the “Issue Date”)

 

 

 

CSG SYSTEMS INTERNATIONAL, INC.

Common Stock Purchase Warrant

CSG Systems International, Inc., a Delaware corporation (the “Company”), for
value received, hereby certifies and agrees that Comcast Alpha Holdings, LLC, a
Delaware limited liability company, or its registered assigns (the “Holder”), is
entitled, subject to the vesting milestones set forth in Section 3(a) and the
other terms and conditions set forth below, to purchase from the Company, at any
time during the Exercise Period (as defined below), 2,851,419 shares (the
“Warrant Shares”) of the Company’s common stock, par value $0.01 per share (the
“Common Stock”), at an initial purchase price per Warrant Share equal to $26.68
(the “Exercise Price”).  This Warrant is being issued on the terms hereof in
partial consideration for the Holder’s entry into an amendment to the Master
Agreement (as defined below), and in order to provide an inducement to the
Holder to achieve the successful completion of the Migration SOW (as defined
below) promptly in accordance with the terms thereof.  The Exercise Price and
the number of Warrant Shares to be purchased upon exercise of this Warrant are
subject to adjustment as hereinafter provided.

1.Defined Terms.

(a)In this Warrant, the following terms shall have the following meanings:

“Additional Subscriber” has the meaning ascribed to such term in the Master
Agreement.

“Affiliate” means, with respect to any Person as of any applicable date of
determination, any other Person that directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, the
first-mentioned Person as of that date.  For purposes of this definition,
“control” (including the correlative terms “controlled by” and “under common
control with”) means the possession, directly or indirectly or as trustee or
executor, of the power to direct or cause the direction of the management or
policies of a Person, whether through the ownership of stock, as trustee or
executor, by contract, or otherwise.

“Alternate Consideration” has the meaning ascribed to such term in Section 7(c).

 

“Appraiser” has the meaning ascribed to such term in the definition of “Fair
Market Value”.

 

“Attempted Exercise” has the meaning ascribed to such term in Section 3(e)(ii).

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

“Board” means the Board of Directors of the Company.

“Business Day” means any day except Saturday, Sunday and any day on which
banking institutions in the State of New York generally are authorized or
required by law or other governmental actions to close.

“Capital Stock” means, with respect to any Person, (i) any capital stock of such
Person, (ii) any security convertible, with or without consideration, into any
capital stock of such Person, (iii) any other shares, interests, rights to
purchase, warrants, options, participations or other equivalents of or interests
in (however designated) the capital stock of such Person, or (iv) any other
equity interest in, or right to vote generally in elections of directors or the
comparable governing body of, such Person.

“Change of Control” means the acquisition by any Person, including any syndicate
or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act of
beneficial ownership (determined in accordance with Rules 13d-3 and 13d-5 under
the Exchange Act), directly or indirectly, through a purchase, merger or other
acquisition transaction or series of purchases, mergers or other acquisition
transactions, of shares of the Capital Stock of the Company (i) entitling that
person to exercise *** or more (but less than ***) of the total voting power of
all shares of the Capital Stock of the Company entitled to vote generally in
elections of directors or (ii) comprising *** or more (but less than ***) of the
total equity value of the Company, other than any acquisition by the Company,
any of its subsidiaries or any of its employee benefit plans.

“Change of Control Election Notice” has the meaning ascribed to such term in
Section 3(c)(ii).

“Comcast” means Comcast Cable Communications Management, LLC, a Delaware limited
liability company.

“Common Stock” has the meaning ascribed to such term in the Preamble.

“Company” has the meaning ascribed to such term in the Preamble.

“Company Financial Statements” has the meaning ascribed to such term in Section
12(f)(ii).

“Connected Subscriber” has the meaning ascribed to such term in the Master
Agreement.

“Equivalent Percentage” means, with respect to any satisfaction of an
Unsatisfied Milestone after the occurrence of a *********** ****** (which shall
be determined on a ******** ********* basis with respect to ******* *(*)(*)(*)),
a fraction (expressed as a percentage), (i) the numerator of which is the total
number of Warrant Shares that, absent the occurrence of such Fundamental Change,
would have vested and become exercisable in connection with such satisfaction
pursuant to Section 3(a)(i) and (ii) the denominator of which is the total
number of Warrant Shares for which this Warrant otherwise would be exercisable,
assuming the satisfaction in full of all *********** ********** (excluding, in
the case of Section *(*)(*)(*), such number of Warrant Shares as shall have
already vested and become exercisable hereunder), as of the date of such
*********** ******, after giving effect to (x) the provisions of Sections
*(*)(*) and *(*)(***) and (y) any adjustments theretofore made pursuant to
******* * (subject to appropriate adjustment to both the numerator and the
denominator in the event of any subsequent adjustment to the number of Warrant
Shares issuable hereunder pursuant to ******* *).

“Escrow Account” means the account to be created pursuant to the Escrow
Agreement in order to secure the Holder’s rights to exercise this Warrant for
the Escrowed Proceeds, subject to the vesting milestones set forth in Section
3(a) and the other terms and conditions set forth herein.

“Escrow Agent” has the meaning ascribed to such term in Section 3(b)(iv).

“Escrow Agreement” has the meaning ascribed to such term in Section 3(b)(iv).

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

“Escrowed Proceeds” means, with respect to any *********** ******, an amount of
cash equal to (i) the ***** ****** ** ******* ****** *** ***** **** *******
********* ***** ** ************ ******** *** ************ ** **** ** ***
*********** ********** (excluding, in the case of Section *(*)(*)(*), such
number of ******* ****** ** ***** **** ******* ****** *** ****** ***********
*********)* ** ** *** **** ** **** *********** ******, after giving effect to
(x) the provisions of Sections *(*)(*) and *(*)(***) and (y) any adjustments
theretofore made pursuant to ******* ** ********** ** (ii) (x) the Fair Market
Value of a Warrant Share as of the date of such *********** ****** ***** (y) the
******** ***** immediately prior to such *********** ******.  For the avoidance
of doubt, in no event shall the amount of Escrowed Proceeds be less than zero
dollars ($0).

“Exchange Act” means Securities Exchange Act of 1934, as amended.

“Exercise Date” has the meaning ascribed to such term in Section 2(a).

“Exercise Notice” has the meaning ascribed to such term in Section 2(a).

“Exercise Period” means the period commencing on the Issue Date and ending on
the Expiration Date.

“Exercise Price” has the meaning ascribed to such term in the Preamble.

 

“Expiration Date” has the meaning ascribed to such term in Section 5.

“Fair Market Value”, as of any date, has a meaning determined as follows:

(i)with respect to any equity interest (including a Warrant Share): (x) if the
class of such equity interest is traded on a securities exchange or quoted on
the NASDAQ Stock Market, then the Fair Market Value thereof shall be deemed to
be the average daily volume weighted average price per share of such equity
interest for the ten consecutive trading days ending on the trading day
immediately prior to such date (as determined by reference to the screen
entitled “CSGS <Equity> AQR” as reported by Bloomberg L.P., without regard to
pre-open or after hours trading outside of any regular trading sessions for any
such scheduled trading day on such trading day); or (y) if clause (x) is not
applicable, then the Fair Market Value of such equity interest (including a
Warrant Share) shall be the price that would be negotiated in an arm’s-length
transaction for cash between a willing seller and a willing and able buyer, both
having full knowledge of the relevant facts and neither of which is under any
compulsion to complete the transaction, without regard for control premiums or
minority or illiquidity discounts, as such price is determined in good faith by
the Board; provided that (A) the Company shall give the Holder prompt written
notice of any such determination, together with reasonable data and
documentation to support such determination, and (B) if the Holder disputes the
Board’s determination, it shall promptly notify the Company of such dispute,
whereupon the Company shall engage a nationally recognized investment bank or
other independent valuation firm reasonably acceptable to the Holder (an
“Appraiser”) to determine such Fair Market Value, the cost of which Appraiser
shall be borne by the Company and the determination of such Appraiser shall be
final and binding on the Company and the Holder; and

(ii)with respect to any asset other than an equity interest, the Fair Market
Value thereof shall be deemed to be the price (after taking into account any
liabilities relating to such assets) that would be negotiated in an arm’s-length
transaction for cash between a willing seller and a willing and able buyer,
neither of which is under any compulsion to complete the transaction, as such
price is determined in good faith by the Board; provided that (A) the Company
shall give the Holder prompt written notice of any such determination, together
with reasonable data and documentation to support such determination), and (B)
if the Holder disputes the Board’s determination, it shall promptly notify the
Company of such dispute, whereupon the Company shall engage an Appraiser to
determine such Fair Market Value, the cost of which Appraiser shall be borne by
the Company and the determination of such Appraiser shall be final and binding
on the Company and the Holder;

provided, however, that, in the case of a Fundamental Change, the Fair Market
Value of a Warrant Share as of the date of such Fundamental Change shall be
equal to the sum of (A) the amount of the cash consideration, if any, that the
Holder of one issued and outstanding Warrant Share would have received in
exchange therefor pursuant to such

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

Fundamental Change plus (B) the Fair Market Value (determined pursuant to
clauses (i) and (ii) of this definition, as applicable) of all forms of
consideration other than cash, if any, that the Holder of one issued and
outstanding Warrant Share would have received in exchange therefor pursuant to
such Fundamental Change.

“Final Additional Subscriber Amount” means, as of the Final Additional
Subscriber Date, 475,237 (subject to appropriate adjustment in the event of any
adjustment to the number of Warrant Shares issuable hereunder pursuant to
Section 7) multiplied by the lesser of (x) 1.0 and (y) a fraction, (i) the
numerator of which is (A) the aggregate number of Additional Subscribers added
as of such date (inclusive of the number of Additional Subscribers described in
Sections 3(a)(i)(2) and (3)) minus (B) 5,500,000, and (ii) the denominator of
which is 5,700,000.  For the avoidance of doubt, the Final Additional Subscriber
Amount shall not be less than zero.

“Final Additional Subscriber Date” means the earlier of (i) the date on which
Comcast provides written notice to the Company that it has completed the
Migration SOW (as determined in Comcast’s sole discretion) or (ii) such date on
which a total of 11,200,000 Additional Subscribers shall have been added as
contemplated by the Migration SOW.

“Fundamental Change” means the occurrence of either of the following events:

 

(i)*** *********** ** *** ******* ********* *** ********* ** ***** ****** ** **
* “******” ***** ******* **(*)(*) ** *** ******** *** ** ********** *********
(********** ** ********** **** ***** ***** *** ***** ***** *** ******** ***)*
******** ** *********** ******* * ********* ****** ** ***** ***********
*********** ** ****** ** ********** ******* ** ***** *********** *************
** ****** ** *** ******* ***** ** *** ******* (*) ********* **** ****** **
******** *** ** **** ** *** ***** ****** ***** ** *** ****** ** *** *******
***** ** *** ******* ******** ** **** ********* ** ********* ** ********* **
(**) ********** *** ** **** ** *** ***** ****** ***** ** *** ******** ***** ****
*** *********** ** *** ******** *** ** *** ************ ** *** ** *** ********
******* *****;

(ii)*** ************* ** ****** ** *** ******* **** ** **** *** ***** *******
*** ****** ** ******* ****** **** *** ******** ** *** *********** *********
***** ***** ** ***** *********** ** *** ** ************* *** ** *** *******’*
********** *** ****** ** ******* ******* ***** **** *** *********** ******** **
***** *** ******* ** *** *******’* ******* ***** ******** ** **** ********* **
********* ** ********* *********** ***** ** **** *********** **** ***
*********** ** ********* ******** ** *********** *** ** **** ** *** ***** ******
***** ** *** ****** ** *** ******* ***** ******** ** **** ********* ** *********
** ********* ** *** ********** ** ********* ****** *********** ***** ******
****** ** **** *********** ** ************* *** **** *********** ** *** *******
** **** ******* ** *** *******’* ******* ***** **** *********** ****** ******
****** ** **** ***********; **

(iii)a Change of Control that the Holder elects to have treated as a Fundamental
Change pursuant to Section 3(c).

“Fundamental Change Exercise Notice” has the meaning ascribed to such term in
Section 3(b)(ii).

“Fundamental Change Warrant Shares” has the meaning ascribed to such term in
Section 3(b)(i).

“Holder” has the meaning ascribed to such term in the Preamble.

“Issue Date” has the meaning ascribed to such term above the Preamble.

“Joint Escrow Notice” has the meaning ascribed to such term in Section 3(b)(vi).

 

“Master Agreement” means the CSG Master Subscriber Management System Agreement,
with an effective date of March 1, 2013, between the Company and Comcast, as
amended.

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

“Material Adverse Effect” means a material adverse effect on the business,
assets, liabilities, financial condition, property or results of operations of
the Company and its subsidiaries taken as a whole; provided, however, that none
of the following, in and of itself or themselves, shall constitute a Material
Adverse Effect:

 

(i)changes in the economy or financial markets generally in the United States or
other countries in which the Company or its subsidiaries conduct operations,
except to the extent the Company and its subsidiaries taken as a whole are
materially and disproportionally affected thereby;

(ii)changes in U.S. generally accepted accounting principles or in any law
applicable to the Company or its subsidiaries or the enforcement or
interpretation thereof, except to the extent the Company and its subsidiaries
taken as a whole are materially and disproportionally affected thereby;

(iii)any regulatory, legislative or political conditions or securities, credit,
financial or other capital markets conditions, in each case in the United States
or any other countries in which the Company or its subsidiaries conduct
operations, except to the extent the Company and its subsidiaries taken as a
whole are materially and disproportionally affected thereby;

(iv)any geopolitical conditions, the outbreak, continuation or escalation of
hostilities, any acts of war (whether or not declared), sabotage, terrorism or
military actions, or any large scale public health epidemics, weather conditions
or other force majeure events, except to the extent the Company and its
subsidiaries taken as a whole are materially and disproportionally affected
thereby;

(v)changes that are the result of factors generally affecting the  industry or
industries in which the Company and its subsidiaries operate, except to the
extent the Company and its subsidiaries taken as a whole are materially and
disproportionally affected thereby;

(vi)any failure by the Company to meet any estimates, projections or
expectations of revenues, earnings or other financial performance or results of
operations for any period, or any failure by the Company to meet its internal
budgets, plans or forecasts of its revenues, earnings or other financial
performance or results of operations, provided that the exception in this clause
(vi) shall not prevent or otherwise affect a determination that any change,
effect, circumstance or development underlying such failure that is not
otherwise excluded pursuant to this definition has resulted in, or contributed
to, a Material Adverse Effect;

(vii)a decline in the price or trading volume of the Warrant Shares on the
NASDAQ Stock Market, provided that the exception in this clause (vii) shall not
prevent or otherwise affect a determination that any change, effect,
circumstance or development underlying such failure that is not otherwise
excluded pursuant to this definition has resulted in, or contributed to, a
Material Adverse Effect; or

(viii)any reduction in the credit rating of the Company or any of its
subsidiaries; provided that the exception in this clause (viii) shall not
prevent or otherwise affect a determination that any change, effect,
circumstance or development underlying such failure that is not otherwise
excluded pursuant to this definition has resulted in, or contributed to, a
Material Adverse Effect.

 

“Maximum Aggregate Ownership Amount” has the meaning ascribed to such term in
Section 3(e)(ii).

“Maximum Aggregate Voting Amount” has the meaning ascribed to such term in
Section 3(e)(ii).

 

“Migration SOW” means the Migration SOW attached to the Master Agreement, as the
same may be amended, modified, supplemented or extended in accordance with the
Master Agreement.

“Net Cash Settlement” has the meaning ascribed to such term in Section 2(d).

 

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

“Net Cash Settlement Election” has the meaning ascribed to such term in Section
3(e)(ii).

“Net Cash Settlement Election Notice” has the meaning ascribed to such term in
Section 3(e)(ii).

“Net Share Settlement” has the meaning ascribed to such term in Section 2(c).

“New Subscriber” means a “New Subscriber” (as such term is defined in the Master
Agreement); provided, in each case, that such New Subscriber (i) as of the Issue
Date, was receiving billing and account services from any Person other than the
Company and (ii) after the Issue Date, was migrated to the Company’s ACP billing
platform.

“Person” means any individual, corporation, limited liability company,
partnership, joint venture, association, joint-stock company, trust,
unincorporated organization, or government or any agency or political
subdivision thereof.

“Physical Delivery” has the meaning ascribed to such term in Section 2(b).

“Registration Rights Agreement” has the meaning ascribed to such term in Section
11(f).

“SEC” means the Securities and Exchange Commission.

“SEC Documents” has the meaning ascribed to such term in Section 12(f)(i).

“Securities Act” has the meaning ascribed to such term in Section 11(a).

“Specified Dividend” means any cash dividend by the Company to all holders of
shares of its Common Stock (or such other class of the Company’s Capital Stock
as is then issuable upon exercise of this Warrant) with respect to which the
average daily volume weighted average price per share of the Common Stock (or
such other class of the Company’s Capital Stock) for the last trading day
preceding the first date on which the Common Stock (or such other class of the
Company’s Capital Stock) trades regular way on the principal national securities
exchange or quotation system on which the Common Stock (or such other class of
the Company’s Capital Stock) is listed or admitted to trading without the right
to receive such dividend is at least ten percent (10%) greater than the average
daily volume weighted average price per share of the Common Stock (or such other
class of the Company’s Capital Stock) for the first trading day on which the
Common Stock (or such other class of the Company’s Capital Stock) trades regular
way on the principal national securities exchange or quotation system on which
the Common Stock (or such other class of the Company’s Capital Stock) is listed
or admitted to trading without the right to receive such dividend.

“Stockholder Approval” has the meaning ascribed to such term in Section
3(e)(ii).

“Total New Subscriber Amount” ****** **** ******* ** *** ***** * ****** ***** **
(*) *******(******* ** *********** ********** ** *** ***** ** *** ********** **
*** ****** ** ******* ****** ******** ********* ******** ** ******* *)
********** ** *** ****** ** (*) *** *** (*) * ********* (*) *** ********* **
***** ** *** ********* ****** ** *** *********** ******** ** ** **** ***** ***
(*) *** *********** ** ***** ** ********** ***** (**) *** ********* ****** **
******* ******* ** **** **** ***** **** ******* ****** *** ****** ***********
***** ** **** **** ******** ** ******* *(*)(*)(*)*  *** *** ********* ** ******
*** ***** *** ********** ****** ***** *** ** **** **** ****.

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

“Unsatisfied Milestone” ****** ** *** ***** ** *** *********** ******* ***
******* ********* ** ******* *(*)(*) ***** *********** ***** ** **** ***********
******* ******** *********** ********* (** ***); ********* ******** ***** ** ***
**** ** ******* *(*)(*)(*)* (*) **** ******* ********* ***** ** ****** ** ** **
*********** ********* ********* ******* ***** ** **** *********** *******
******* (******* ** *********** ********** ** *** ***** ** *** ********** ** ***
****** ** ******* ****** ******** ********* ******** ** ******* *) *******
****** ***** **** ******* ****** *** ****** *********** *********** *** (*) ***
********** ** *** ********** ** “********** **********” *** ** ******** *(*)(*)
*** (**) ** *** “************” ** ** *********** ********* ***** ** ****** **
******* *** ************ ** ***** ******* ******* ****** **** ***********
******* ********* ***** **** ****** *** ****** *********** ******** ** *******
*(*)(*)(*).

“Warrant” means this Warrant and all other warrants issued upon transfer,
division or combination of, or in substitution for, this Warrant or such other
warrants in accordance with the terms and conditions hereof.

“Warrant Shares” has the meaning ascribed to such term in the Preamble.

 

(b)Capitalized terms used but not defined herein shall have the respective
meanings ascribed to such terms in the Master Agreement.  For the avoidance of
doubt, in the event of any inconsistency between the definitions set forth
herein and the definitions set forth in the Master Agreement, the definitions
set forth herein shall govern for purposes of this Warrant.

2.Method of Exercise.

(a)Exercise Notice.  Subject to the terms and conditions set forth herein,
including the vesting milestones set forth in Section 3(a), this Warrant may be
exercised by the Holder at any time and from time to time during the Exercise
Period for all or any portion of the number of Warrant Shares purchasable
hereunder; it being understood and agreed that this Warrant shall be void and
all rights represented hereby shall cease unless vested and exercised on or
before the Expiration Date.  In order to exercise this Warrant, in whole or in
part, the Holder shall deliver this Warrant, together with a duly executed copy
of the form of notice of exercise attached hereto as Exhibit A (together, the
“Exercise Notice”), to the Company at its principal offices, which Exercise
Notice shall specify the number of Warrant Shares subject to such Exercise
Notice (subject to the last sentence of Section 3(b)(ii), the date on which such
delivery shall have taken place being referred to as the “Exercise Date”).  Each
exercise of this Warrant shall be settled through Physical Delivery or Net Share
Settlement, as elected by the Holder in its sole discretion and set forth in the
Exercise Notice, which may also include, at the Holder’s sole discretion, a
request for a settlement of such exercise through Net Cash
Settlement.  Notwithstanding anything herein to the contrary, including this
Section 2, from and after the occurrence of a Fundamental Change, the exercise
of this Warrant shall be governed by Section 3(b).

(b)Physical Delivery.  Subject to Section 2(d) (if the Exercise Notice included
a request for Net Cash Settlement) and Section 3(e), if the Holder has elected
to settle the exercise of this Warrant through physical delivery of Warrant
Shares upon cash payment of the Exercise Price by the Holder (“Physical
Delivery”) in accordance with Section 2(a), then, within three (3) Business Days
following the Exercise Date, the Holder shall deliver to the Company the
aggregate Exercise Price for the Warrant Shares specified in the applicable
Exercise Notice by wire transfer of immediately available funds to an account or
accounts designated by the Company.  The Warrant Shares to be issued and
delivered to the Holder upon Physical Delivery shall be issued and delivered as
provided in Section 2(e).

(c) Net Share Settlement.  Subject to Section 2(d) (if the Exercise Notice
included a request for Net Cash Settlement) and Section 3(e), if the Holder has
elected to settle the exercise of this Warrant through a net, or “cashless”,
exercise by using certain Warrant Shares that the Holder otherwise would have
received upon such settlement as payment of the Exercise Price (“Net Share
Settlement”), then the Company shall issue and deliver to the Holder, as
provided in Section 2(e), a number of Warrant Shares computed using the
following formula:

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

 

X=

Y * (A-B)

 

A

Where:

X =

the number of Warrant Shares to be issued to the Holder.

Y =

the number of Warrant Shares subject to the applicable Exercise Notice.

A =

the Fair Market Value as of the Exercise Date.

B =

the Exercise Price as of the Exercise Date.

* =

multiplied by.

(d)Net Cash Settlement.  If (i) the Holder has requested to settle the exercise
of this Warrant through payment of cash by the Company to the Holder, net of the
Exercise Price, in lieu of issuing any Warrant Shares (“Net Cash Settlement”) in
accordance with Section 2(a) and the Company agrees, in its sole discretion, to
effect such Net Cash Settlement in lieu of the settlement election made by the
Holder in the Exercise Notice (in which case the Company shall so notify the
Holder in writing within two (2) Business Days following the Exercise Date) or
(ii) the Holder makes a Net Cash Settlement Election pursuant to Section
3(e)(ii)), then the Company shall issue and deliver to the Holder an amount of
cash computed using the following formula:

X = Y * (A-B)

 

Where:

X =

the Net Cash Settlement amount.

Y =

the number of Warrant Shares subject to the applicable Exercise Notice.

A =

the Fair Market Value as of the Exercise Date.

B =

the Exercise Price as of the Exercise Date.

* =

multiplied by.

The Company shall make any payment of such Net Cash Settlement amount to the
Holder by wire transfer of immediately available funds to an account or accounts
designated by the Holder in the Exercise Notice within five (5) Business Days
following the Exercise Date (or, in the case of a Net Cash Settlement Election,
within five (5) Business Days following delivery of the Net Cash Settlement
Election Notice).

 

(e)Delivery of Warrant Shares.  Subject to Section 3(e), if the Holder has
elected to settle the relevant exercise of this Warrant through Physical
Delivery or Net Share Settlement (and has not requested or the Company has not
agreed to settle such exercise through Net Cash Settlement), then, as soon as
practicable after each exercise of this Warrant, and in any event within three
(3) Business Days thereafter (but, if the Holder has elected to settle the
exercise of this Warrant through Physical Delivery, subject to the Holder’s
payment of the aggregate Exercise Price as contemplated in Section 2(b)), the
Company shall execute (or cause to be executed) and deliver (or cause to be
delivered) to the Holder a certificate or certificates representing the
aggregate number of Warrant Shares issuable and issued upon such exercise
(which, upon the Holder’s request, will be issued in book entry form in lieu of
physical certificates) and its calculation pursuant to Section 2(c) of the
number of Warrant Shares so issued, if applicable.  If a physical stock
certificate or certificates are so delivered, such certificate(s) shall be, to
the extent possible, in such

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

denomination or denominations as the exercising Holder shall reasonably request
in the Exercise Notice or otherwise and shall be registered in the name of the
Holder or, subject to Section 11, such permitted transferees as shall have been
designated in the Exercise Notice.  This Warrant shall be deemed to have been
exercised, and such stock certificate or certificates shall be deemed to have
been issued (or book entry made), and the Holder or any other Person so
designated to be named therein shall be deemed to have become a holder of record
of such Warrant Shares, for all purposes, as of the Exercise Date.

(f)No Fractional Shares.  No fractional shares of any security will be issued in
connection with any exercise hereunder.  Rather, in the event that any number of
shares that would otherwise be issuable hereunder includes a fractional share,
such total number shall be rounded up to the nearest whole share.

(g)Delivery of New Warrant.  If this Warrant shall have been exercised in part,
the Company shall, not later than the time of delivery of the certificate or
certificates  representing (or the book entry of) the Warrant Shares being
issued pursuant to such exercise (in the case of an exercise by Physical
Delivery or Net Share Settlement) or the cash settlement amount (in the case of
an exercise by Net Cash Settlement), deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unexercised Warrant Shares
subject to this Warrant.  Such new Warrant shall in all other respects be
identical to this Warrant, including with respect to the vesting milestones set
forth in Section 3(a), taking into account the issuance of Warrant Shares
pursuant to such exercise.

(h)Certain Expenses.  The Company shall pay all of its expenses in connection
with, and all issuance, transfer, stamp and other similar incidental taxes
imposed by any taxing authority in the United States with respect to, the
exercise of this Warrant or the issue or delivery of Warrant Shares or the
payment of any cash settlement amount hereunder; provided, however, that the
Company shall not be required to pay any tax (including any applicable
withholding tax) or governmental charge that may be imposed with respect to the
issuance or delivery of the Warrant Shares or cash, as applicable, to any Person
other than the Holder, and no such issuance or delivery shall be made unless and
until such other Person has paid to the Company the amount of any such tax, or
has established to the satisfaction of the Company that such tax has been paid;
provided, further, that the Holder shall be responsible for all other tax
liability that may arise as a result of holding or transferring this Warrant or
receiving Warrant Shares or cash upon exercise hereof.

3.Vesting; Fundamental Change; Limitations.

(a)Vesting.

(i) Subject to Sections 3(b), 3(c) and 3(d), this Warrant and the Holder’s
rights hereunder shall vest and become exercisable in accordance with the
following vesting schedule:

(1)a number of Warrant Shares equal to  475,237 (subject to appropriate
adjustment in the event of any adjustment to the number of Warrant Shares
issuable hereunder pursuant to Section 7) shall vest and become exercisable on
January 24, 2015;

(2)a number of Warrant Shares equal to 475,237 (subject to appropriate
adjustment in the event of any adjustment to the number of Warrant Shares
issuable hereunder pursuant to Section 7) shall vest and become exercisable as
and when a total of 500,000 Additional Subscribers shall have been added as
contemplated by the Migration SOW;

(3)a number of Warrant Shares equal to 475,237 (subject to appropriate
adjustment in the event of any adjustment to the number of Warrant Shares
issuable hereunder pursuant to Section 7) shall vest and become exercisable as
and when a total of 5,500,000 Additional Subscribers (inclusive of the number of
Additional Subscribers described in Section 3(a)(i)(2)) shall have been added as
contemplated by the Migration SOW;

(4)a number of Warrant Shares equal to the Final Additional Subscriber Amount
shall vest and become exercisable on the Final Additional Subscriber Date; and

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

(5)a number of Warrant Shares equal to the Total New Subscriber Amount shall
vest and become exercisable on the first Business Day of each calendar quarter
from and after the date on which the total number of New Subscribers added in
accordance with the Master Agreement equals or exceeds 500,000.

(ii)All determinations and calculations with respect to the satisfaction of the
conditions to the vesting of any of the Warrant Shares pursuant to Section
3(a)(i)(2)-(5) shall be made in a manner consistent with the reporting of
Connected Subscribers (in the case of Section 3(a)(i)(2)-(4)) or New Subscribers
(in the case of Section 3(a)(i)(5)) in accordance with the terms of the Master
Agreement.

(b)Fundamental Change.  Notwithstanding anything herein to the contrary:

(i)Upon the occurrence of a Fundamental Change: (A) **** ******* *** ***
******’* ****** ********* ***** *********** **** *** ****** *********** ****
******* ** * ****** ** ******* ****** (*** “*********** ****** ******* ******”)
***** ** (*) *** ********** ** (*) *** ********* ****** ** ******* ****** (**
***) ** ****** *********** ***** ** **** *********** ******* ****** ********
*********; *** (*) *** ****** ** ******* ****** *** ***** ** **** ***********
********* (*** ** *** **** ** ******** *(*)(*)(*) *** (*)* *** ****** ** *******
****** *** ***** ** *** *********** ** “***** ********** ********** ******” ***
“***** *** ********** ******”* ************) ***** ** *************** *********
** *** ** ******* *** ******* ******* ******* ******** ** ****** (*).

(ii)Prior to a Fundamental Change, the Company shall send written notice thereof
to the Holder as contemplated by Section 6.  Subject to Section 3(b)(iii), from
and after the Company’s delivery of such notice, the ****** ***** ** *********
** ******* ** ******** ****** (* “*********** ****** ******** ******”) ****
******* ** *** *********** ****** ******* ****** ******* ** * ****** ** ****
*********** ****** ******** ** ******* *(*)(*) (** ******** ** *** *******
****** **** **** ******* ******); ********* ******** **** *** ******’* ********
** **** ******* ******** ** **** *********** ****** ******** ****** ***** **
*********** ***** *** ***** ** ****** ** ***** *********** ***** ***
************ ** *** ******** *********** *******  *** ****** *** ******** ***
*********** ****** ******** ****** ** *** **** ***** ** *** ********** ** ***
********** *********** *******  *** *** ******** ********** *** “******** ****”
** *** ******** ******** ** * *********** ****** ******** ****** ***** ** ******
** ** *** **** ** *** *********** ******.  

(iii)Upon the occurrence of a Fundamental Change, any vested portion of this
Warrant (including with respect to any Fundamental Change Warrant Shares) that
has not, prior to or concurrently with such Fundamental Change, **** *********
** *** ****** ***** ********* ** ****** ******* ********* *** ***** ** ****** **
*********** ** ***********.

(iv)If, immediately prior to the occurrence of a Fundamental Change, there are
any Unsatisfied Milestones, then upon or prior to such Fundamental Change, the
******* *** *** ****** ***** ***** **** ** ****** ********** ** **** ***
********* ********** ************ ** *** ******* *** *** ****** (*** “******
*********”)* **** * ********** ********** **** ******** ** *** ****** (*******
** *** ********** ******** ** *** *******) ** ****** ***** ********** (***
“****** *****”)* ******** ** ****** ***** ***** ******* ********* ****
*********** ******* *** ****** ***** **** **** *** ******** ********* ******* **
*** ***** ** **** ******* *** *** ****** **********  **** *** ********** ** ****
*********** ******* (*) *** ******* ***** ***** *** ******** ******** ** **
********* **** *** ****** ******** ******** ** *** ***** ** **** ******* *** ***
****** ********** *** (*) *** ****** ***** ***** ****** *** ******* ** ***
******** ******** **** *** ****** ******* *** ***** ********** *** ******
******* ***** *** ******* ** (*) *** ******* ** *** ******** ******** ** ***
****** ** ********** **** *** ***** ** **** ******* *** *** ****** ********* ***
(**) *** ********** *****  *** ******* ***** ** *********** *** *** **** ***
***** ******* ** *** ****** ***** ***** *** ****** *********.

(v)If, immediately prior to the occurrence of a Fundamental Change, there are
any Unsatisfied Milestones, **** **** *** ***** **** *********** ******* ****
*** ********** ************ (** ***) ** **** **** *********** ********* **
********** **** ******* *(*) (***** ***** ** ********** ** *

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

******** ********* ***** **** ******* ** ******* *(*)(*)(*))* **** ******* *****
***** *** *** ****** ***** ****** ******** ** ******* (*** *** ****** *****
***** *** ** *** ******)* * ********** ** *** ******* ******** ******** ***** **
*** ********** **********.

(vi)From and after the occurrence of a Fundamental Change, promptly following
the satisfaction of *** *********** ********* ** ********** **** ******* *(*)
(***** ***** ** ********** ** * ******** ********* ***** **** ******* ** *******
*(*)(*)(*))* *** ** *** ***** ** ** ***** ** *** ********** ***** *** *******
*** *** ****** ***** **** *** ****** ***** ***** ******* ****** (**** ****
******* * “***** ****** ******”) ** ******* **** ******* ** *** ********
******** ** ***** *** ****** ** ******** ******** ** ******* *(*)(*) *** ***
***** ***** ** **** ******* (********* *** ******* ****** ** *** ********
******* ** **** *******) ** ********** ** **** ********* *** **** ***** ******
****** ***** ******* ************ **** *** ****** ** ** *** ******** ** ****
******* ** *** ******** *********  ** ***** **** ***** (*) ******** **** *****
*** ********** ***** *** ****** ***** ***** ******* *** ********** ** ***
******* *** ******** ******** (********* *** ******** ******* *******) ***
********** ******** *** *********** ** *** *******  *** *** ********* ** ******
*** ****** ***** **** ** ********** ** ******* *** ******** ***** ** ********
*** *** ******* ** *** ******** ******** ** ***** ** ** ******** *********.

(vii)In no event shall the Company be obligated to cause Escrowed Proceeds to be
deposited into the Escrow Account more than once. For the avoidance of doubt,
if, after the occurrence of a Fundamental Change, there occurs one or more
additional Fundamental Changes, no additional obligations of the Company shall
arise under this Section 3(b) as a result of such subsequent Fundamental
Changes, but this Warrant and the Holder’s right to receive the Escrowed
Proceeds shall continue to vest in accordance with Section 3(b)(v).

(viii)The Holder acknowledges and agrees that it shall not, by virtue hereof or
otherwise, have or exercise any rights to veto, prevent, hinder or delay any
Fundamental Change (other than by virtue of its rights as a stockholder of the
Company, if applicable, under applicable law, the Certificate of Incorporation
of the Company, and the Bylaws of the Company).

(c)

Change of Control.  Notwithstanding anything herein to the contrary:

(i)Upon the occurrence of a Change of Control, the Holder shall have the option,
exercisable in its sole discretion, (A) to have this Warrant continue to remain
outstanding and vest in accordance with Section 3(a) or (B) to treat such Change
of Control as a *********** ****** *** ********** *** ******* ** **** *******
(******* ** *** ********** **********) ** ********** **** ******* *(*).

(ii)Prior to a Change of Control, the Company shall send written notice thereof
to the Holder as contemplated by Section 6.  Following the Company’s delivery of
such notice, the Holder shall deliver notice to the Company electing how to
treat this Warrant pursuant to Section 3(c)(i) (a “Change of Control Election
Notice”); provided that if the Holder fails to deliver a Change of Control
Election Notice on or before the date of the Change of Control it shall be
deemed to have elected to have this Warrant continue to remain outstanding and
vest in accordance with Section 3(a).  The Holder may withdraw and/or amend its
Change of Control Election Notice at any time prior to the occurrence of the
applicable Change of Control.

(iii)For the avoidance of doubt, if the Holder elects (or is deemed to elect) to
have this Warrant continue to remain outstanding and vest in accordance with
Section 3(a) in connection with any Change of Control, then the Holder’s rights
under the Section 3(c) shall continue to apply to any future Change of Control.

(iv)The Holder acknowledges and agrees that it shall not, by virtue hereof or
otherwise, have or exercise any rights to veto, prevent, hinder or delay any
Change of Control (other than by virtue of its rights as a stockholder of the
Company, if applicable, under applicable law, the Certificate of Incorporation
of the Company, and the Bylaws of the Company).

(d)Company Failure to Perform.  Notwithstanding anything herein to the contrary,
if either (or both) vesting milestone(s) set forth in clause (1) or (2) of
Section 3(a)(i) is not achieved as a result, directly or

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

indirectly, of the Company’s failure to perform any of its obligations under,
and in accordance with, the Master Agreement (which failure remains uncured
following any applicable cure period provided in the Master Agreement), ****
**** ******* *********(*) ***** ** ****** ** **** **** ********* *** ***
******** ********* *** **** ******* *** *** ******’* ****** ********* *****
*********** **** *** ****** *********** **** ******* ** **** ** *** *******
****** *** ***** ** **** ******* *********(*).

(e)Limitations.

(i)Notwithstanding anything herein to the contrary, if any exercise of all or
any portion of this Warrant pursuant to Section 2, or any transfer of all or any
portion of this Warrant pursuant to Section 11, requires the consent, approval,
order, waiver, exemption or authorization of, registration, declaration, filing
or qualification with, certification, notice, application or report to, or
expiration of any waiting period (including under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended) applicable to, any governmental
authority, self-regulatory organization (including the NASDAQ Stock Market or
any other applicable national securities exchange) or any other third party as a
condition to the lawful and valid exercise or transfer, as the case may be, of
this Warrant, then, in each case: (x) the Company shall not issue to the Holder
any Warrant Shares upon such attempted exercise of this Warrant, or such
attempted transfer of this Warrant shall not be deemed effective, as applicable,
unless and until any such consent, approval, order, waiver, exemption or
authorization has been obtained, any such registration, declaration, filing or
qualification has been made, any such certification, notice, application or
report has been given or any such waiting period has expired, and then only to
the extent permitted thereunder; (y) each of the time periods provided in
Section 2, Section 3 or Section 11, as applicable, for the consummation of such
exercise or transfer, as applicable, shall be suspended for the period of time
during which any such consent, approval, order, waiver, exemption,
authorization, registration, declaration, filing, qualification, certification,
notice, application, report or waiting period expiration is being pursued; and
(z) if and to the extent that any such suspension causes the consummation
thereof to occur after the Expiration Date, then such Expiration Date shall be
extended to (A) in the event of an exercise, the date of consummation thereof,
and (B) in the event of a transfer, ten (10) days following the date of
consummation thereof.  The Company agrees to use its commercially reasonable
efforts to obtain, make or file (as applicable), or to assist the affected
Person in obtaining, making or filing (as applicable), any such consent,
approval, order, waiver, exemption, authorization, registration, declaration,
filing, qualification, certification, notice, application, report or waiting
period expiration and shall cooperate and use its commercially reasonable
efforts to respond as promptly as practicable to all inquiries received by it or
by the affected Person from any governmental authority for initial or additional
information or documentation in connection therewith.  Each of the Company and
the Holder shall bear its own costs and expenses in connection with this Section
3(e)(i).

(ii)Without limiting the generality of Section 3(e)(i), and notwithstanding
anything herein to the contrary, the Company shall not issue to the Holder any
Warrant Shares upon any attempted exercise of this Warrant, if and to the extent
that, after giving effect to such issuance, such Holder (together with such
Holder’s Affiliates, and any other Persons acting as a group together with the
Holder or any of the Holder’s Affiliates) would beneficially own in excess of
****** of the number of shares of Common Stock outstanding immediately after
giving effect to such issuance (the “Maximum Aggregate Ownership Amount”) or
(ii) control in excess of ****** of the total voting power of the Company’s
securities outstanding immediately after giving effect to such issuance that are
entitled to vote on a matter being voted on by holders of the Common Stock (the
“Maximum Aggregate Voting Amount”), unless and until the Company obtains
stockholder approval permitting such issuance in accordance with applicable
rules of the NASDAQ Stock Market (or any other applicable national securities
exchange) (“Stockholder Approval”); provided, however, that this Section 3(e)(i)
shall not apply to any exercise of this Warrant for which the Holder requests,
and the Company agrees to, Net Cash Settlement. For purposes of this Section
3(e)(ii), beneficial ownership shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated by the SEC
thereunder.  Within three (3) Business Days of any written request of the
Holder, the Company shall confirm in writing to the Holder the number of shares
of Common Stock then outstanding. If on any attempted exercise of this Warrant
the resulting issuance of Warrant Shares would result in the Holder exceeding
the Maximum Aggregate Ownership Amount or the Maximum Aggregate Voting Amount
(each, an “Attempted Exercise”) and the Company shall not have previously
obtained Stockholder Approval, then the Company shall only issue to the Holder
such number of Warrant Shares as may be issued below the Maximum Aggregate
Ownership Amount or Maximum Aggregate Voting Amount, as the case may be, and the
Company shall, at its expense, use its commercially reasonable efforts to obtain
Stockholder Approval; provided, however, that, if such Stockholder Approval has
not been obtained

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

within ****** (**) days after the Exercise Date with respect to the Attempted
Exercise, then at any time thereafter prior to such Stockholder Approval being
obtained the Holder shall be permitted to (x) deliver to the Company a notice (a
“Net Cash Settlement Election Notice”), pursuant to which the Holder may elect
that the Attempted Exercise be settled through Net Cash Settlement pursuant to
Section 2(d) (a “Net Cash Settlement Election”) or (y) withdraw its Exercise
Notice with respect to such Attempted Exercise.  In the event of any Attempted
Exercise, notwithstanding any delay in settling such exercise, if and when such
exercise is settled (including as a result of a Net Cash Settlement Election),
the Fair Market Value for purposes of calculating the number of Warrant Shares
issuable (in the case of a Net Share Settlement) or the amount of cash payable
(in the case of a Net Cash Settlement) shall be determined as of the original
Exercise Date and not any subsequent date based upon such delayed settlement.

(iii)The Holder shall cooperate with and take such actions as may be reasonably
requested by the Company in order carry out the provisions of this Section
3(e).  If and when the Holder (or any subsequent transferee thereof) elects to
sell any of the Warrant Shares issued pursuant to this Warrant in a manner that
complies with an exemption from registration under the Securities Act, and the
Company is requested to issue to the Company’s transfer agent an opinion of
counsel permitting removal of any restrictive legend thereon, then, as and to
the extent reasonably requested by the Company in support of such opinion, the
Holder shall deliver or cause to be delivered to the Company (A) an opinion of
counsel, in form and substance reasonably satisfactory to the Company, to the
effect that the proposed transaction may be effected without registration under
the Securities Act, together with a duly executed officer’s certificate
containing reasonably requested certifications and representations related
thereto, or (B) any other evidence reasonably satisfactory to counsel to the
Company to the effect that the proposed transaction may be effected without
registration under the Securities Act; provided, however, that (x) no such legal
opinion will be required for any transaction effected in compliance with Rule
144 under the Securities Act and (y) no such legal opinion or other evidence
will be required for any transaction in which the Holder sells or otherwise
transfers this Warrant or any Warrant Shares to Comcast Corporation (or any
successor publicly-held parent company of the Holder) or any subsidiary thereof
in a transaction in which this Warrant or any Warrant Shares (as applicable)
remain restricted legended securities subject to the provisions of this Section
3(e)(iii).

4.No Impairment.  The Company will not, by amendment of its Certificate of
Incorporation or through reorganization, consolidation, merger, dissolution,
sale of assets or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the
taking of all such action as may be necessary or appropriate in order to protect
the rights of the Holder of this Warrant against impairment.  Without limiting
the generality of the foregoing, the Company will (i) take all such action as
may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of
this Warrant and (ii) use its commercially reasonable efforts to obtain, make or
file (as applicable) any consents, approvals, orders, waivers, exemptions,
authorizations, registrations, declarations, filings, qualifications,
certifications, notices, applications, reports or waiting period expirations
from, to or with any regulatory body having jurisdiction thereof as may be
necessary to enable the Company to perform its obligations under this Warrant,
including obtaining Stockholder Approval if necessary.

5.Expiration.  This Warrant and the right to purchase Warrant Shares upon
exercise hereof shall expire at 11:59 p.m., New York City time, on July 24, 2024
(such date, as it may be extended pursuant to Section 3(e)(i), the “Expiration
Date”).

6.Notices of Record Date, etc.  In case of:

(a)any Change of Control, any Fundamental Change or any other consolidation or
merger of the Company, capital reorganization of the Company, or
reclassification or recapitalization of the Capital Stock of the Company, in
each case, in any one transaction or a series of related transactions, or

(b)the voluntary or involuntary dissolution, liquidation or winding-up of the
Company, or

(c)any grant by the Company to the holders of its Common Stock or any other
Company security then issuable upon exercise of this Warrant of (or the taking
by the Company of a record of such holders for the purpose of determining their
entitlement to receive) any dividend or other distribution or any right to
subscribe for,

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

purchase, receive or otherwise acquire any shares of Capital Stock of any class
or any option, warrant or security convertible into or exercisable or
exchangeable therefor, then, and in each such case, or

(d)any reduction in the number of outstanding shares of its Common Stock or any
other Company security then issuable upon exercise of this Warrant, whether as a
result of repurchases by the Company or otherwise:

the Company will mail or cause to be mailed to the Holder of this Warrant a
notice specifying, as the case may be, the estimated effective date on which
such Change of Control, Fundamental Change, consolidation, merger,
reorganization, reclassification, recapitalization, dissolution, liquidation,
winding-up, dividend, distribution, other grant of rights or reduction is to
take place, and the time, if any is to be fixed, as of which the holders of
record of the Common Stock shall be entitled to exchange their shares for
securities or other property deliverable upon such Change of Control,
Fundamental Change, consolidation, merger, reorganization, reclassification,
recapitalization, dissolution, liquidation or winding-up or to receive (or be
entitled to receive) such dividend, distribution or other grant of rights.  Such
notice shall be mailed at least ten (10) Business Days prior to the record date
or effective date for the event specified in such notice. Such notice shall also
set forth such facts with respect thereto as shall be reasonably necessary to
indicate the effect of such action on the Exercise Price and the number and kind
or class of shares or other securities or property which shall be deliverable or
purchasable upon the occurrence of such action or deliverable upon exercise of
this Warrant.

 

7.Adjustment to Warrant Shares and Exercise Price. The number and kind of
Warrant Shares (including as set forth in the vesting milestones in Section
3(a)) and the Exercise Price shall be subject to adjustment from time to time
upon the occurrence of certain events, as follows (in each case, except with
respect to a Fundamental Change, in which event Section 3(b) shall govern);
provided that if more than one subsection of this Section 7 is applicable to a
single event, then the subsection that produces *** ******* ********** ***** **
*******, and no single event shall cause an adjustment under more than one
subsection of this Section 7 to the extent of any resulting duplication:

(a)**** ***** ********* ** ******.  If, at any time after the Issue Date, ***
****** ** ****** ** ****** ***** (** ***** ***** ** ******* ***** ** *** *******
**** ******** **** ******** ** **** *******) *********** ** ********* ** * *****
******** ******* ** ****** ** ****** ***** (** **** ***** ***** ** *******
*****) ** ** * *********** ** ******** ** ****** ** ****** ***** (** **** *****
***** ** ******* *****)* ***** ********* ** ** *** ****** **** *** ***
************* ** ******* ** ****** ***** (** **** ***** ***** ** ******* *****)
******** ** ******* **** ***** ********* ** ****** ** ** ******** ** ****
*********** ** ********* *** ******** ***** ***** ** ********* ** ***********
*** ******** ***** **** ** ****** ** * ********* (*) *** ********* ** *****
***** ** *** ****** ** ****** ** ****** ***** (** **** ***** ***** ** *******
*****) *********** *********** ***** ** **** ***** ********* *********** **
********* *** (**) *** *********** ** ***** ***** ** *** ****** ** ****** **
****** ***** (** **** ***** ***** ** ******* *****) *********** ***********
***** **** ***** ********* *********** ** ********* *** *** ******* ** ********
***** ********** ** *** ******** *****.

(b)**** ************* *************** ****  If, at any time after the Issue
Date, *** ****** ** ****** ** ****** ***** (** ***** ***** ** ******* ***** **
*** ******* **** ******** **** ******** ** **** *******) *********** **
********* ** * *********** ** * ************* ** *** *********** ****** **
****** ***** (** **** ***** ***** ** ******* *****) **** * ******* ****** **
****** ** ****** ***** (** **** ***** ***** ** ******* *****)* ***** *********
** ** *** ****** **** *** *** ************* ** ****** ** ** ******** ** ****
*********** ** ************** *** ******** ***** ***** ** ********* **
*********** *** ******** ***** **** ** ****** ** * ********* (*) *** *********
** ***** ***** ** *** ****** ** ****** ** ****** ***** (** **** ***** ***** **
******* *****) *********** *********** ***** ** **** *********** **
************** *** (**) *** *********** ** ***** ***** ** *** ****** ** ******
** ****** ***** (** **** ***** ***** ** ******* *****) *********** ***********
***** **** *********** ** ************** *** *** ******* ** ******** *****
********** ** *** ******** *****.

(c)Upon Reclassifications, Reorganizations, Consolidations or Mergers.  In the
event of (i) any capital reorganization of the Company, (ii) any
reclassification or recapitalization of the stock of the Company (other

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

than (x) a change in par value or from par value to no par value or from no par
value to par value or (y) as a result of a stock dividend or subdivision or
split-up of shares as to which Section 7(a) shall apply or a combination or
consolidation of shares as to which Section 7(b) shall apply), or (iii) any
consolidation or merger of the Company with or into another corporation (where
the Company is not the surviving corporation or where there is a change in or
distribution with respect to the Common Stock or any other class of Capital
Stock then issuable upon exercise of this Warrant), this Warrant shall, after
such reorganization, reclassification, recapitalization, consolidation or
merger, be exercisable for the kind and number of shares of stock or other
securities or property (“Alternate Consideration”) of the Company or of the
successor corporation resulting from such consolidation or surviving such
merger, if any, to which the holder of the number of Warrant Shares underlying
this Warrant (at the time of such reorganization, reclassification,
recapitalization, consolidation or merger, but assuming the satisfaction of all
vesting milestones set forth in Section 3(a)) would have been entitled upon such
reorganization, reclassification, recapitalization, consolidation or merger.  In
such event, the aggregate Exercise Price otherwise payable for the shares of
Common Stock (or such other class of Capital Stock) issuable upon exercise of
this Warrant shall be allocated among the Alternative Consideration receivable
as a result of such reorganization, reclassification, recapitalization,
consolidation, or merger in proportion to the respective Fair Market Values of
such Alternate Consideration.  If and to the extent that the holders of Common
Stock (or such other class of Capital Stock) have the right to elect the kind or
amount of consideration receivable upon consummation of such reorganization,
reclassification, recapitalization, consolidation or merger, then the
consideration that the Holder shall be entitled to receive upon exercise shall
be specified by the Holder, which specification shall be made by the Holder by
the later of (A) ten (10) Business Days after the Holder is provided with a
final version of all material information concerning such choice as is provided
to the holders of Common Stock (or such other class of Capital Stock), and (B)
the last time at which the holders of Common Stock (or such other class of
Capital Stock) are permitted to make their specifications known to the Company;
provided, however, that if the Holder fails to make any specification within
such time period, the Holder’s choice shall be deemed to be whatever choice is
made by a plurality of all holders of Common Stock (or such other class of
Capital Stock) that are not affiliated with the Company (or, in the case of a
consolidation or merger, any other party thereto) and affirmatively make an
election (or of all such holders if none of them makes an election).  From and
after any such reorganization, reclassification, recapitalization, consolidation
or merger, all references to “Warrant Shares” herein (including with respect to
the calculation of the amount of cash payable upon a Net Cash Settlement or
required to be deposited as Escrowed Proceeds upon a Fundamental Change) shall
be deemed to refer to the Alternate Consideration to which the Holder is
entitled pursuant to this Section 7(c).  The provisions of this clause shall
similarly apply to successive reorganizations, reclassifications,
recapitalizations, consolidations, or mergers.  

(d)Other Distributions.  In case the Company shall fix a record date for the
making of a distribution (or, if no record date is set, the date of any
distribution) to all holders of shares of its Common Stock (or other class of
Capital Stock of the Company then issuable upon exercise of this Warrant) of
securities, evidences of indebtedness, assets, cash, rights, warrants or other
property (excluding (x) any cash dividends other than Specified Dividends and
(y) any other dividends or distributions referred to in Section 7(a), 7(b) or
7(c)), then in each such case the Exercise Price in effect prior to such record
date (or, if no record date is set, the date of such distribution) shall be
reduced immediately thereafter to the price determined by multiplying the
Exercise Price in effect immediately prior to the reduction by a fraction, (i)
the numerator of which is (A) the average daily volume weighted average price
per share of the Common Stock (or such other Company security as is then
issuable upon exercise of this Warrant) for the last trading day preceding the
first date on which the Common Stock (or such other Company security as is then
issuable upon exercise of this Warrant) trades regular way on the principal
national securities exchange or quotation system on which the Common Stock (or
such other Company security) is listed or admitted to trading without the right
to receive such distribution (or if the Common Stock or such other Company
securities do not trade on a national securities exchange or quotation system,
the Fair Market Value thereof as of the record date with respect to such
distribution) minus (B) the amount of cash and/or the Fair Market Value of the
securities, evidences of indebtedness, assets, rights, warrants or other
property to be so distributed in respect of one share of Common Stock (or such
other Company security) and (ii) the denominator of which is such average daily
volume weighted average price per share (or, if applicable, Fair Market Value)
specified in the preceding clause (i)(A).  The adjustment described in this
clause shall be made successively whenever such a record date is fixed or
distribution is made.

(e)Adjustment of Number of Shares Purchasable.  Upon any adjustment of the
Exercise Price as provided in Section 7(a) or 7(b), the Holder shall thereafter
be entitled to purchase upon the exercise of this Warrant, at the Exercise Price
resulting from such adjustment, the number of Warrant Shares obtained by
multiplying the

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

number of Warrant Shares as to which this Warrant is exercisable immediately
prior to such adjustment by a fraction, the numerator of which is the Exercise
Price in effect immediately prior to such adjustment and the denominator of
which is the Exercise Price resulting from such adjustment.

(f)Rounding of Calculations; Minimum Adjustments. All calculations under this
Section 7 shall be made to the nearest one-tenth (1/10th) of a cent or to the
nearest one-hundredth (1/100th) of a share, as the case may be. Any provision of
this Section 7 to the contrary notwithstanding, no adjustment in the Exercise
Price or the number of Warrant Shares as to which this Warrant is exercisable
shall be made if the amount of such adjustment would be less than $0.01 or
one-tenth (1/10th) of a share, but any such amount shall be carried forward and
an adjustment with respect thereto shall be made at the time of and together
with any subsequent adjustment which, together with such amount and any other
amount or amounts so carried forward, shall aggregate $0.01 or 1/10th of a
share, or more.

(g)Notice of Adjustment.  Whenever the terms of this Warrant are adjusted
pursuant to this Section 7 or pursuant to any other applicable provision hereof,
the Company shall deliver to the Holder in accordance with the notice provisions
below a certificate signed by a duly authorized officer of the Company
describing, in reasonable detail, the change or event requiring such adjustment
and the newly adjusted Exercise Price, number of Warrant Shares and, as
applicable, the kind and amount of Alternate Consideration purchasable hereunder
after giving effect to such adjustment.

(h)Proceedings Prior to Any Action Requiring Adjustment.  As a condition
precedent to the taking of any action that would require an adjustment pursuant
to this Section 7, the Company shall take any and all actions that may be
necessary, including obtaining regulatory, the NASDAQ Stock Market or other
applicable national securities exchange or stockholder approvals or exemptions,
in order that Company may thereafter validly and legally issue as fully paid and
nonassessable all Warrant Shares and, as applicable, all Alternate Consideration
that the Holder is entitled to receive upon exercise of this Warrant.

8.Reservation of Stock.  Unless a Fundamental Change has occurred, the Company
will at all times reserve and keep available, solely for the issuance and
delivery upon the exercise of this Warrant, such Common Stock and, as
applicable, Alternate Consideration as from time to time shall be issuable upon
the exercise of this Warrant.  All securities which shall be so issuable, when
issued upon exercise of this Warrant in accordance herewith, shall be duly and
validly issued and fully paid and nonassessable, and not subject to preemptive
rights.

9.Replacement of Warrants.  Upon delivery by the Holder to the Company of (i)
notice of the loss, theft, destruction or mutilation of this Warrant, and (ii)
in the case of loss, theft or destruction, an indemnity agreement in a form and
amount reasonably satisfactory to the Company, or in the case of mutilation,
this Warrant, the Company will issue, in lieu thereof, a new Warrant of like
tenor and dated as of the Issue Date.

10.No Rights as Stockholder.  Until the exercise of this Warrant, the Holder of
this Warrant shall not have or exercise any rights by virtue hereof as a
stockholder of the Company (and then only to the extent of such Holder’s
ownership of Capital Stock).

11.Transfer.

(a)Securities Laws.  Neither this Warrant nor the Warrant Shares issuable upon
the exercise hereof have been registered under the Securities Act of 1933, as
amended (the “Securities Act”), or under any state securities laws and, unless
so registered, may not be transferred, sold, pledged, hypothecated or otherwise
disposed of unless an exemption from such registration is available, including
if this Warrant or the Warrant Shares are sold in accordance with Rule 144
promulgated under the Securities Act or any successor rule or regulation
hereafter adopted by the SEC.  

(b)Restrictions on Transfer.

(i)The Holder shall not, directly or indirectly, by operation of law or
otherwise, pledge, sell, encumber, assign, or otherwise transfer all or any
unvested portion of this Warrant without the prior

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

written consent of the Company (which consent shall be in the Company’s sole
discretion), other than (A) as part of a transaction in which at least 50% of
the cable systems owned and/or operated by Comcast Corporation and its
subsidiaries (as measured by number of subscribers) are being transferred or (B)
to Comcast Corporation (or any successor publicly-held parent company of the
Holder) or any subsidiary thereof (provided that, in the event of any sale or
other change in control of any such subsidiary to which any unvested portion of
this Warrant has been transferred, other than as part of a transaction described
in clause (A), such subsidiary shall be required to transfer such unvested
portion of this Warrant to Comcast Corporation (or any successor publicly-held
parent company of the Holder) or another subsidiary thereof).  For the avoidance
of doubt, in no event shall any transactions in the securities of Comcast
Corporation (or any successor publicly-held parent company of the Holder)
constitute a transfer of this Warrant.

(ii)The Holder shall be permitted to pledge, sell, encumber, assign or otherwise
transfer all or any vested portion of this Warrant and all or any portion of the
Warrant Shares received upon exercise of this Warrant to any Person; provided
that any such pledge, sale, encumbrance, assignment or transfer is effected in
accordance with applicable law (including the Securities Act).

(c)Transfer Notice.  Promptly following the pledge, sale, encumbrance,
assignment or other transfer of all or a portion of this Warrant in accordance
herewith, the Holder shall surrender this Warrant to the Company, together with
written notice of (i) the name, address, telephone number and facsimile number
of the transferee and (ii) the portion of this Warrant so transferred
(designated by the number of Warrant Shares underlying such portion of this
Warrant).  Promptly following delivery by the Holder of such notice, the Company
shall promptly (and in any event within five days thereafter) (A) deliver to the
designated transferee a new Warrant evidencing the rights of such transferee to
purchase the Warrant Shares in the denominations as set forth in such notice,
(B) if applicable, deliver to the Holder a new Warrant evidencing the balance of
this Warrant not assigned by the Holder, and (C) register on the books and
records of the Company such transfer.  Such new Warrants shall in all other
respects be identical to this Warrant (including the vesting milestones set
forth in Section 3(a), to the extent applicable).  All or any portion of this
Warrant, if properly assigned in compliance with this Section 11, may be
exercised by the new Holder for the purchase of Warrant Shares without having a
new Warrant issued.

(d)Legends.  Unless and until the Warrant Shares have been registered under the
Securities Act or transferred pursuant to Rule 144, it is understood and agreed
that any Warrant or certificate representing Warrant Shares shall bear any
legend considered necessary or desirable by the Company to comply with the
Securities Act or other applicable state securities laws, including
substantially the following:

THE SECURITIES EVIDENCED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND MAY
NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OFFERED FOR SALE, OR OTHERWISE
DISPOSED OF EXCEPT (A) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
SUCH ACT AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAWS OR (B) IN A
TRANSACTION THAT QUALIFIES AS AN EXEMPT TRANSACTION UNDER SUCH ACT AND ANY
APPLICABLE STATE SECURITIES LAWS.

(e)Rule 144 Information.  Unless a Fundamental Change has occurred, the Company
covenants that it will use its reasonable best efforts to file timely all
reports and other documents required to be filed by it under the Securities Act
and the Exchange Act and the rules and regulations promulgated by the SEC
thereunder (or, if the Company is not required to file such reports, it will,
upon the request of the Holder, make publicly available such information as
necessary to permit sales pursuant to Rule 144 under the Securities Act), and it
will use its reasonable best efforts to take such further action as a Holder may
reasonably request, in each case, to the extent required from time to time to
enable the Holder to, if permitted by the terms of this Warrant, sell this
Warrant and the Warrant Shares without registration under the Securities Act
within the limitations of the exemptions provided by (A) Rule 144 under the
Securities Act, as such rule may be amended from time to time, or (B) any
successor rule or regulation hereafter

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

adopted by the SEC.  Upon the written request of the Holder, the Company will
deliver to such Holder a written statement that it has complied with such
requirements.

(f)Registration Rights.  The Holder shall be entitled to request registration of
the Warrant Shares under the Securities Act in accordance with that certain
Registration Rights Agreement dated as of the Issue Date by and between the
Company and the Holder (the “Registration Rights Agreement”).

(g)Survival.  This Section 11 shall survive any exercise of this Warrant with
respect to the Warrant Shares issued upon such exercise.

12.Company Representations and Warranties. The Company hereby represents and
warrants to the Holder that, as of the Issue Date, except as set forth in the
SEC Documents filed with the SEC on or prior to the Issue Date:

(a)Organization, Good Standing and Corporate Power.  The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Colorado.  Except as would not reasonably be expected to have a
Material Adverse Effect, each of the Company’s subsidiaries is a corporation
duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization.  The Company and each of its subsidiaries has
all requisite corporate power and authority to carry on its business as now
conducted and as presently proposed to be conducted, except for any failure of
any subsidiaries to have such corporate power and authority as would not
reasonably be expected to have a Material Adverse Effect. The Company has all
requisite corporate power and authority to execute, deliver and perform its
obligations under this Warrant and the Registration Rights Agreement.  The
Company and each of its subsidiaries is duly qualified to transact business as a
foreign corporation and is in good standing in each jurisdiction in which the
failure to so qualify would have a Material Adverse Effect.

(b)Authorization.  All corporate action on the part of the Company (including
its Board, officers and stockholders) necessary to authorize the execution,
delivery and performance of this Warrant and the Registration Rights Agreement
by the Company has been taken (except to the extent that Stockholder Approval is
required in accordance with Section 3(e)(ii)).  This Warrant and the
Registration Rights Agreement constitute valid and legally binding obligations
of the Company, enforceable against the Company in accordance with their
respective terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance, or other laws of general
application relating to or affecting the enforcement of creditors’ rights
generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, and (iii) to the
extent the indemnification provisions contained in the Registration Rights
Agreement may be limited by applicable federal or state securities laws.

(c)Valid Issuance of Shares.  The Warrant Shares have been duly reserved for
issuance and, upon issuance in accordance with the terms of this Warrant, will
be duly authorized, validly issued, fully paid and nonassessable and issued free
and clear of any lien, encumbrance, security interest, pledge, mortgage,
hypothecation, charge, adverse claim, title retention agreement of any nature or
kind, or other encumbrance (except any applicable securities law
restrictions).  The offer, sale and issuance of this Warrant and the issuance of
the Warrant Shares upon exercise hereof (i) are not subject to and will not give
rise to any preemptive rights or rights of first refusal with respect thereto
and (ii) are and will be in compliance with all applicable federal and state
securities laws.  

(d)Governmental Consents and Filings. No consent, approval, order, waiver,
exemption or authorization of, registration, declaration, filing or
qualification with, certification, notice, application or report to, or
expiration of any waiting period applicable to, any governmental authority,
self-regulatory organization (including the NASDAQ Stock Market or any other
applicable national securities exchange) or any other third party is required on
the part of the Company in connection with the execution and delivery of this
Warrant and the Registration Rights Agreement or the offer, sale and issuance of
this Warrant or, except as provided in Sections 3(e)(i) and 3(e)(ii), the
issuance of the Warrant Shares upon exercise hereof.

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

(e)Compliance with Laws and Other Instruments.  

(i)Neither the Company nor any of its subsidiaries is in violation of or default
under, and from December 31, 2013 through the Issue Date has not received any
notices of violation or default with respect to, (A) any provisions of its
certificate of incorporation, bylaws or other organizational documents, (B) any
instrument, judgment, order, writ or decree of any court or governmental
authority applicable to the Company or any of its subsidiaries, or (C) any note,
indenture, mortgage, lease, agreement, instrument or other contract to which it
is a party or by which it is bound, except in the case of clauses (B) and (C)
for such violations or defaults as would not, individually or in the aggregate,
have a Material Adverse Effect.  

(ii)Neither the Company nor any of its subsidiaries is in violation of, and the
operation of the Company’s and its subsidiaries’ businesses as now conducted
does not violate, any provision of any federal, state, local or foreign law,
statute, rule or regulation applicable to the Company or its subsidiaries,
except for such violations as would not, individually or in the aggregate, have
a Material Adverse Effect.  

(iii)The execution, delivery and, subject to Sections 3(e)(i) and 3(e)(ii),
performance of this Warrant and the Registration Rights Agreement by the Company
and the offer, sale and issuance of this Warrant and, subject to Sections
3(e)(i) and 3(e)(ii), the issuance of the Warrant Shares upon exercise hereof do
not and will not conflict with, result in a violation of or default under (with
or without the passage of time and/or the giving of notice), or give rise to a
right of termination, cancellation or acceleration of any obligation or to a
loss of a material benefit under, (A) any provisions of the Company’s or any of
its subsidiaries’ certificate of incorporation, bylaws or other organizational
documents, (B) any instrument, judgment, order, writ or decree of any court or
governmental authority applicable to the Company or any of its subsidiaries, or
(C) any note, indenture, mortgage, lease, agreement, instrument or other
contract to which the Company or any of its subsidiaries is a party or by which
the Company or any of its subsidiaries is bound, except in the case of clauses
(B) and (C) for such violations or defaults as would not, individually or in the
aggregate, have a Material Adverse Effect.

(f)SEC Documents; Company Stock Exchange Listing.

(i)The Company is current in its obligations to file and furnish all periodic
reports with the SEC required to be filed or furnished by it under the Exchange
Act and any applicable rules and regulations promulgated thereunder. The
Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2013, and any other reports, proxy statements and information the Company filed
with or furnished to the SEC since December 31, 2012 (the “SEC Documents”), at
the time of their filing or being furnished, (A) did not contain an untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, and (B) complied in
all material respects with the applicable requirements of the Exchange Act and
the Securities Act and the respective rules and regulations promulgated
thereunder.  

(ii)The financial statements of the Company (whether audited or unaudited and
including any notes thereto or schedules included therein) included in the SEC
Documents (the “Company Financial Statements”) (A) at the time of their filing
or being furnished, complied as to form in all material respects with applicable
accounting requirements and the published rules and regulations of the SEC with
respect thereto, (B) were prepared in accordance with U.S. generally accepted
accounting principles applied on a consistent basis during the periods involved
(except as may be indicated in the notes thereto or as otherwise permitted by
Form 10-Q with respect to any Company Financial Statements filed on Form 10-Q),
and (C) fairly presented in all material respects the consolidated financial
position of the Company as of the dates thereof and the consolidated results of
its operations and cash flows for the periods then ended.

(iii)The Company is in compliance in all material respects with the applicable
listing rules of the NASDAQ Stock Market and has not received any written notice
from the NASDAQ Stock Market asserting any material non-compliance with such
rules.

(iv)Since the date of the audited financial statements of the Company included
in the Company’s Annual Report on Form 10-K for the fiscal year ended December
31, 2013, there has not been any event,

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

change, occurrence or circumstance that, individually or in the aggregate, has
had or would reasonably be expected to have a Material Adverse Effect.

(g)Capitalization.  As of July 18, 2014, the authorized and outstanding capital
stock of the Company consisted solely of (i) 100,000,000 shares of Common Stock,
of which 34,091,572 were issued and outstanding, and (ii) 10,000,000 shares of
preferred stock, par value $.01, of which none of which were issued and
outstanding.  All outstanding shares of the Company’s Capital Stock are duly
authorized, validly issued, fully paid and nonassessable.  Except for (x)
********* shares of Common Stock reserved and not granted for issuance to
employees under existing benefit plans disclosed in the SEC Documents filed
publicly with the SEC prior to the Issue Date, and (y) the Company’s 2010
Convertible Notes due March 1, 2017 as defined and disclosed in the SEC
Documents filed publicly with the SEC prior to the Issue Date, there are no (A)
securities convertible into or exchangeable or exercisable for shares of the
Company’s Capital Stock, (B) subscriptions, options, warrants, calls, rights,
convertible securities or other contracts, agreements or commitments of any kind
or character obligating the Company to issue, transfer or sell any of its
Capital Stock, or (C) any equity equivalents or any agreements, arrangements or
understandings granting any Person any rights in the Company similar to Capital
Stock.  As of the Issue Date, there are no outstanding obligations of the
Company to repurchase, redeem or otherwise acquire any of the Company’s Capital
Stock.  As of **** *** ****, there were ******* outstanding and unvested
restricted stock units granted by the Company.

(h)Litigation.  There is no action, suit, proceeding, arbitration, mediation,
complaint, claim, charge or investigation pending or, to the Company’s
knowledge, currently threatened before any court, arbitrator, mediator or
governmental agency or instrumentality against the Company, any of its
subsidiaries or any officer or director of the Company or any of its
subsidiaries: (i) that questions the validity of this Warrant or the
Registration Rights Agreement or the right of the Company to enter into either
of them; or (ii) that would reasonably be expected to have, individually or in
the aggregate, a Material Adverse Effect.  

13.Miscellaneous.

(a)Notices.  All notices and other communications from the Company to the Holder
of this Warrant shall be sufficiently made if sent by nationally recognized
overnight courier (with tracking capability) or personal delivery to the mailing
address of the Holder appearing on the books of the Company maintained for such
purpose (as changed by the Holder from time to time by like notice).  All
notices and other communications from the Holder of this Warrant to the Company,
including any Exercise Notice, shall be sufficiently made if sent by nationally
recognized overnight courier (with tracking capability), personal delivery or by
e-mail to the mailing or e-mail address, as applicable, of the Company at its
principal offices as shown below or as changed by the Company from time to time
by like notice.  Any notice and other communication in accordance with this
Section 13(a) shall be deemed to be delivered, given and received for all
purposes as of: (i) if sent by a nationally recognized overnight courier (with
tracking capability), the Business Day immediately following the date sent, (ii)
if delivered personally, the date so delivered, and (iii) if and to the extent
permitted to be sent by e-mail, the date sent (unless the sender receives an
automatic error message from the server of the intended recipient indicating
that the applicable notice or communication has not been received by such
intended recipient or delivery thereof is delayed for any reason whatsoever).

(b)Nonwaiver.  No course of dealing or any delay or failure to exercise any
right hereunder on the part of the Company or the Holder shall operate as a
waiver of such right or otherwise prejudice the rights, powers or remedies of
such Person.

(c)Limitation of Liability.  No provision hereof, in the absence of affirmative
action by the Holder to purchase Warrant Shares, and no enumeration herein of
the rights or privileges of the Holder hereof, shall give rise to any liability
of such Holder to pay the Exercise Price for any Warrant Shares other than
pursuant to an exercise of this Warrant or give rise to any status of or
liability as a stockholder of the Company, whether such status or liability is
asserted by the Company or by creditors of the Company.

(d)Saturdays, Sundays, Holidays, etc.  If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then such action may be taken or such right may be
exercised on the next succeeding day that is a Business Day.

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

(e)Change or Waiver.  Any term of this Warrant may be changed or waived only by
an instrument in writing signed by the party against which enforcement of the
change or waiver is sought.

(f)Successors and Assigns.  The rights and obligations of the Company set forth
herein may not be assigned or delegated by the Company without the prior written
consent of the Holder.  Subject to the restrictions on transferability set forth
in Section 11 hereof, the rights and obligations of the Holder set forth herein
may be assigned or delegated by the Holder without the prior written consent of
the Company.  Subject to the foregoing, this Warrant and the rights evidenced
hereby shall inure to the benefit of and be binding upon the successors of the
Company and the permitted successors and assigns of the Holder hereof.  The
provisions of this Warrant are intended to be for the benefit of all Holders
from time to time of this Warrant and to the extent applicable, all Holders of
Warrant Shares issued upon the exercise hereof (including transferees), and
shall be enforceable only by such Holders.

(g)Severability.  The provisions of this Warrant shall be deemed severable and
the invalidity or unenforceability of any provision shall not affect the
validity or enforceability of the other provisions hereof.  If any provision of
this Warrant, or the application of such provision to any Person or any
circumstance, is invalid or unenforceable, (i) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (ii) the remainder of this Warrant and the application of such
provision to other Persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application of
such provision, in any other jurisdiction.

(h)Construction. Unless the express context otherwise requires:

(i)the words “hereof,” “herein,” and “hereunder” and words of similar import,
when used in this Warrant, shall refer to this Warrant as a whole and not to any
particular provision of this Warrant;

(ii)any singular forms of nouns, pronouns and verbs use herein shall include the
plural, and vice versa;

(iii)any references herein to any gender include each other gender;

(iv)any references herein to “$” are to United States Dollars;

(v)any references herein to the Preamble shall refer to the preamble to this
Warrant, and any references herein to a specific Section shall refer to such
section of this Warrant;

(vi)any references to any Person include references to such Person’s successors
and permitted assigns;

(vii)any references to any agreement, document or instrument means such
agreement, document or instrument as amended or otherwise modified from time to
time in accordance with the terms thereof and, if applicable, hereof;

(viii)wherever the words “include,” “includes,” or “including” are used in this
Warrant, they shall be deemed to be followed by the words “without limitation”;
and

(ix)the headings in this Warrant are for purposes of reference only and shall
not limit or otherwise affect the meaning of any provision of this Warrant.

(i)Governing Law.  This Warrant shall be governed by and construed in accordance
with the laws of the State of New York.

[Signature page follows]

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

IN WITNESS WHEREOF, the Company has executed this Warrant as of the Issue Date.

 

CSG SYSTEMS INTERNATIONAL, INC.

By:/s/ Randy Wiese

Name: Randy Wiese

Title: EVP / CFP

7/25/14

Principal Office:

9555 Maroon Circle

Englewood, CO  80112

E-mail Address:  ******************
Attention: General Counsel

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

EXHIBIT A

NOTICE OF EXERCISE

CSG Systems International, Inc. (the “Company”)

Attention:   [________]

 

The undersigned Holder of this Warrant exercises this Warrant [in full] [for
______ Warrant Shares], as follows:

q

by Physical Delivery, subject to delivery of the aggregate Exercise Price for
the Warrant Shares as to which this Warrant is so exercised, and the undersigned
Holder hereby instructs the Company to issue the applicable number of Warrant
Shares in the name of ______________, with delivery [of physical certificates
for such Warrant Shares in these denominations _________________ to the
following address: _____________________] [of such Warrant Shares via book entry
with the Company’s transfer agent]

 

q

by Net Share Settlement, and the undersigned Holder hereby instructs the Company
to issue certificates for the applicable number of Warrant Shares in the name of
and delivered to ______________, whose address is ___________________________

 

[Include if the Holder requests Net Cash Settlement: The undersigned Holder
hereby requests that this exercise be settled through Net Cash Settlement, and,
if the Company so agrees, the undersigned Holder hereby instructs the Company to
remit payment of the Net Cash Settlement to the following account:

 

Bank Name:

ABA#:

Account #:

Swift Code:

Ref: ]

 

[Include if the Warrant is not exercised in full:  Because the undersigned is
not exercising this Warrant in full, the undersigned hereby instructs the
Company to deliver to the undersigned a new Warrant of like tenor and date for
the balance of the Warrant Shares.]

The undersigned Holder hereby represents and warrants to the Company that, as of
the date hereof, the Holder and its Affiliates beneficially own ______________
shares of Common Stock (without giving effect to the exercise of this Warrant
pursuant to this Notice of Exercise).

___________________________________

(Name of Registered Owner)

 

___________________________________

(Signature of Registered Owner)

___________________________________

(Street Address)

 

___________________________________

(City, State, Zip)

 

___________________________________

(Dated)

 

 

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

 

Schedule R-2

 

Registration Rights Agreement

 

(See Attached)

 

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

REGISTRATION RIGHTS AGREEMENT

 

THIS REGISTRATION RIGHTS AGREEMENT, dated as of July 24, 2014 (this
“Agreement”), is being made and entered into by and between CSG SYSTEMS
INTERNATIONAL, INC., a Delaware corporation (the “Company”), and COMCAST ALPHA
HOLDINGS, LLC, a Delaware limited liability company (the “Holder”).

WHEREAS, concurrently herewith, the Company is issuing to the Holder that
certain Common Stock Purchase Warrant, dated the date hereof (the “Warrant”), in
accordance with the terms and subject to the conditions of which the Holder may
purchase certain shares of the Company’s common stock, par value $0.01 per share
(the “Common Shares”); and

WHEREAS, in connection with the transactions contemplated by the Warrant, the
Company has agreed to grant to the Holder the Registration Rights (as defined in
Section 1 hereof).

NOW, THEREFORE, the parties hereto, in consideration of the foregoing and the
mutual covenants and agreements hereinafter set forth, hereby agree as follows:

Section 1.Registration Rights

 

1.1Registration Rights.  With respect to any Common Shares issued pursuant to an
exercise of the Warrant or issuable pursuant to the exercise of a then-vested
portion of the Warrant (such Common Shares, the “Registrable Shares”), unless
such Registrable Shares have been disposed of pursuant to a Registration
Statement as provided in Section 2 below or have been sold pursuant to Rule 144
under the Securities Act of 1933, as amended (the “Securities Act”), the Holder
shall be entitled to the registration rights in accordance with the terms and
subject to the conditions set forth in Section 2 below (the “Registration
Rights”).

 

1.2Registrable Shares.  For purposes hereof, “Registrable Shares” shall also be
deemed to include any shares of capital stock of the Company issued or issuable
with respect to the Common Shares, including, without limitation, (x) as a
result of any stock split, stock dividend or other distribution,
recapitalization, merger, consolidation, exchange or similar event or otherwise
and (y) shares of capital stock of the Company into which the Common Shares are
converted or exchanged, and shares of capital stock of a successor entity into
which the Common Shares are converted or exchanged (it being understood and
agreed that this Agreement shall apply with full force and effect with respect
to any of the foregoing).

 

Section 2.Demand Registration Rights

 

2.1(a) Registration Procedure.  (i) Subject to Sections 2.1(c) and 2.2 hereof,
if the Holder desires to exercise Registration Rights with respect to any
Registrable Shares, then the Holder shall deliver to the Company a written
notice (a “Registration Notice”) informing the Company of such exercise and
specifying the number of Registrable Shares to be offered by the Holder.  Such
notice may be given with respect to any Common Shares, at any time and from time
to time, on or after the date on which the Holder has the right to purchase such
Common Shares pursuant to the exercise of a vested portion of the Warrant
(including after the purchase thereof).  Upon receipt of any Registration Notice
(provided that the Company has not already caused the Registrable Shares to be
included as part of an existing, effective shelf registration statement and
related prospectus that the Company then has on file with the Commission (a
“Shelf Registration Statement”), in which event, notwithstanding anything herein
to the contrary, the Company shall be deemed to have satisfied its registration
obligation under this Section 2 with respect to such Registrable Shares that
have been included on the Shelf Registration Statement, subject to the
maintenance of the effectiveness thereof in accordance with clause (ii) below),
the Company shall cause to be filed with the Commission as soon as reasonably
practicable after receiving the Registration Notice (but in any event within 45
days after the receipt thereof) a registration statement and related prospectus
that complies as to form in all material respects with applicable Commission
rules providing for the sale by the Holder of the Registrable Shares on a
continuous or delayed basis pursuant to Rule 415 of the Securities Act (a “New
Registration Statement”), which shall include the Registrable Shares that are
the subject of the Registration Notice, and, if the Company is not then eligible
to file an automatic shelf registration statement on Form S-3, the Company
agrees (subject to Section 2.2 hereof) to use its reasonable best efforts to
cause such New Registration Statement to be declared effective by the Commission
as soon as reasonably practicable (and in any event within 105 days after the
receipt of a Registration Notice with respect

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

thereto).  As used herein, “Registration Statement” and “Prospectus” refer to
the Shelf Registration Statement and related prospectus (including any
preliminary prospectus) or the New Registration Statement and related prospectus
(including any preliminary prospectus), whichever is utilized by the Company to
satisfy the Holder’s Registration Rights pursuant to this Section 2, including
in each case any documents incorporated therein by reference.

 

(ii)The Holder agrees to provide in writing in a timely manner information
regarding the proposed plan of distribution by the Holder of the Registrable
Shares and such other information reasonably requested by the Company in
connection with the preparation of and for inclusion in the Registration
Statement.  The Company agrees (subject to Section 2.2 hereof) to use its
reasonable best efforts to keep the Registration Statement effective (including
the preparation and filing of any amendments and supplements necessary for that
purpose) until the earlier of (x) the date on which the sale of all of the
Registrable Shares registered under the Registration Statement is consummated
and (y) two years (in the event the Company is then eligible to use Form S-3 (or
any successor registration form under the Securities Act subsequently adopted by
the SEC that permits incorporation of substantial information by reference to
other documents filed by the Company with the SEC)) or one year (in the event
the Company is not then eligible to use Form S-3 (or any such successor
registration form)) after (A) the effective date of the Registration Statement
(in the case of a New Registration Statement) or (B) the date on which the
Company supplements the Registration Statement for the offering described in the
applicable Registration Notice (in the case of a Shelf Registration Statement).

(iii)Notwithstanding the foregoing, the Company may at any time, in its sole
discretion and prior to receiving any Registration Notice from the Holder,
include all of the Common Shares issuable pursuant to the exercise of the
Warrant (whether vested or unvested) or any portion thereof in any Shelf
Registration Statement.  In connection with any Registration Statement utilized
by the Company to satisfy the Holder’s Registration Rights pursuant to this
Section 2, the Holder agrees that it will respond in writing (which may be via
email) within 15 calendar days to any reasonable request by the Company to
provide or verify information regarding the Holder or the Holder’s Registrable
Shares as may be required to be included in such Registration Statement pursuant
to the rules and regulations of the Commission.

(b)Underwritten Offerings.  On two (2) occasions, the Holder shall have the
right to distribute Registrable Shares by means of an underwriting, provided
that the Registrable Shares to be so distributed have an expected aggregate sale
price of at least $**********.  If the Holder so intends to distribute
Registrable Shares by means of an underwriting, (i) it shall so advise the
Company in the Registration Notice; (ii) the Company and the Holder shall
jointly select the managing underwriter or underwriters for such offering; (iii)
the Company shall enter into an underwriting agreement in customary form with
the underwriter(s) selected for such underwriting, and the Company shall prepare
or, if necessary, amend and supplement the Registration Statement for purposes
of such underwriting; and (iv) in no event shall the Company permit any other
shares of capital stock to be included in such underwriting without the Holder’s
written consent.

(c)Limitations on Registration Rights.  Except as otherwise provided in Section
2.1(b) with respect to underwritten offerings (as to which Section 2.1(b) shall
apply), each exercise by the Holder of its Registration Rights shall be with
respect to a minimum of the lesser of (i) an amount of Common Shares having an
expected aggregate sale price of at least $********** or (ii) the total number
of Registrable Shares held by the Holder at such time.  The Holder shall not be
entitled to deliver (x) more than one Registration Notice during any *** *****
period (whether for an underwritten offering or a non-underwritten offering) or
(y) any Registration Notice for a non-underwritten offering if all Registrable
Shares are then eligible for sale purchase to Rule 144(b)(1) under the
Securities Act.

 

2.2Suspension.   (a)  Before a Registration Statement for any Registrable Shares
has been declared effective, upon any notice by the Company to the Holder that
the Company in good faith has concluded that disclosure by the Company in such
Registration Statement of Confidential Information (as hereinafter defined)
would be required and the nondisclosure of such Confidential Information would
reasonably be expected to cause such Registration Statement to fail to comply
with applicable disclosure requirements, the Holder agrees that (i) the Company
may discontinue its efforts to register such Registrable Shares during the
relevant Suspension Period (as hereinafter defined), and (ii) its rights to
require the Company to take action to register any Registrable Shares pursuant
to a Registration Statement shall be suspended during such Suspension Period.

 

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

(b)After a Registration Statement for any Registrable Shares has been declared
effective, upon notice by the Company to the Holder that the Company has
concluded that disclosure by the Company in such Registration Statement of
Confidential Information would be required and the nondisclosure of such
Confidential Information would reasonably be expected to cause such Registration
Statement to fail to comply with applicable disclosure requirements, the Holder
agrees that (i) it will immediately discontinue offers and sales of the
Registrable Shares under such Registration Statement until the Holder receives
copies of a supplemented and amended Prospectus that corrects the
misstatement(s) or omission(s) referred to above and receives notice that any
post-effective amendment has become effective, and (ii) its rights to require
the Company to take any action with respect to the registration or sale of any
Registrable Shares pursuant to such Registration Statement (or to take any
action to amend or supplement such Registration Statement) shall be suspended
during such Suspension Period.

 

(c)As used herein, (i) the term “Confidential Information” means any material,
non-public information, which, if disclosed, would interfere with, delay or
impede (in each case, in any material respect) a significant acquisition,
divestiture, merger, amalgamation, scheme of arrangement, tender offer, share
exchange, recapitalization, restructuring, consolidation, corporate
reorganization, liquidation, dissolution, financing, joint venture, partnership,
strategic alliance, licensing arrangement, or other business combination
transaction or extraordinary corporate transaction or series of related
transactions involving the Company or would result in the premature disclosure
of material information that the Company has a bona fide business purpose for
preserving as confidential, and (ii) the term “Suspension Period” means any
period commencing on the date that the Company reasonably concludes that it
cannot register Registrable Shares without disclosing Confidential Information
and ending on the earlier of (x) the date the Company discloses such
Confidential Information, or (y) the date on which the Company concludes that it
is not required to disclose such Confidential Information; provided, however,
that (i) the period during which a Registration Statement may be suspended shall
not exceed *** **** ** *** *** *** period, except that such ******* period may
be extended to *** **** if, based on advice of counsel, the Company reasonably
concludes that, following such initial ******* period, it still cannot register
Registrable Shares without disclosing Confidential Information; and (ii) the
Company shall not register any securities for its own account or that of any
other stockholder during a Suspension Period (other than a registration relating
to the sale of securities to employees of the Company pursuant to a stock
option, stock purchase or similar plan on a registration statement on Form S-8).

 

2.3Qualification.  The Company agrees to use its reasonable best efforts to
register or qualify the Registrable Shares by the time the applicable
Registration Statement is declared effective by the Commission under all
applicable state securities or “blue sky” laws of such jurisdictions as the
Holder shall reasonably request in writing, to keep each such registration or
qualification effective during the period such Registration Statement is
required to be kept effective or during the period offers or sales are being
made by the Holder after delivery of a Registration Notice to the Company, and
to do any and all other acts and things which may be reasonably necessary or
advisable to enable the Holder to consummate the disposition in each such
jurisdiction of the Registrable Shares owned by the Holder; provided, however,
that the Company shall not be required to (x) qualify generally to do business
in any jurisdiction or to register as a broker or dealer in such jurisdiction
where it would not otherwise be required to qualify but for this Section 2.3,
(y) subject itself to taxation in any such jurisdiction or (z) submit to the
general service of process in any such jurisdiction.

 

2.4Actions by the Company.  Whenever the Company is required to effect the
registration of Registrable Shares under the Securities Act pursuant to Section
2.1 of this Agreement (subject to Section 2.2 hereof), the Company shall:

(a)prepare and file with the Commission within the time frames set forth in
Section 2.1 the requisite Registration Statement to effect such registration,
which Registration Statement shall comply as to form in all material respects
with the requirements of the applicable form and include or incorporate by
reference all financial statements required by the Commission to be filed
therewith, and the Company shall use its reasonable best efforts to cause such
Registration Statement to become effective within the time frames set forth in
Section 2.1; provided that, before filing such Registration Statement or any
amendments or supplements thereto, the Company shall furnish to the Holder and
counsel for the Holder a draft copy of the Registration Statement and shall use
its reasonable best efforts to reflect in such Registration Statement, when
filed with the Commission, such comments as the Holder or such counsel shall
reasonably and timely propose;

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

(b)subject to the proviso in clause (a) above, prepare and file with the
Commission such amendments and supplements to such Registration Statement and
the Prospectus used in connection therewith as may be necessary (i) to keep such
Registration Statement effective and (ii) to comply with the provisions of the
Securities Act with respect to the disposition of the Registrable Shares covered
by such Registration Statement, in each case for the time period provided in
Section 2.1(a)(ii);

(c)furnish, without charge, to the Holder such number of copies of such
Registration Statement, each amendment and supplement thereto (in each case
including all exhibits), and the Prospectus included in such Registration
Statement, and other documents, as the Holder may reasonably request in order to
facilitate the public sale or other disposition of the Registrable Shares owned
by the Holder; and the Company hereby consents (except during the continuance of
a Suspension Period) to the use of such Prospectus and each amendment or
supplement thereto by the Holder, in connection with any offering and sale of
the Registrable Shares covered by such Prospectus or any amendment or supplement
thereto in the manner set forth therein;

(d)promptly notify the Holder: (i) when the Registration Statement or
post-effective amendment thereto has been filed, when the same has become
effective, (ii) of any request by the Commission or any state securities or blue
sky authority for amendments to the Registration Statement, (iii) of the
issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement, (iv) of the receipt by the Company of any notification
with respect to the suspension of the qualification of any Registrable Shares
for sale under the securities or blue sky laws of any jurisdiction, (v) of the
existence of any fact of which the Company becomes aware or the happening of any
event which results in (A) the Registration Statement containing an untrue
statement of a material fact or omitting to state a material fact required to be
stated therein or necessary to make any statements therein, in the light of the
circumstances under which they were made, not misleading or (B) the Prospectus
included in such Registration Statement containing an untrue statement of a
material fact or omitting to state a material fact required to be stated therein
or necessary to make any statements therein, in the light of the circumstances
under which they were made, not misleading, and (vi) of the Company’s reasonable
determination that a post-effective amendment to the Registration Statement
would be appropriate or that there exist circumstances not yet disclosed to the
public which make further sales under such Registration Statement inadvisable
pending such disclosure and post-effective amendment;

(e)use its reasonable best efforts to cause all such Registrable Shares to be
listed (i) on the United States national securities exchange on which the Common
Shares are then listed or (ii) if the Common Shares are not at the time listed
on any United States national securities exchange (or if the listing of
Registrable Shares is not permitted under the rules of such United States
national securities exchange on which the Common Shares are then listed), on
another United States national securities exchange;

(f)use its reasonable best efforts to take all other steps necessary to expedite
or facilitate the registration and disposition of the Registrable Shares
contemplated hereby, including (i) obtaining necessary governmental approvals
and effecting required filings; (ii) cooperating with the Holder in connection
with any filings required by FINRA; (iii) providing appropriate certificates not
bearing restrictive legends representing the Registrable Shares; and (iv)
providing a CUSIP number and maintaining a transfer agent and registrar for the
Registrable Shares;

(g)keep the Holder’s counsel reasonably apprised as to the intention and
progress of the Company with respect to any Registration Statement hereunder,
including by providing the Holder’s counsel with copies of all written
correspondence with the SEC in connection with any Registration Statement or
Prospectus filed hereunder; and

 

(h)ensure that (i) at the time of filing, no Registration Statement (including
any amendments thereto) shall contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein, or necessary to
make the statements therein, in the light of the circumstances under which they
were made, not misleading, and (ii) at the time of filing, no Prospectus
(including any supplements thereto) shall contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
therein, in light of the circumstances under which they were made, not
misleading, in each case, except for any untrue statement or alleged untrue
statement of a material fact or omission or alleged omission of a material fact
made in reliance on and in

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

conformity with written information furnished to the Company by or on behalf of
the Holder specifically for use therein.

 

2.5Indemnification by the Company.  The Company shall indemnify, defend and hold
harmless, to the fullest extent permitted by applicable law, the Holder, its
affiliates (within the meaning of Rule 405 under the Securities Act), any
underwriter (within the meaning of the Securities Act), each person who controls
the Holder or any underwriter (within the meaning of the Securities Act or the
Exchange Act), and each of their respective officers and directors against all
losses, claims, damages, liabilities and expenses (collectively, “Damages”)
arising out of or based upon (a) any untrue or alleged untrue statement of a
material fact contained in any Registration Statement, Prospectus or preliminary
Prospectus or any amendment thereof or supplement thereto, (b) any omission or
alleged omission of a material fact required to be stated therein or necessary
to make the statements therein, in the light of the circumstances under which
they were made, not misleading, or (c) any violation or alleged violation by the
Company (or any of its affiliates or agents) of the Securities Act, the Exchange
Act, any state securities law or any rule or regulation promulgated thereunder,
and the Company shall pay to each such Holder, affiliate, underwriter, control
person, or other aforementioned person any legal or other expenses reasonably
incurred thereby in connection with investigating or defending any claim or
proceeding from which Damages may result; provided, however, that the Company
shall not be liable for any Damages to the extent such Damages (i) relate to the
Holder and (ii) were caused by the Holder’s failure to deliver to the Holder’s
immediate purchaser a copy of the Registration Statement or Prospectus or any
amendments or supplements thereto (if the same was required by applicable law to
be so delivered) after the Company has furnished the Holder with a sufficient
number of copies of the same.

 

2.6Indemnification by the Holder.  The Holder shall furnish to the Company in
writing such information as the Company reasonably requests for use in
connection with any Registration Statement or Prospectus and shall indemnify,
defend and hold harmless, to the fullest extent permitted by applicable law, the
Company, its affiliates (within the meaning of Rule 405 under the Securities
Act), any underwriter (within the meaning of the Securities Act), each person
who controls the Company or any underwriter (within the meaning of the
Securities Act), and each of their respective officers and directors against all
Damages arising out of or based upon (a) any untrue or alleged untrue statement
of a material fact contained in any Registration Statement, Prospectus or
preliminary Prospectus or any amendment thereof or supplement thereto or (b) any
omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, but in each case only to the extent
such Damages arise out of or are based upon (i) statements or omissions that
were made in reliance upon and in conformity with such information relating to
the Holder furnished in writing to the Company by the Holder expressly for use
therein or (ii) the Holder’s failure to deliver to the Holder’s immediate
purchaser a copy of the Registration Statement or Prospectus or any amendments
or supplements thereto (if the same was required by applicable law to be so
delivered) after the Company has furnished the Holder with a sufficient number
of copies of the same.  In no event shall the aggregate amounts payable by the
Holder by way of indemnity or contribution under this Section 2.6 or Section 2.8
exceed the proceeds from the offering received by the Holder (net of any
brokerage and sales commissions), except in the case of fraud or willful
misconduct by the Holder.

 

2.7Indemnification Procedures.  Any person entitled to indemnification hereunder
shall (i) give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification and (ii) unless in such indemnified
party’s reasonable judgment a conflict of interest between such indemnified
party and indemnifying party may exist with respect to such claim, permit such
indemnifying party to assume the defense of any third-party claim with counsel
reasonably satisfactory to the indemnified party.  If such defense is assumed,
then the indemnifying party shall not be subject to any liability for any
settlement made by the indemnified party without its prior written consent (so
long as such consent is not unreasonably withheld, conditioned or delayed).  An
indemnifying party who is not entitled to, or elects not to, assume the defense
of a claim shall not be obligated to pay the fees and expenses of more than one
counsel for all parties indemnified by such indemnifying party with respect to
such claim, unless in the reasonable judgment of any indemnified party there may
be one or more legal or equitable defenses available to such indemnified party
that are in addition to or may conflict with those available to another
indemnified party with respect to such claim.  Failure to give prompt written
notice of a claim shall not release the indemnifying party from its obligations
hereunder except to the extent that the indemnifying party is materially
prejudiced thereby.

 

2.8Contribution.  If the indemnification provided for in Section 2.5 or Section
2.6 is due in accordance with the terms hereof but is held by a court to be
unavailable or unenforceable in respect of any Damages

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

(except, for purposes of clarity, any exclusions to indemnification expressly
provided for in Section 2.5 or Section 2.6), then each applicable indemnifying
party, in lieu of indemnifying such indemnified party, shall contribute to the
amount paid or payable by such indemnified party as a result of such Damages in
such proportion as is appropriate to reflect the relative fault of the
indemnifying party, on the one hand, and of the indemnified party, on the other,
in connection with the statements, omissions or actions that result in such
Damages as well as any other relevant equitable considerations.  The relative
fault of the indemnifying party, on the one hand, and of the indemnified party,
on the other, shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party, and by such party’s relative
intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission; provided, however, that no person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation.  In no event shall the aggregate
amounts payable by the Holder by way of indemnity or contribution under Section
2.6 or this Section 2.8 exceed the proceeds from the offering received by the
Holder (net of any brokerage and sales commissions), except in the case of fraud
or willful misconduct by the Holder.

 

Section 3.Expenses

 

The Company shall pay all expenses incident to the performance by the Company of
the Company’s registration obligations under Section 2, including (i) all stock
exchange, Commission and state securities registration, listing and filing fees,
(ii) all expenses incurred in connection with the preparation and filing of any
Registration Statement and Prospectus, (iii) fees and disbursements of counsel
for the Company and of the independent public accountants of the Company, and
(iv) the costs of any other consents necessary for the Company in connection
with any Registration Statement and Prospectus.  The Holder shall be responsible
for the payment of any brokerage and sales commissions, fees and disbursements
of the Holder’s counsel, accountants and other advisors and any transfer taxes
relating to the sale or disposition of the Registrable Shares by the Holder
pursuant to Section 2 or otherwise.

Section 4.Rule 144 Compliance

 

The Company covenants that it will timely file the reports required to be filed
by the Company under the Securities Act and the Exchange Act so as to enable the
Holder to sell Registrable Shares pursuant to Rule 144 under the Securities
Act.  In connection with any sale, transfer or other disposition by the Holder
of any Registrable Shares pursuant to Rule 144 under the Securities Act, the
Company shall cooperate with the Holder to facilitate the timely preparation and
delivery of certificates representing Registrable Shares to be sold (or the book
entry of such Registrable Shares) and not bearing any Securities Act legend, and
enable certificates for (or the book entry of) such Registrable Shares to be for
such number of shares and registered in such names as the Holder may reasonably
request at least three business days prior to any sale of Registrable Shares
hereunder.

Section 5.Miscellaneous

 

5.1Notices.  All notices and other communications called for under this
Agreement shall be in writing and shall be sufficiently made if sent by
nationally recognized overnight courier (with tracking capability), personal
delivery, or e-mail transmission; provided that if given by e-mail, such notice
or other communication shall be followed up within one business day by personal
delivery or overnight courier as described in this Section 5.1.  All such
notices and other communications shall be deemed to have been delivered: (i)
upon actual receipt, if delivered personally; (ii) on the date sent by email, if
sent on a business day in the place of receipt; otherwise on the next business
day in the place of receipt (unless, in each case, the sender receives an
automatic error message from the server of the intended recipient indicating
that the applicable notice or communication has not been received by such
intended recipient or delivery thereof is delayed for any reason whatsoever); or
(iii) on the next business day after deposit with a recognized overnight
courier, if sent by an overnight courier, in each case addressed to the
respective parties at their address set forth on Schedule A.  Either party
hereto may designate a different address by providing written notice of such new
address to the other party hereto as provided above.

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

 

5.2Nonwaiver.  No course of dealing or any delay or failure to exercise any
right hereunder on the part of the Company or the Holder shall operate as a
waiver of such right or otherwise prejudice the rights, powers or remedies of
such Person.

 

5.3Saturdays, Sundays, Holidays, etc.  If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein
shall not be a business day, then such action may be taken or such right may be
exercised on the next succeeding day that is a business day.

 

5.4Change or Waiver.  Any term of this Agreement may be changed or waived only
by an instrument in writing signed by the party against which enforcement of the
change or waiver is sought.

 

5.5Successors and Assigns.  Except for an assignment (i) by operation of law or
(ii) by the Holder to a transferee of the Warrant, this Agreement and the rights
granted hereunder may not be assigned by either party hereto.  Subject to the
foregoing, this Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective legal representatives, successors and
assigns.

 

5.6Severability.  The provisions of this Agreement shall be deemed severable and
the invalidity or unenforceability of any provision shall not affect the
validity or enforceability of the other provisions hereof.  If any provision of
this Agreement, or the application of such provision to any person or any
circumstance, is invalid or unenforceable, (i) a suitable and equitable
provision shall be substituted therefor in order to carry out, so far as may be
valid and enforceable, the intent and purpose of such invalid or unenforceable
provision, and (ii) the remainder of this Agreement and the application of such
provision to other persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability
affect the validity or enforceability of such provision, or the application of
such provision, in any other jurisdiction.

 

5.7Construction. Unless the express context otherwise requires:

(a)the words “hereof,” “herein,” and “hereunder” and words of similar import,
when used in this Agreement, shall refer to this Agreement as a whole and not to
any particular provision of this Agreement;

(b)any singular forms of nouns, pronouns and verbs used herein shall include the
plural, and vice versa;

(c)any references herein to any gender include each other gender;

(d)any references herein to “$” are to United States Dollars;

(e)any references to any person include references to such person’s successors
and permitted assigns;

(f)any references to any agreement, document or instrument means such agreement,
document or instrument as amended or otherwise modified from time to time in
accordance with the terms thereof and, if applicable, hereof;

(h)wherever the words “include,” “includes,” or “including” are used in this
Agreement, they shall be deemed to be followed by the words ”without
limitation”; and

 

(i)the headings in this Agreement are for purposes of reference only and shall
not limit or otherwise affect the meaning of any provision of this Agreement.

 

5.8Governing Law and Venue.  This Agreement shall be deemed to be made in and in
all respects shall be interpreted, construed and governed by and in accordance
with the laws of the State of New York without regard to the conflicts of law
principles thereof to the extent that such principles would direct a matter to

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

another jurisdiction.  The parties hereby irrevocably submit to the personal
jurisdiction of the courts of the State of New York and the Federal courts of
the United States of America located in the County of New York solely in respect
of the interpretation and enforcement of the provisions of this Agreement and
hereby waive, and agree not to assert, as a defense in any action, suit or
proceeding for the interpretation or enforcement hereof, that it is not subject
thereto or that such action, suit or proceeding may not be brought or is not
maintainable in said courts or that the venue thereof may not be appropriate or
that this Agreement may not be enforced in or by such courts, and the parties
irrevocably agree that all claims relating to such action, proceeding or
transactions shall be heard and determined in such a New York State or Federal
court.  The parties hereby consent to and grant any such court jurisdiction over
the person of such parties and, to the extent permitted by law, over the subject
matter of such dispute and agree that delivery of process or other papers in
connection with any such action or proceeding in any manner as may be permitted
by law shall be valid and sufficient service thereof.  EACH OF THE PARTIES
HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT.

 

5.9Integration; Amendment. This Agreement (together with the Warrant)
constitutes the entire agreement among the parties hereto with respect to the
matters set forth herein and supersedes and renders of no force and effect all
prior oral or written agreements, commitments and understandings among the
parties with respect to the matters set forth herein.  Except as otherwise
expressly provided in this Agreement, no amendment, modification or discharge of
this Agreement shall be valid or binding unless set forth in writing and duly
executed by the Company and the Holder.

 

5.10Execution in Counterparts.  This Agreement may be executed by facsimile
signatures and in any number of counterparts with the same effect as if all
signatory parties had signed the same document.  All counterparts shall be
construed together and shall constitute one and the same instrument.

 

[Signature page follows]

 

 

--------------------------------------------------------------------------------

FOIA CONFIDENTIAL TREATMENT REQUEST BY

CSG SYSTEM INTERNATIONAL, INC.

Exhibit 10.22I

 

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be
duly executed on its behalf as of the date first herein above set forth.

CSG SYSTEMS INTERNATIONAL, INC.

 

 

By:

/s/ Randy Wiese                            July 25, 2014

 

Name:

Randy Wiese

 

Title:

CFO /EVP

 

 

COMCAST ALPHA HOLDINGS, LLC

 

 

By:

/s/ Kristin M. Kipp

 

Name:

Kristin M. Kipp

 

Title:

Vice President

 

 

 

--------------------------------------------------------------------------------

 

SCHEDULE A

If to the Company:

CSG Systems International, Inc.
9555 Maroon Circle

Englewood, CO 80112
Attention:  General Counsel

Email:  ******************

with a copy to:

Sullivan & Cromwell LLP
125 Broad Street
New York, New York 10004

Attention:  Krishna Veeraraghavan

Email:  ***************************

SC1:3640045.6

--------------------------------------------------------------------------------

If to the Holder:

c/o Comcast Capital Corporation

1201 N. Market Street, Suite 1000
Wilmington, DE  19801
Attention:  President

Email:  **************************

with a copy to:

Comcast Corporation

One Comcast Center
1701 John F. Kennedy Blvd.

Philadelphia, PA 19103
Attention:  General Counsel

Email:  *********************

 

--------------------------------------------------------------------------------

EXHIBIT C-30

 

WFX Scheduling and WFX Resource Allocation Manager

 

 

WFX Scheduling.  WFX Scheduling provides available appointment times and
scheduling of Customer's Subscriber-requested service calls through CSG's and
any other third party's integrated order management system.

 

WFX Resource Allocation Manager.  WFX Resource Allocation Manager integrates
with WFX Scheduling to generate available appointment times based on Customer's
field resource scheduling capacity and passes those appointment times to WFX
Scheduling.  WFX Resource Allocation Manager has the ability to allocate
Customer's field resource scheduling capacity based on Customer's existing
technician shift data within CSG Workforce Express® ("WFX") and to facilitate
Customer's scheduling adjustments as necessary to meet Customer's field resource
operational demands (for example: promotional campaigns, time to install and
repair, regulatory) and other business factors.